

Table 1.1

Estimated New Cancer Cases and Deaths for 2021
All Races, By Sex

Primary Site	Estimated New Cases			Estimated Deaths		
	Total	Males	Females	Total	Males	Females
All Sites	1,898,160	970,250	927,910	608,570	319,420	289,150
Oral Cavity and Pharynx	54,010	38,800	15,210	10,850	7,620	3,230
Tongue	17,960	13,040	4,920	2,870	1,930	940
Mouth	14,290	8,400	5,890	2,650	1,520	1,130
Pharynx	18,470	14,990	3,480	3,870	3,060	810
Other Oral Cavity	3,290	2,370	920	1,460	1,110	350
Digestive System	338,090	191,090	147,000	169,280	98,140	71,140
Esophagus	19,260	15,310	3,950	15,530	12,410	3,120
Stomach	26,560	16,160	10,400	11,180	6,740	4,440
Small Intestine	11,390	6,130	5,260	2,100	1,110	990
Colon ^a	104,270	52,590	51,680	52,980	28,520	24,460
Rectum	45,230	26,930	18,300			
Anus, Anal Canal, and Anorectum	9,090	3,020	6,070	1,430	560	870
Liver and Intrahepatic Bile Duct	42,230	29,890	12,340	30,230	20,300	9,930
Gallbladder and Other Biliary	11,980	5,730	6,250	4,310	1,770	2,540
Pancreas	60,430	31,950	28,480	48,220	25,270	22,950
Other Digestive	7,650	3,380	4,270	3,300	1,460	1,840
Respiratory System	254,170	132,910	121,260	137,040	73,340	63,700
Larynx	12,620	9,940	2,680	3,770	3,020	750
Lung and Bronchus	235,760	119,100	116,660	131,880	69,410	62,470
Other Respiratory	5,790	3,870	1,920	1,390	910	480
Bones and Joints	3,610	2,100	1,510	2,060	1,190	870
Soft Tissue	13,460	7,720	5,740	5,350	2,840	2,510
Skin (excl. basal & squamous)	115,320	68,120	47,200	11,540	7,660	3,880
Melanoma of the Skin ^b	106,110	62,260	43,850	7,180	4,600	2,580
Other non-epithelial skin	9,210	5,860	3,350	4,360	3,060	1,300
Breast ^b	284,200	2,650	281,550	44,130	530	43,600
Genital Organs	376,970	260,210	116,760	69,110	35,030	34,080
Cervix (uterus)	14,480		14,480	4,290		4,290
Endometrium (uterus)	66,570		66,570	12,940		12,940
Ovary	21,410		21,410	13,770		13,770
Vulva	6,120		6,120	1,550		1,550
Vagina and other genital organs, female	8,180		8,180	1,530		1,530
Prostate	248,530	248,530		34,130	34,130	
Testis	9,470	9,470		440	440	
Penis and other genital organs, male	2,210	2,210		460	460	
Urinary System	164,000	115,750	48,250	31,940	21,640	10,300
Urinary Bladder	83,730	64,280	19,450	17,200	12,260	4,940
Kidney and Renal Pelvis	76,080	48,780	27,300	13,780	8,790	4,990
Ureter and other urinary organs	4,190	2,690	1,500	960	590	370
Eye and Orbit	3,320	1,750	1,570	400	220	180
Brain and Other Nervous System	24,530	13,840	10,690	18,600	10,500	8,100
Endocrine System	47,200	13,730	33,470	3,290	1,620	1,670
Thyroid	44,280	12,150	32,130	2,200	1,050	1,150
Other Endocrine	2,920	1,580	1,340	1,090	570	520
Lymphoma	90,390	50,460	39,930	21,680	12,740	8,940
Hodgkin Lymphoma	8,830	4,830	4,000	960	570	390
Non-Hodgkin Lymphoma	81,560	45,630	35,930	20,720	12,170	8,550
Myeloma	34,920	19,320	15,600	12,410	6,840	5,570
Leukemia	61,090	35,530	25,560	23,660	13,900	9,760
Acute lymphocytic leukemia	5,690	3,000	2,690	1,580	900	680
Chronic lymphocytic leukemia	21,250	13,040	8,210	4,320	2,620	1,700
Acute myeloid leukemia	20,240	11,230	9,010	11,400	6,620	4,780
Chronic myeloid leukemia	9,110	5,150	3,960	1,220	680	540
Other leukemia	4,800	3,110	1,690	5,140	3,080	2,060
All Other Sites ^c	32,880	16,270	16,610	47,230	25,610	21,620

Cancer Facts & Figures - 2021, American Cancer Society (ACS), Atlanta, Georgia, 2021.
Excludes basal and squamous cell skin and *in situ* carcinomas except urinary bladder.

Estimated new cases are based on 2003-2017 incidence rates reported by the North American Association of Central Cancer Registries (NAACCR).

Estimated deaths are based on 2004-2018 US mortality data, National Center for Health Statistics, Centers for Disease Control and Prevention.

^a Estimated deaths for colon & rectum cancers are combined.

^b Carcinoma *in situ* of the breast accounts for about 49,290 new cases annually, and melanoma *in situ* accounts for about 101,280 new cases annually.

^c More deaths than cases suggests lack of specificity in recording underlying causes of death on death certificate.

Table 1.2

69-Year Trends in U.S. Cancer Death Rates^a

All Races, Males and Females

All Primary Cancer Sites Combined

Age Group	1950	1984	2018	Annual Percent Change		Total Percent Change
				1950-1984	1984-2018	1950-2018
Ages 0-4	11.1	3.8	1.9	-3.2*	-2.0*	-82.9
Ages 5-14	6.7	3.6	2.1	-1.8*	-1.6*	-69.2
Ages 15-24	8.6	5.4	3.2	-1.4*	-1.5*	-63.0
Ages 25-34	20.4	13.4	8.3	-1.5*	-1.6*	-59.5
Ages 35-44	63.6	48.5	26.1	-0.8*	-1.9*	-58.9
Ages 45-54	174.2	168.9	87.6	0.0	-1.9*	-49.7
Ages 55-64	391.3	444.3	265.2	0.4*	-1.7*	-32.2
Ages 65-74	710.0	848.4	562.2	0.5*	-1.3*	-20.8
Ages 75-84	1,167.2	1,269.8	1,031.5	0.3*	-0.7*	-11.6
Ages 85+	1,450.7	1,622.0	1,577.7	0.4*	-0.2*	8.8
All Ages	195.4	210.9	149.0	0.2*	-1.1*	-23.7

Lung and Bronchus Cancer^b

Age Group	1950	1984	2018	Annual Percent Change		Total Percent Change
				1950-1984	1984-2018	1950-2018
Ages 0-4	-	-	-	-	-	-
Ages 5-14	-	0.0	-	-	-	-
Ages 15-24	0.2	0.1	0.0	-2.8*	-0.4	-73.5
Ages 25-34	0.8	0.6	0.3	-0.8*	-2.8*	-66.1
Ages 35-44	4.6	8.3	2.0	1.9*	-3.5*	-57.3
Ages 45-54	20.2	51.1	14.5	2.9*	-3.1*	-28.1
Ages 55-64	48.9	148.7	67.3	3.1*	-2.6*	37.7
Ages 65-74	59.4	257.5	153.7	3.9*	-1.5*	158.7
Ages 75-84	55.4	274.6	268.8	4.7*	-0.1	385.3
Ages 85+	42.3	193.6	287.4	4.9*	1.0*	579.5
All Ages	14.9	53.6	34.9	3.6*	-1.2*	133.3

Source: US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^a Rates are per 100,000 and age-adjusted to the 2000 US Std Population (18 age groups - Census P25-1130).

^b Due to coding changes throughout the years, Lung and Bronchus includes trachea and pleura.

* The APC is significantly different from zero ($p < .05$).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 1.3

Summary of Changes in Cancer Mortality, 1950-2018 and
5-Year Relative Survival (Percent), 1950-2017
Males and Females, By Primary Cancer Site

Primary Site	Whites			
	U.S. Mortality Percent Change 1950-2018 ^a		5-Year Relative Survival (Percent) ^b	
	Total	APC	1950-1954	2011-2017
Oral cavity and pharynx	-50.3	-1.2*	46	67.4
Esophagus	19.0	0.7*	4	21.4
Stomach	-89.6	-3.3*	12	28.2
Colon and rectum	-60.1	-1.4*	37	67.4
Colon	-55.6	-1.2*	41	67.1
Rectum	-70.3	-2.0*	40	68.1
Liver and intrahepatic bile duct	66.7	1.0*	1	16.9
Pancreas	29.0	0.1*	1	7.5
Larynx	-46.3	-0.9*	52	64.2
Lung and bronchus	134.9	0.8*	6	18.3
Males	69.2	0.1	5	15.7
Females	415.5	2.0*	9	21.1
Melanoma of the skin	115.2	0.9*	49	93.3
Breast(females)	-41.0	-0.8*	60	92.3
Cervix uteri	-82.3	-3.0*	59	71.9
Corpus and uterus, NOS	-62.3	-1.2*	72	86.3
Ovary	-24.8	-0.5*	30	44.9
Prostate	-39.2	-0.7*	43	99.8
Testis	-71.4	-2.6*	57	97.4
Urinary bladder	-32.3	-0.6*	53	80.8
Kidney and renal pelvis	21.1	0.3*	34	74.6
Brain and nervous system	55.7	0.4*	21	33.9
Thyroid	-39.9	-0.8*	80	98.1
Hodgkin lymphoma	-85.5	-3.3*	30	89.2
Non-Hodgkin lymphoma	53.2	0.4*	33	72.5
Myeloma	188.5	0.8*	6	46.3
Leukemia	-13.2	-0.4*	10	63.8
Childhood (Ages 0-14)	-75.7	-2.6*	20	-
All Sites	-23.5	-0.3*	35	69.7

The APC is the Annual Percent Change over the time interval.

Rates used in the calculation of the APC are age-adjusted to the 2000 U.S. standard population (18 age groups - Census P25-1130).

^a U.S. Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

Due to coding changes throughout the years: Colon excludes other digestive tract; Rectum includes anal canal; Liver & intrahepatic bile duct includes gallbladder & biliary tract, NOS; Lung & bronchus includes trachea & pleura; Ovary includes fallopian tube; Urinary bladder includes other urinary organs; Kidney & Renal pelvis includes ureter; NHL and myeloma each include a small number of leukemias; NHL includes a small number of ill-defined sites.

^b Survival estimates for 1950-54 are from NCI Survival Report 5 with the exception of All Sites, Oral cavity & pharynx, Colon & rectum, Non-Hodgkin lymphoma and Childhood cancers which come from historical Connecticut data. Survival estimates for 2011-2017 are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Rates are based on follow-up of patients into 2018.

* The APC is significantly different from zero ($p < .05$).

Table 1.4
Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)
By Primary Cancer Site, Sex and Time Period

All Races

Site	Incidence ^a (2014-2018)			US Mortality ^b (2014-2018)			Survival ^c (%) (2011-2017)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	450.5	489.2	425.6	155.5	185.5	133.5	67.7	66.4	68.9
Oral Cavity & Pharynx:	11.5	17.3	6.5	2.5	3.9	1.3	66.9	66.4	68.1
Lip	0.6	0.9	0.3	0.0	0.0	0.0	90.9	91.2	89.8
Tongue	3.6	5.4	2.0	0.7	1.0	0.4	68.1	68.4	67.1
Salivary gland	1.3	1.7	1.1	0.3	0.4	0.2	72.0	66.0	80.4
Floor of mouth	0.4	0.6	0.3	0.0	0.0	0.0	51.6	49.2	57.0
Gum & other oral cavity	1.6	1.9	1.3	0.4	0.5	0.3	61.3	58.7	64.5
Nasopharynx	0.6	0.9	0.3	0.2	0.3	0.1	61.9	60.0	66.7
Tonsil	2.1	3.6	0.7	0.3	0.4	0.1	75.5	76.0	72.9
Oropharynx	0.5	0.9	0.2	0.3	0.5	0.1	49.6	51.9	40.8
Hypopharynx	0.5	0.9	0.2	0.1	0.2	0.0	37.2	36.8	38.6
Other oral cavity & pharynx	0.2	0.4	0.1	0.4	0.7	0.2	50.6	52.7	42.5
Digestive System:	80.6	98.0	66.2	40.6	51.9	31.2	43.7	41.5	46.6
Esophagus	4.2	7.3	1.7	3.9	6.9	1.4	19.9	19.3	22.3
Stomach	7.2	9.7	5.3	3.0	4.0	2.2	32.4	29.1	37.4
Small intestine	2.4	2.8	2.1	0.4	0.5	0.3	68.3	68.0	68.6
Colon & Rectum:	37.8	43.2	33.3	13.7	16.3	11.5	64.7	64.3	65.3
Colon	26.5	29.1	24.3	-	-	-	63.6	63.3	63.8
Rectum	11.3	14.1	9.0	-	-	-	67.4	66.1	69.2
Anus, anal canal & anorectum	2.0	1.6	2.3	0.3	0.2	0.3	68.7	64.0	71.4
Liver & intrahepatic bile duct	9.0	13.8	4.9	6.6	9.7	4.0	20.3	20.1	20.9
Gallbladder	1.2	0.9	1.5	0.6	0.4	0.7	19.4	20.4	18.9
Other biliary	1.8	2.3	1.5	0.5	0.5	0.4	19.3	20.2	18.2
Pancreas	13.2	15.0	11.8	11.0	12.7	9.6	10.8	10.9	10.7
Retroperitoneum	0.4	0.4	0.4	0.1	0.1	0.1	55.1	52.9	56.9
Peritoneum, omentum & mesentery	0.5	0.1	0.8	0.3	0.1	0.4	32.8	39.1	32.4
Other digestive system	0.8	0.9	0.7	0.4	0.5	0.3	7.9	6.8	9.0
Respiratory System:	56.8	66.1	49.6	39.7	49.0	32.5	24.5	22.6	26.6
Nose, nasal cavity & middle ear	0.7	0.9	0.5	0.1	0.2	0.1	58.9	58.2	60.1
Larynx	2.8	4.9	1.1	0.9	1.7	0.4	60.7	61.4	57.8
Lung & bronchus	53.1	60.1	47.9	38.5	46.9	32.0	21.7	18.1	25.4
Pleura ^d	0.0	0.0	0.0	0.1	0.1	0.0	22.0	18.5	26.5
Trachea & other respiratory organs	0.2	0.3	0.1	0.1	0.1	0.1	56.2	54.8	59.9
Bones & joints	1.0	1.2	0.9	0.5	0.6	0.4	66.8	64.5	69.8
Soft tissue (including heart)	3.5	4.2	2.9	1.3	1.5	1.2	65.0	64.7	65.2
Skin (excl. basal & squamous):	24.8	32.1	19.4	3.3	5.1	1.9	92.5	90.8	94.8
Melanoma of the skin	22.8	29.3	18.0	2.3	3.4	1.4	93.3	91.7	95.3
Other non-epithelial skin	2.0	2.9	1.4	1.0	1.8	0.5	83.7	81.0	87.6
Breast	69.1	1.3	129.1	11.1	0.3	20.1	90.2	82.4	90.3
Breast (<i>in situ</i>)	17.1	0.1	32.5	-	-	-	100.0	100.0	100.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^c SEER 18 areas. Based on follow-up of patients into 2018. [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^d Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidence but are included in the Pleura grouping for mortality.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table 1.4 - continued
Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)
By Primary Cancer Site, Sex and Time Period

All Races									
Site	Incidence ^a (2014-2018)			US Mortality ^b (2014-2018)			Survival ^c (%) (2011-2017)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	27.4	-	51.6	8.2	-	14.9	70.2	-	70.2
Cervix uteri	3.8	-	7.5	1.2	-	2.2	66.3	-	66.3
Corpus uteri	14.5	-	27.2	1.3	-	2.4	82.7	-	82.7
Uterus, NOS	0.5	-	0.9	1.4	-	2.5	27.7	-	27.7
Ovary ^d	5.8	-	10.9	3.7	-	6.7	49.1	-	49.1
Vagina	0.4	-	0.7	0.1	-	0.2	48.7	-	48.7
Vulva	1.4	-	2.6	0.3	-	0.6	71.1	-	71.1
Other female genital system	1.0	-	1.8	0.2	-	0.4	50.2	-	50.2
Male Genital System:	54.4	118.4	-	8.1	19.5	-	97.1	97.1	-
Prostate	50.9	111.3	-	7.8	19.0	-	97.5	97.5	-
Testis	3.0	6.0	-	0.1	0.3	-	94.9	94.9	-
Penis	0.4	0.9	-	0.1	0.2	-	64.7	64.7	-
Other male genital system	0.1	0.3	-	0.0	0.0	-	85.1	85.1	-
Urinary System:	37.0	58.1	20.3	8.2	13.1	4.5	75.8	76.5	74.3
Urinary bladder	19.7	34.2	8.5	4.3	7.4	2.1	77.1	78.5	72.6
Kidney & renal pelvis	16.4	22.6	11.2	3.6	5.3	2.3	75.6	74.9	76.8
Ureter	0.5	0.8	0.4	0.1	0.1	0.1	47.7	49.3	45.5
Other urinary system	0.4	0.6	0.2	0.1	0.2	0.1	48.8	51.6	43.2
Eye & Orbit	0.8	1.0	0.8	0.1	0.1	0.1	83.6	83.6	83.7
Brain & Nervous System: ^e	6.4	7.6	5.4	4.4	5.4	3.6	32.6	31.2	34.3
Brain	6.0	7.1	5.0	-	-	-	29.4	28.4	30.6
Cranial nerves & other nervous system	0.4	0.4	0.4	-	-	-	79.5	77.5	81.5
Endocrine System:	16.3	8.9	23.5	0.8	0.8	0.8	96.7	93.0	97.9
Thyroid	15.5	8.0	22.8	0.5	0.5	0.5	98.3	96.0	98.9
Other endocrine & thymus	0.8	0.9	0.7	0.3	0.3	0.3	65.6	66.8	64.2
Lymphoma:	22.2	26.7	18.5	5.7	7.4	4.3	75.1	74.0	76.5
Hodgkin lymphoma	2.6	2.9	2.3	0.3	0.4	0.2	88.3	87.7	89.1
Non-Hodgkin lymphoma	19.6	23.7	16.2	5.4	7.0	4.1	73.2	72.0	74.6
Myeloma	7.1	8.8	5.7	3.2	4.1	2.6	55.6	55.7	55.5
Leukemia:	14.3	18.3	11.1	6.3	8.4	4.7	65.0	65.7	64.0
Lymphocytic:	7.1	9.3	5.2	1.7	2.4	1.2	82.5	82.7	82.3
Acute lymphocytic	1.8	2.0	1.5	0.4	0.5	0.4	69.9	69.5	70.3
Chronic lymphocytic	4.9	6.7	3.5	1.1	1.6	0.8	87.2	86.8	87.8
Other lymphocytic	0.4	0.6	0.2	0.1	0.2	0.1	84.3	87.5	73.8
Myeloid & Monocytic:	6.5	8.1	5.3	3.4	4.4	2.6	43.5	43.3	43.8
Acute myeloid	4.3	5.2	3.6	2.8	3.6	2.2	29.5	28.5	30.7
Chronic myeloid	1.9	2.5	1.5	0.3	0.4	0.2	70.6	69.5	72.2
Acute monocytic	0.2	0.2	0.2	0.0	0.0	0.0	24.8	24.0	25.6
Other myeloid & monocytic	0.1	0.2	0.1	0.3	0.4	0.2	38.4	39.6	36.2
Other leukemia:	0.7	0.9	0.6	1.2	1.6	0.9	50.9	50.2	51.7
Other acute leukemia	0.2	0.3	0.2	0.4	0.5	0.3	26.9	27.9	25.7
Aleukemic, subleukemic & NOS	0.5	0.6	0.4	0.8	1.1	0.6	60.2	59.5	61.0
Kaposi Sarcoma ^f	0.5	0.9	0.1	-	-	-	73.9	73.3	80.2
Mesothelioma ^f	0.8	1.4	0.4	-	-	-	11.5	9.1	18.2
Ill-defined & unspecified	15.9	19.0	13.6	11.5	14.4	9.3	40.8	40.8	40.8

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^c SEER 18 areas. Based on follow-up of patients into 2018. [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^d Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

^e Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

^f Rate not shown for mortality. Category did not exist in mortality coding until 1999.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table 1.5
Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)
By Primary Cancer Site, Sex and Time Period

Site	Whites								
	Incidence ^a (2014-2018)			US Mortality ^b (2014-2018)			Survival ^c (%) (2011-2017)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	460.9	495.8	439.5	156.3	185.9	134.3	68.0	66.4	69.5
Oral Cavity & Pharynx:	12.1	18.2	6.7	2.5	3.9	1.4	68.2	68.0	68.7
Lip	0.7	1.1	0.4	0.0	0.0	0.0	90.8	91.4	89.3
Tongue	4.0	6.0	2.1	0.7	1.0	0.4	69.4	69.8	68.1
Salivary gland	1.3	1.7	1.0	0.3	0.4	0.2	70.0	63.8	79.6
Floor of mouth	0.5	0.7	0.3	0.0	0.0	0.0	52.6	50.4	57.9
Gum & other oral cavity	1.6	1.9	1.3	0.4	0.5	0.3	61.0	58.8	63.9
Nasopharynx	0.4	0.5	0.2	0.1	0.2	0.1	57.4	55.6	62.3
Tonsil	2.3	4.0	0.8	0.3	0.5	0.1	76.9	77.3	74.8
Oropharynx	0.6	0.9	0.2	0.3	0.5	0.1	52.7	55.3	42.5
Hypopharynx	0.5	0.9	0.2	0.1	0.2	0.0	39.7	39.4	41.2
Other oral cavity & pharynx	0.3	0.4	0.1	0.4	0.6	0.2	54.0	56.9	42.7
Digestive System:	79.0	95.5	64.8	39.8	50.8	30.4	43.9	41.6	46.8
Esophagus	4.6	7.8	1.8	4.1	7.4	1.4	20.6	20.1	22.7
Stomach	6.5	8.7	4.6	2.6	3.5	1.9	31.1	27.9	36.6
Small intestine	2.4	2.7	2.1	0.4	0.5	0.3	69.4	69.2	69.7
Colon & Rectum:	37.4	42.5	33.0	13.4	15.9	11.3	65.1	64.7	65.5
Colon	26.3	28.7	24.2	-	-	-	64.2	64.0	64.4
Rectum	11.2	13.8	8.8	-	-	-	67.1	66.1	68.4
Anus, anal canal & anorectum	2.1	1.6	2.5	0.3	0.2	0.3	69.7	65.0	72.1
Liver & intrahepatic bile duct	8.2	12.5	4.5	6.2	9.0	3.8	19.3	19.3	19.2
Gallbladder	1.1	0.8	1.4	0.5	0.4	0.7	19.6	21.2	18.8
Other biliary	1.8	2.2	1.4	0.5	0.5	0.4	18.8	20.2	17.2
Pancreas	13.3	15.2	11.7	11.0	12.8	9.5	10.7	10.9	10.6
Retroperitoneum	0.4	0.4	0.4	0.1	0.1	0.1	54.9	52.3	57.3
Peritoneum, omentum & mesentery	0.5	0.1	0.9	0.3	0.1	0.4	32.6	38.0	32.3
Other digestive system	0.8	0.9	0.7	0.4	0.4	0.3	7.7	6.8	8.7
Respiratory System:	58.7	66.6	52.6	40.5	49.1	33.8	24.5	22.7	26.6
Nose, nasal cavity & middle ear	0.7	0.9	0.5	0.1	0.2	0.1	59.5	59.4	59.8
Larynx	2.8	4.9	1.1	0.9	1.6	0.4	61.8	62.4	59.0
Lung & bronchus	54.9	60.5	50.8	39.3	47.1	33.3	21.7	18.1	25.4
Pleura ^d	0.0	0.0	0.0	0.1	0.2	0.0	22.1	21.0	21.7
Trachea & other respiratory organs	0.2	0.3	0.1	0.1	0.1	0.1	55.7	53.9	60.5
Bones & joints	1.1	1.2	0.9	0.5	0.6	0.4	66.3	63.4	69.9
Soft tissue (including heart)	3.5	4.3	2.9	1.3	1.6	1.1	65.1	65.2	65.1
Skin (excl. basal & squamous):	29.6	37.8	23.5	3.8	5.8	2.2	92.0	90.1	94.4
Melanoma of the skin	27.4	34.7	22.1	2.6	3.9	1.7	92.8	91.0	95.0
Other non-epithelial skin	2.2	3.1	1.5	1.1	1.9	0.5	80.8	78.0	85.1
Breast	69.7	1.2	131.8	10.8	0.3	19.6	91.2	84.8	91.3
Breast (<i>in situ</i>)	16.6	0.1	32.1	-	-	-	100.0	99.9	100.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^c SEER 18 areas. Based on follow-up of patients into 2018. [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^d Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidence but are included in the Pleura grouping for mortality.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table 1.5 - continued
Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)
By Primary Cancer Site, Sex and Time Period

Whites									
Site	Incidence ^a (2014-2018)			US Mortality ^b (2014-2018)			Survival ^c (%) (2011-2017)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	27.6	-	52.7	8.0	-	14.8	71.5	-	71.5
Cervix uteri	3.7	-	7.3	1.1	-	2.1	67.6	-	67.6
Corpus uteri	14.5	-	27.8	1.3	-	2.3	84.8	-	84.8
Uterus, NOS	0.4	-	0.8	1.2	-	2.2	28.5	-	28.5
Ovary ^d	6.0	-	11.3	3.8	-	6.9	49.0	-	49.0
Vagina	0.4	-	0.7	0.1	-	0.2	48.7	-	48.7
Vulva	1.5	-	2.8	0.3	-	0.6	70.6	-	70.6
Other female genital system	1.0	-	1.9	0.2	-	0.4	49.3	-	49.3
Male Genital System:	52.3	112.3	-	7.6	18.4	-	97.1	97.1	-
Prostate	48.2	104.1	-	7.4	17.9	-	97.4	97.4	-
Testis	3.6	7.1	-	0.1	0.3	-	94.9	94.9	-
Penis	0.4	0.9	-	0.1	0.2	-	65.2	65.2	-
Other male genital system	0.1	0.2	-	0.0	0.0	-	84.7	84.7	-
Urinary System:	39.7	62.2	21.5	8.5	13.7	4.7	76.1	76.6	74.8
Urinary bladder	21.7	37.5	9.3	4.5	7.8	2.2	77.5	78.7	73.6
Kidney & renal pelvis	17.0	23.2	11.6	3.8	5.5	2.3	75.6	74.8	76.9
Ureter	0.6	0.8	0.4	0.1	0.2	0.1	48.6	48.9	48.3
Other urinary system	0.4	0.7	0.2	0.1	0.2	0.1	48.6	50.9	43.5
Eye & Orbit	1.0	1.1	0.9	0.1	0.1	0.1	83.5	83.4	83.7
Brain & Nervous System: ^e	7.1	8.3	6.0	4.8	5.9	3.9	31.2	29.9	32.9
Brain	6.6	7.9	5.5	-	-	-	28.2	27.2	29.5
Cranial nerves & other nervous system	0.4	0.4	0.4	-	-	-	79.8	78.5	81.2
Endocrine System:	17.0	9.4	24.6	0.8	0.9	0.7	97.1	93.7	98.3
Thyroid	16.2	8.5	23.9	0.5	0.5	0.5	98.5	96.4	99.1
Other endocrine & thymus	0.8	0.9	0.7	0.3	0.3	0.3	65.2	66.8	63.3
Lymphoma:	23.3	28.0	19.5	5.9	7.7	4.5	75.5	74.3	76.9
Hodgkin lymphoma	2.8	3.1	2.5	0.3	0.4	0.2	88.5	88.0	89.2
Non-Hodgkin lymphoma	20.6	24.9	17.0	5.6	7.3	4.3	73.6	72.4	75.1
Myeloma	6.5	8.2	5.0	3.0	3.8	2.3	54.5	54.8	54.0
Leukemia:	15.2	19.4	11.8	6.5	8.7	4.9	65.3	65.6	64.9
Lymphocytic:	7.8	10.2	5.7	1.8	2.5	1.2	82.7	82.4	83.0
Acute lymphocytic	1.9	2.2	1.7	0.5	0.6	0.4	70.0	69.1	71.1
Chronic lymphocytic	5.4	7.3	3.9	1.2	1.7	0.8	87.0	86.3	88.1
Other lymphocytic	0.5	0.7	0.2	0.1	0.2	0.1	85.2	88.3	75.4
Myeloid & Monocytic:	6.7	8.3	5.4	3.5	4.6	2.7	42.7	42.2	43.4
Acute myeloid	4.4	5.4	3.7	2.9	3.7	2.2	29.0	27.8	30.4
Chronic myeloid	2.0	2.5	1.5	0.3	0.4	0.2	69.6	68.4	71.4
Acute monocytic	0.2	0.2	0.2	0.0	0.0	0.0	26.2	24.5	28.1
Other myeloid & monocytic	0.1	0.2	0.1	0.3	0.4	0.2	36.2	37.4	34.1
Other leukemia:	0.7	0.9	0.6	1.3	1.7	1.0	49.3	47.7	51.1
Other acute leukemia	0.2	0.3	0.2	0.4	0.5	0.3	26.6	27.3	25.8
Aleukemic, subleukemic & NOS	0.5	0.6	0.4	0.8	1.1	0.6	58.6	56.5	60.8
Kaposi Sarcoma ^f	0.4	0.7	0.1	-	-	-	76.7	75.2	87.9
Mesothelioma ^f	1.0	1.6	0.5	-	-	-	11.0	8.5	18.3
Ill-defined & unspecified	16.4	19.7	13.9	11.7	14.6	9.4	40.6	40.9	40.3

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^c SEER 18 areas. Based on follow-up of patients into 2018. [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^d Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

^e Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

^f Rate not shown for mortality. Category did not exist in mortality coding until 1999.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table 1.6
Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)
By Primary Cancer Site, Sex and Time Period

Blacks									
Site	Incidence ^a (2014-2018)			US Mortality ^b (2014-2018)			Survival ^c (%) (2011-2017)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	445.2	518.9	396.4	177.5	221.1	150.5	63.1	64.7	61.4
Oral Cavity & Pharynx:	8.5	13.2	4.9	2.6	4.4	1.2	50.7	48.9	54.9
Lip	0.1	0.1	0.0	-	-	-	71.9	64.0	-
Tongue	1.9	3.1	1.0	0.5	0.8	0.2	49.3	51.0	44.7
Salivary gland	1.1	1.2	1.1	0.2	0.3	0.1	74.8	69.5	78.8
Floor of mouth	0.3	0.6	0.2	0.0	0.0	-	40.9	39.1	44.7
Gum & other oral cavity	1.3	1.6	1.0	0.3	0.5	0.2	57.1	52.4	62.2
Nasopharynx	0.7	1.1	0.4	0.2	0.4	0.1	54.3	54.4	54.1
Tonsil	1.5	2.9	0.5	0.3	0.5	0.1	55.8	57.2	49.7
Oropharynx	0.6	1.0	0.2	0.4	0.6	0.2	31.0	31.0	30.2
Hypopharynx	0.8	1.3	0.3	0.2	0.3	0.0	24.3	23.2	27.9
Other oral cavity & pharynx	0.2	0.4	0.1	0.6	1.0	0.2	32.2	28.0	44.8
Digestive System:	93.4	115.3	77.6	50.8	66.2	39.7	40.5	37.2	44.2
Esophagus	3.6	5.8	2.0	3.0	5.0	1.6	13.7	12.2	16.9
Stomach	10.0	13.5	7.7	5.2	7.6	3.5	32.3	26.5	39.6
Small intestine	3.9	4.5	3.5	0.7	0.8	0.6	64.0	63.8	64.2
Colon & Rectum:	42.6	49.9	37.5	18.0	22.5	14.8	59.3	57.6	60.9
Colon	31.4	35.6	28.4	-	-	-	57.5	56.7	58.2
Rectum	11.3	14.3	9.1	-	-	-	64.1	59.7	69.2
Anus, anal canal & anorectum	2.0	2.2	1.8	0.3	0.3	0.3	62.4	58.3	66.2
Liver & intrahepatic bile duct	10.6	17.6	5.3	8.4	13.1	4.8	17.5	16.2	21.1
Gallbladder	1.8	1.4	2.2	0.8	0.7	1.0	16.5	14.5	17.4
Other biliary	1.7	2.1	1.5	0.4	0.5	0.4	16.0	13.6	18.0
Pancreas	15.5	17.0	14.3	13.3	15.0	12.0	10.2	9.4	10.9
Retroperitoneum	0.4	0.4	0.4	0.1	0.1	0.1	55.7	57.4	54.3
Peritoneum, omentum & mesentery	0.3	0.1	0.5	0.2	0.1	0.3	33.7	32.2	33.8
Other digestive system	0.9	0.9	0.8	0.5	0.6	0.4	7.3	3.4	9.3
Respiratory System:	58.3	77.3	45.3	41.9	58.7	30.4	22.5	20.9	24.6
Nose, nasal cavity & middle ear	0.6	0.8	0.5	0.2	0.2	0.1	54.5	51.8	58.0
Larynx	3.8	7.0	1.4	1.5	2.9	0.5	52.7	53.5	49.8
Lung & bronchus	53.7	69.3	43.3	40.1	55.4	29.7	19.6	16.4	23.3
Pleura ^d	-	-	-	0.0	0.1	0.0	-	-	-
Trachea & other respiratory organs	0.2	0.2	0.1	0.1	0.1	0.1	56.5	53.1	61.8
Bones & joints	0.8	0.9	0.7	0.5	0.6	0.4	67.9	69.2	66.1
Soft tissue (including heart)	3.5	4.0	3.1	1.5	1.6	1.5	61.3	61.3	61.0
Skin (excl. basal & squamous):	2.0	2.2	1.9	0.8	1.1	0.5	84.2	80.0	87.3
Melanoma of the skin	0.9	1.0	0.9	0.3	0.4	0.3	71.2	64.2	76.4
Other non-epithelial skin	1.1	1.2	1.0	0.4	0.7	0.3	93.7	90.7	95.2
Breast	71.1	1.8	124.7	16.0	0.5	27.3	82.3	70.9	82.4
Breast (<i>in situ</i>)	18.5	0.2	32.9	-	-	-	100.0	96.3	100.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^c SEER 18 areas. Based on follow-up of patients into 2018. [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^d Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidence but are included in the Pleura grouping for mortality.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table 1.6 - continued
Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)
By Primary Cancer Site, Sex and Time Period

Blacks									
Site	Incidence ^a (2014-2018)			US Mortality ^b (2014-2018)			Survival ^c (%) (2011-2017)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	28.5	-	50.4	10.9	-	18.8	57.5	-	57.5
Cervix uteri	4.7	-	8.6	1.9	-	3.3	56.3	-	56.3
Corpus uteri	15.2	-	26.7	2.3	-	3.9	65.7	-	65.7
Uterus, NOS	1.0	-	1.8	2.8	-	4.7	22.7	-	22.7
Ovary ^d	5.1	-	9.0	3.4	-	5.9	41.3	-	41.3
Vagina	0.6	-	1.0	0.2	-	0.3	44.5	-	44.5
Vulva	1.0	-	1.8	0.2	-	0.3	72.2	-	72.2
Other female genital system	0.8	-	1.5	0.2	-	0.4	51.8	-	51.8
Male Genital System:	76.1	178.8	-	14.1	37.8	-	96.0	96.0	-
Prostate	74.8	175.8	-	13.9	37.4	-	96.2	96.2	-
Testis	0.8	1.7	-	0.1	0.1	-	91.8	91.8	-
Penis	0.4	1.0	-	0.1	0.2	-	58.3	58.3	-
Other male genital system	0.1	0.2	-	0.0	0.1	-	77.6	77.6	-
Urinary System:	29.5	44.4	19.0	7.1	10.9	4.7	71.2	71.8	70.4
Urinary bladder	11.5	19.2	6.4	3.5	5.3	2.3	64.6	68.2	57.7
Kidney & renal pelvis	17.4	24.4	12.1	3.5	5.3	2.2	75.7	74.6	77.2
Ureter	0.2	0.3	0.2	0.0	0.0	0.0	32.3	32.3	30.4
Other urinary system	0.4	0.6	0.3	0.1	0.2	0.1	41.1	43.7	37.9
Eye & Orbit	0.3	0.3	0.2	0.0	0.0	0.0	86.4	84.3	88.8
Brain & Nervous System: ^e	3.9	4.6	3.3	2.7	3.2	2.3	39.6	37.6	42.0
Brain	3.5	4.2	3.0	-	-	-	35.6	34.4	37.0
Cranial nerves & other nervous system	0.3	0.4	0.3	-	-	-	76.8	71.4	80.7
Endocrine System:	10.4	5.0	15.0	0.8	0.8	0.8	94.3	87.6	95.9
Thyroid	9.4	4.0	14.0	0.5	0.4	0.5	96.9	92.8	97.7
Other endocrine & thymus	1.0	1.0	1.0	0.4	0.4	0.3	68.8	68.8	68.6
Lymphoma:	17.3	20.6	14.8	4.2	5.5	3.3	72.3	70.1	74.7
Hodgkin lymphoma	2.6	2.9	2.3	0.3	0.3	0.2	86.2	84.0	88.5
Non-Hodgkin lymphoma	14.7	17.7	12.4	4.0	5.1	3.1	69.1	66.8	71.6
Myeloma	13.8	16.3	12.1	6.0	7.3	5.1	58.1	58.2	58.0
Leukemia:	11.0	13.9	9.1	5.3	6.8	4.3	60.9	64.1	57.2
Lymphocytic:	4.4	6.0	3.3	1.4	1.8	1.1	77.4	80.4	73.4
Acute lymphocytic	1.0	1.1	0.9	0.3	0.3	0.3	64.8	66.5	63.0
Chronic lymphocytic	3.2	4.7	2.2	1.0	1.4	0.7	82.2	84.8	78.5
Other lymphocytic	0.2	0.3	0.1	0.1	0.1	0.1	74.1	80.2	59.9
Myeloid & Monocytic:	5.8	7.0	5.0	2.7	3.4	2.3	45.5	46.5	44.5
Acute myeloid	3.7	4.4	3.3	2.2	2.7	1.9	29.8	29.2	30.4
Chronic myeloid	1.8	2.3	1.5	0.3	0.4	0.2	72.2	71.7	72.6
Acute monocytic	0.1	0.2	0.1	0.0	0.0	-	17.8	27.6	8.8
Other myeloid & monocytic	0.1	0.2	0.1	0.2	0.3	0.1	38.2	39.7	35.7
Other leukemia:	0.8	0.9	0.7	1.2	1.6	1.0	56.2	57.7	53.9
Other acute leukemia	0.2	0.3	0.2	0.3	0.4	0.3	28.0	25.4	29.8
Aleukemic, subleukemic & NOS	0.6	0.7	0.6	0.9	1.2	0.7	64.5	68.3	60.1
Kaposi Sarcoma ^f	1.0	1.9	0.2	-	-	-	65.0	66.5	46.4
Mesothelioma ^f	0.4	0.8	0.2	-	-	-	14.0	13.1	16.5
Ill-defined & unspecified	15.3	17.5	13.9	12.4	15.7	10.1	38.9	36.4	41.1

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^c SEER 18 areas. Based on follow-up of patients into 2018. [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^d Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

^e Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

^f Rate not shown for mortality. Category did not exist in mortality coding until 1999.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table 1.7
SEER Incidence and U.S. Mortality Trends by Primary Cancer Site and Sex
All Races, 2009-2018

Site	Incidence ^a			US Mortality ^b		
	Total APC	Males APC	Females APC	Total APC	Males APC	Females APC
All Sites	-0.9*	-1.6*	-0.3*	-1.6*	-1.9*	-1.5*
Oral Cavity & Pharynx:	0.5*	0.5*	0.2	0.5	0.7*	0.0
Lip	-1.9	-2.5*	-0.8	-1.1	-2.9	1.8
Tongue	1.5*	1.4*	1.6*	1.4*	1.7*	0.8
Salivary gland	0.3	-0.2	0.8	0.8	0.4	1.4
Floor of mouth	-3.8*	-3.7*	-4.0*	-2.8	-3.3	-2.1
Gum & other oral cavity	0.0	0.1	-0.2	0.5	0.8	0.1
Nasopharynx	-0.8	-0.5	-1.5	-1.0*	-0.3	-2.3
Tonsil	1.7*	2.0*	0.3	2.2*	2.8*	0.1
Oropharynx	4.2*	4.7*	2.2	3.2*	3.7*	1.4
Hypopharynx	-2.7*	-2.9*	-2.2	1.4	1.4*	1.1
Other oral cavity & pharynx	-0.7	-0.3	-1.9	-2.9*	-3.0*	-2.9*
Digestive System:	-0.8*	-0.9*	-0.8*	-0.6*	-0.7*	-0.6*
Esophagus	-1.1*	-1.3*	-1.2*	-1.3*	-1.4*	-1.5*
Stomach	-1.0*	-1.6*	-0.4*	-2.1*	-2.4*	-1.9*
Small intestine	1.3*	1.1*	1.3*	2.2*	2.5*	1.9
Colon & Rectum:	-1.9*	-2.0*	-1.9*	-2.0*	-2.1*	-2.0*
Colon	-2.2*	-2.4*	-2.0*	-	-	-
Rectum	-1.3*	-1.4*	-1.5*	-	-	-
Anus, anal canal & anorectum	0.8	0.3	1.1*	2.8*	2.4*	3.1*
Liver & intrahepatic bile duct	1.0*	0.7	1.8*	1.5*	1.3*	1.9*
Gallbladder	-0.5	-0.3	-0.5	-1.6*	-2.0*	-1.3*
Other biliary	-0.6	-0.6	-0.7	1.1*	1.0	1.1*
Pancreas	0.6*	0.6*	0.6*	0.2*	0.2*	0.1
Retroperitoneum	-0.1	0.1	-0.4	3.9*	4.0*	3.7*
Peritoneum, omentum & mesentery	-3.7*	-2.8	-3.6*	0.9	3.0*	0.5
Other digestive system	5.0*	4.4*	5.5*	3.5*	2.9*	3.9*
Respiratory System:	-2.2*	-2.9*	-1.5*	-3.5*	-4.0*	-2.9*
Nose, nasal cavity & middle ear	-0.2	-0.6	0.2	-0.5	-0.4	-1.1
Larynx	-3.0*	-3.2*	-2.7*	-2.1*	-2.3*	-2.1*
Lung & bronchus	-2.2*	-3.0*	-1.5*	-3.6*	-4.1*	-3.0*
Pleura	-5.7	-6.1	-6.3	4.3*	4.0*	3.9*
Trachea & other respiratory organs	-0.7	-0.9	-0.6	1.6*	0.6	2.8*
Bones & joints	0.5	0.5	0.5	1.5*	1.5*	1.3*
Soft tissue (including heart)	0.3	0.6*	-0.1	0.1	-0.1	0.1
Skin (excl. basal & squamous):	1.0*	0.9*	1.1*	-2.0*	-2.0*	-2.1*
Melanoma of the skin	1.0*	0.9*	1.1*	-3.5*	-3.7*	-3.4*
Other non-epithelial skin	0.4	0.6	0.1	2.0*	1.7*	2.4*
Breast	0.1	0.7*	0.3	-1.5*	-0.6	-1.4*
Breast (<i>in situ</i>)	-1.2*	0.9	-1.1*	-	-	-

The APC is the Annual Percent Change over the time interval.

Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

* The APC is significantly different from zero (p<.05).

- Statistic could not be calculated. Trend based on less than 10 cases for at least one year within the time interval.

Table 1.7 - continued
SEER Incidence and U.S. Mortality Trends by Primary Cancer Site and Sex
All Races, 2009-2018

Site	Incidence ^a			US Mortality ^b		
	Total APC	Males APC	Females APC	Total APC	Males APC	Females APC
Female Genital System:	0.1	-	0.2	-0.7*	-	-0.4*
Cervix uteri	-0.4	-	-0.3	-0.6*	-	-0.5*
Corpus uteri	0.8*	-	0.9*	5.1*	-	5.4*
Uterus, NOS	2.2*	-	2.5*	-1.1	-	-0.9
Ovary ^c	-2.5*	-	-2.3*	-2.6*	-	-2.4*
Vagina	-1.5*	-	-1.3*	-2.7*	-	-2.4*
Vulva	0.2	-	0.4	1.6*	-	1.9*
Other female genital system	9.1*	-	9.1*	6.6*	-	6.8*
Male Genital System:	-3.0*	-3.2*	-	-1.0*	-1.7*	-
Prostate	-3.2*	-3.4*	-	-1.1*	-1.7*	-
Testis	0.6*	0.5*	-	0.1	0.0	-
Penis	0.0	-0.1	-	2.7*	2.5*	-
Other male genital system	-1.1	-1.6	-	2.5	1.9	-
Urinary System:	-0.6*	-0.9*	-0.4	-0.9*	-1.0*	-1.1*
Urinary bladder	-1.5*	-1.7*	-1.5*	-0.5*	-0.7*	-0.6*
Kidney & renal pelvis	0.6*	0.5*	0.6*	-1.3*	-1.3*	-1.6*
Ureter	-1.6*	-1.8*	-1.5	-0.2	0.0	-0.6
Other urinary system	3.4*	2.7*	4.2*	0.2	0.8	-1.2
Eye & Orbit	-0.7	-1.0	-0.4	0.6	1.2	-0.1
Brain & Nervous System: ^d	-0.6*	-0.5*	-0.7	0.4*	0.4	0.4
Brain	-0.5*	-0.5*	-0.6	-	-	-
Cranial nerves & other nervous system	-1.9*	-1.5	-2.2	-	-	-
Endocrine System:	0.2	0.8	0.0	-0.2	0.2	-0.4
Thyroid	0.1	0.8	0.0	-0.1	0.5	-0.4
Other endocrine & thymus	0.4	0.8	-0.1	-0.3	-0.3	-0.3
Lymphoma:	-0.8*	-0.9*	-0.8*	-2.3*	-2.1*	-2.7*
Hodgkin lymphoma	-1.4*	-1.5*	-1.3*	-4.4*	-4.1*	-4.9*
Non-Hodgkin lymphoma	-0.7*	-0.8*	-0.7*	-2.2*	-2.0*	-2.6*
Myeloma	0.2	0.0	0.3	-0.8*	-0.8*	-0.9*
Leukemia:	-0.6	-0.7	-0.6	-1.8*	-1.9*	-1.8*
Lymphocytic:	-1.2*	-1.4*	-1.2*	-2.3*	-2.5*	-2.1*
Acute lymphocytic	0.6	0.7*	0.4	-0.2	0.1	-0.6
Chronic lymphocytic	-1.8*	-2.0*	-1.9*	-3.2*	-3.3*	-3.0*
Other lymphocytic	-1.5*	-1.5*	-1.6	-0.6	-1.3	0.4
Myeloid & Monocytic:	0.2	0.0	0.2	-0.2	-0.3	-0.2
Acute myeloid	0.5	0.3	0.6	-0.4*	-0.5*	-0.3
Chronic myeloid	0.2	0.1	0.2	-0.3	-0.4	-0.3
Acute monocytic	-3.8*	-4.0*	-3.7*	-1.9	-1.7	-2.3
Other myeloid & monocytic	-3.7*	-3.3*	-4.4*	2.3*	2.8*	1.5
Other leukemia:	-1.1	-0.7	-1.6	-4.9*	-5.0*	-5.1*
Other acute leukemia	-2.7*	-2.3*	-3.1*	-6.6*	-6.6*	-6.9*
Aleukemic, subleukemic & NOS	-0.4	0.1	-0.9	-4.1*	-4.2*	-4.2*
Kaposi Sarcoma ^e	-3.9*	-3.9*	-5.1*	-	-	-
Mesothelioma ^e	-3.3*	-4.6*	0.1	-	-	-
Ill-defined & unspecified	-2.1*	-2.3*	-2.0*	-1.4*	-1.7*	-1.2*

The APC is the Annual Percent Change over the time interval.

Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

- ^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
- ^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.
- ^c Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.
- ^d Due to coding changes, Brain & Nervous System mortality are no longer shown separately.
- ^e Trend not shown for mortality. Category did not exist in mortality coding until 1999.
- * The APC is significantly different from zero (p<.05).
- Statistic could not be calculated. Trend based on less than 10 cases for at least one year within the time interval.

Table 1.8
SEER Incidence and U.S. Mortality Trends by Primary Cancer Site and Sex
Whites, 2009-2018

Site	Incidence ^a			US Mortality ^b		
	Total APC	Males APC	Females APC	Total APC	Males APC	Females APC
All Sites	-1.0*	-1.6*	-0.3*	-1.5*	-1.8*	-1.4*
Oral Cavity & Pharynx:	0.6*	0.7*	0.3*	0.9*	1.0*	0.3
Lip	-1.9	-2.5*	-0.6	-0.9	-3.0	3.2
Tongue	1.8*	1.7*	1.9*	1.9*	2.2*	1.4*
Salivary gland	-0.1	-0.4	0.2	1.0*	0.6	1.5
Floor of mouth	-3.5*	-3.4*	-3.8*	-3.1*	-3.0	-3.5
Gum & other oral cavity	-0.2	-0.2	-0.2	0.5	0.7	0.3
Nasopharynx	-2.1*	-2.0*	-2.4*	-1.3*	-0.9	-2.1
Tonsil	1.9*	2.2*	0.6	2.6*	3.2*	0.2
Oropharynx	5.1*	5.5*	3.6*	3.9*	4.4*	2.1*
Hypopharynx	-2.9*	-2.8*	-3.5*	1.5	1.4	1.0
Other oral cavity & pharynx	0.1	0.5	-1.1	-2.5*	-2.5*	-2.9*
Digestive System:	-0.7*	-0.9*	-0.6*	-0.4*	-0.5*	-0.5*
Esophagus	-0.9*	-1.1*	-0.9	-0.8*	-0.9*	-1.1*
Stomach	-0.9*	-1.6*	0.1	-2.0*	-2.3*	-1.8*
Small intestine	0.9*	0.8	1.0*	2.1*	2.6*	1.3
Colon & Rectum:	-1.8*	-2.0*	-1.7*	-1.8*	-2.0*	-1.8*
Colon	-2.0*	-2.3*	-1.9*	-	-	-
Rectum	-1.4*	-1.5*	-1.4*	-	-	-
Anus, anal canal & anorectum	1.1*	0.6	1.5*	3.1*	2.9*	3.3*
Liver & intrahepatic bile duct	1.6*	1.1*	2.5*	1.9*	1.6*	2.2*
Gallbladder	-0.9*	-0.6	-0.9*	-1.7*	-2.0*	-1.4*
Other biliary	-0.8	-0.8	-0.9	1.0*	0.9	1.0*
Pancreas	0.7*	0.7*	0.6*	0.3*	0.3*	0.2*
Retroperitoneum	-0.3	0.0	-0.7	3.4*	3.8*	2.8
Peritoneum, omentum & mesentery	-4.0*	-3.0	-4.0*	0.7	2.9*	0.3
Other digestive system	5.3*	5.0*	5.5*	3.6*	2.7*	4.3*
Respiratory System:	-2.2*	-2.9*	-1.4*	-3.4*	-3.9*	-2.8*
Nose, nasal cavity & middle ear	-0.3	-0.7	0.1	-0.2	-0.1	-0.7
Larynx	-2.9*	-3.2*	-2.6*	-1.8*	-1.9*	-2.0*
Lung & bronchus	-2.2*	-3.0*	-1.4*	-3.4*	-4.1*	-2.8*
Pleura	-4.4	-5.7	-3.7	4.6*	4.3*	4.2*
Trachea & other respiratory organs	-0.7	-0.6	-1.1	1.7	0.8	2.7*
Bones & joints	0.3	0.4	0.1	1.6*	1.6*	1.4*
Soft tissue (including heart)	0.0	0.1	-0.3	0.1	-0.1	0.1
Skin (excl. basal & squamous):	1.1*	0.9*	1.1*	-1.8*	-1.9*	-1.9*
Melanoma of the skin	1.1*	1.0*	1.2*	-3.3*	-3.5*	-3.2*
Other non-epithelial skin	0.4	0.7	-0.2	2.4*	2.0*	2.7*
Breast	-0.1	0.4	0.1	-1.5*	-0.6	-1.4*
Breast (<i>in situ</i>)	-1.9*	1.3	-1.8*	-	-	-

The APC is the Annual Percent Change over the time interval.

Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

* The APC is significantly different from zero (p<.05).

- Statistic could not be calculated. Trend based on less than 10 cases for at least one year within the time interval.

Table 1.8 - continued
SEER Incidence and U.S. Mortality Trends by Primary Cancer Site and Sex
Whites, 2009-2018

Site	Incidence ^a			US Mortality ^b		
	Total APC	Males APC	Females APC	Total APC	Males APC	Females APC
Female Genital System:	-0.2	-	0.0	-0.7*	-	-0.4*
Cervix uteri	-0.4	-	-0.3	0.0	-	0.2
Corpus uteri	0.5*	-	0.6*	5.0*	-	5.3*
Uterus, NOS	2.2*	-	2.6*	-1.4	-	-1.1
Ovary ^c	-2.8*	-	-2.6*	-2.6*	-	-2.4*
Vagina	-1.8*	-	-1.6*	-2.7*	-	-2.5*
Vulva	0.3	-	0.6	2.0*	-	2.4*
Other female genital system	9.1*	-	9.1*	6.7*	-	6.9*
Male Genital System:	-3.3*	-3.5*	-	-0.8*	-1.4*	-
Prostate	-3.6*	-3.8*	-	-0.8*	-1.5*	-
Testis	0.5*	0.5*	-	-0.1	-0.2	-
Penis	0.0	-0.1	-	3.4*	3.2*	-
Other male genital system	-1.2	-1.7	-	1.6	0.9	-
Urinary System:	-0.6*	-0.9*	-0.4	-0.7*	-0.8*	-0.9*
Urinary bladder	-1.5*	-1.7*	-1.5*	-0.4	-0.6*	-0.4
Kidney & renal pelvis	0.6*	0.5*	0.6*	-1.2*	-1.2*	-1.4*
Ureter	-1.6*	-1.7*	-1.7	0.0	0.2	-0.3
Other urinary system	3.8*	2.7*	5.4*	0.2	0.6	-1.1
Eye & Orbit	-0.6	-1.0	-0.3	0.8	1.2	0.3
Brain & Nervous System: ^d	-0.5*	-0.5*	-0.6	0.5*	0.4*	0.5
Brain	-0.4	-0.5*	-0.4	-	-	-
Cranial nerves & other nervous system	-2.1*	-1.3	-2.9*	-	-	-
Endocrine System:	-0.1	0.6	-0.3	-0.1	0.2	-0.2
Thyroid	-0.1	0.6	-0.3	0.2	0.5	0.0
Other endocrine & thymus	-0.2	0.3	-0.9	-0.4	-0.3	-0.6
Lymphoma:	-0.9*	-0.9*	-0.9*	-2.3*	-2.0*	-2.7*
Hodgkin lymphoma	-1.5*	-1.5*	-1.5*	-4.4*	-4.0*	-5.0*
Non-Hodgkin lymphoma	-0.8*	-0.8*	-0.8*	-2.2*	-1.9*	-2.6*
Myeloma	0.2	0.0	0.2	-0.8*	-0.8*	-1.0*
Leukemia:	-0.7	-0.8	-0.7	-1.7*	-1.8*	-1.7*
Lymphocytic:	-1.3*	-1.4*	-1.3*	-2.1*	-2.2*	-2.2*
Acute lymphocytic	0.2	0.5	-0.1	-0.1	0.4	-1.0
Chronic lymphocytic	-1.8*	-2.0*	-1.8*	-3.0*	-3.1*	-2.9*
Other lymphocytic	-0.9	-1.0	-0.9	-0.5	-1.1	0.4
Myeloid & Monocytic:	0.1	-0.1	0.2	-0.1	-0.2	-0.1
Acute myeloid	0.4	0.2	0.6	-0.4*	-0.5*	-0.3
Chronic myeloid	0.1	0.0	0.1	0.1	-0.1	0.2
Acute monocytic	-4.0*	-4.2*	-3.8*	-2.1	-1.8	-2.6
Other myeloid & monocytic	-3.8*	-3.3*	-4.8*	2.4*	2.6*	1.9*
Other leukemia:	-1.4	-0.8	-2.0	-4.8*	-4.9*	-4.9*
Other acute leukemia	-3.5*	-3.0*	-3.9*	-6.4*	-6.4*	-6.8*
Aleukemic, subleukemic & NOS	-0.4	0.2	-1.1	-3.9*	-4.2*	-3.8*
Kaposi Sarcoma ^e	-5.1*	-5.2*	-6.5*	-	-	-
Mesothelioma ^e	-3.3*	-4.5*	0.1	-	-	-
Ill-defined & unspecified	-2.1*	-2.3*	-1.9*	-1.3*	-1.5*	-1.1*

The APC is the Annual Percent Change over the time interval.

Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

- ^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
- ^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.
- ^c Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.
- ^d Due to coding changes, Brain & Nervous System mortality are no longer shown separately.
- ^e Trend not shown for mortality. Category did not exist in mortality coding until 1999.
- * The APC is significantly different from zero (p<.05).
- Statistic could not be calculated. Trend based on less than 10 cases for at least one year within the time interval.

Table 1.9
SEER Incidence and U.S. Mortality Trends by Primary Cancer Site and Sex
Blacks, 2009-2018

Site	Incidence ^a			US Mortality ^b		
	Total APC	Males APC	Females APC	Total APC	Males APC	Females APC
All Sites	-1.5*	-2.5*	-0.6*	-2.2*	-2.8*	-1.7*
Oral Cavity & Pharynx:	-1.3*	-1.3*	-1.2*	-1.8*	-2.2*	-1.3
Lip	-3.2	-4.7	-0.6	-	-	-
Tongue	-1.9*	-1.6	-2.5	-2.5*	-2.4*	-3.0*
Salivary gland	1.3	0.3	1.9	-1.1	-1.2	-0.9
Floor of mouth	-6.7*	-6.5*	-7.1	-	-	-
Gum & other oral cavity	-1.1	-1.3	-1.1	0.2	-0.7	1.8
Nasopharynx	0.8	1.4	-0.6	-0.8	0.3	-3.4
Tonsil	-0.2	0.5	-2.6*	-0.7	-0.5	-0.9
Oropharynx	-0.4	0.9	-3.6	-0.5	-0.4	-1.2
Hypopharynx	-3.3*	-4.7*	2.7	0.1	0.7	-
Other oral cavity & pharynx	-5.4*	-4.4*	-6.8	-4.9*	-5.8*	-2.1
Digestive System:	-1.7*	-1.8*	-1.6*	-1.5*	-1.7*	-1.4*
Esophagus	-3.8*	-4.1*	-3.7*	-4.5*	-5.2*	-3.1*
Stomach	-2.3*	-2.2*	-2.3*	-3.2*	-3.2*	-3.5*
Small intestine	1.6*	1.3	1.7*	2.5*	2.0	3.5
Colon & Rectum:	-2.9*	-3.0*	-2.9*	-2.8*	-2.7*	-3.0*
Colon	-3.1*	-3.3*	-3.0*	-	-	-
Rectum	-2.3*	-2.1*	-2.7*	-	-	-
Anus, anal canal & anorectum	-0.3	-0.9	0.0	1.7*	-0.2	3.7*
Liver & intrahepatic bile duct	0.0	0.0	0.1	0.8*	0.5	1.5*
Gallbladder	0.4	-1.2	1.1	-1.3	-2.5*	-0.8
Other biliary	0.1	0.9	-0.7	2.3*	1.9	2.5
Pancreas	0.2	0.0	0.4	-0.3*	-0.1	-0.3
Retroperitoneum	-0.1	-0.6	0.4	7.6*	-	-
Peritoneum, omentum & mesentery	-0.3	1.5	-0.6	3.9*	-	4.7*
Other digestive system	1.5	-1.0	3.7	2.8*	3.4*	1.9
Respiratory System:	-2.8*	-3.6*	-2.1*	-4.0*	-4.6*	-3.3*
Nose, nasal cavity & middle ear	-0.1	-0.7	0.7	-2.1	-2.2	-1.6
Larynx	-3.3*	-3.8*	-2.7*	-3.0*	-3.5*	-1.8
Lung & bronchus	-2.8*	-3.6*	-2.1*	-4.0*	-4.7*	-3.3*
Pleura	-	-	-	-	-	-
Trachea & other respiratory organs	-4.9	-6.7	-2.4	3.3	-	-
Bones & joints	1.0	0.8	1.0	0.9	1.7	0.5
Soft tissue (including heart)	0.8	2.0*	-0.2	0.7	1.1	0.3
Skin (excl. basal & squamous):	-1.0	-1.4	-0.5	-1.8*	-2.2	-1.4
Melanoma of the skin	-2.0	-1.3	-2.3*	-3.8*	-3.9*	-3.7*
Other non-epithelial skin	-0.1	-1.4	1.3	-0.1	-1.1	1.8
Breast	0.0	1.1	0.2	-1.6*	-0.5	-1.5*
Breast (<i>in situ</i>)	0.1	-0.9	0.2	-	-	-

The APC is the Annual Percent Change over the time interval.

Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

* The APC is significantly different from zero (p<.05).

- Statistic could not be calculated. Trend based on less than 10 cases for at least one year within the time interval.

Table 1.9 - continued
SEER Incidence and U.S. Mortality Trends by Primary Cancer Site and Sex
Blacks, 2009-2018

Site	Incidence ^a			US Mortality ^b		
	Total APC	Males APC	Females APC	Total APC	Males APC	Females APC
Female Genital System:	0.3	-	0.5*	-0.6*	-	-0.4
Cervix uteri	-1.7*	-	-1.5*	-3.1*	-	-3.0*
Corpus uteri	1.5*	-	1.6*	5.3*	-	5.5*
Uterus, NOS	2.2*	-	2.3*	-0.9	-	-0.6
Ovary ^c	-2.0*	-	-1.7*	-2.4*	-	-2.2*
Vagina	-0.9	-	-0.6	-2.3	-	-2.0
Vulva	-0.8	-	-0.7	-0.4	-	-0.3
Other female genital system	8.5*	-	8.6*	6.4*	-	6.7*
Male Genital System:	-3.4*	-3.7*	-	-2.6*	-3.3*	-
Prostate	-3.5*	-3.7*	-	-2.7*	-3.3*	-
Testis	2.1*	2.0	-	3.1	3.1	-
Penis	-0.3	-0.8	-	-2.6	-3.1	-
Other male genital system	0.7	-0.1	-	-	-	-
Urinary System:	-0.6	-0.9*	-0.4	-1.2*	-0.7*	-1.9*
Urinary bladder	-1.2*	-1.6*	-1.1*	-0.8*	-0.6	-1.3*
Kidney & renal pelvis	-0.2	-0.3	-0.1	-1.6*	-1.1	-2.6*
Ureter	-0.3	-3.4	2.5	-3.6	-	-
Other urinary system	0.5	-1.6	1.6	3.7	-	-0.6
Eye & Orbit	-1.3	-1.3	-1.7	-	-	-
Brain & Nervous System: ^d	-1.2*	-0.5	-2.0*	0.7	0.4	1.0
Brain	-1.0	-0.3	-1.8*	-	-	-
Cranial nerves & other nervous system	-2.8	-1.9	-3.3	-	-	-
Endocrine System:	0.0	-0.4	0.1	-1.1	-0.6	-1.5
Thyroid	0.0	-0.2	0.1	-1.6	-0.1	-2.3
Other endocrine & thymus	0.2	-0.9	1.0	-0.5	-1.1	0.0
Lymphoma:	-0.8*	-1.2*	-0.4	-2.2*	-2.2*	-2.4*
Hodgkin lymphoma	-1.3*	-1.9	-0.7	-5.3*	-4.6*	-5.7*
Non-Hodgkin lymphoma	-0.7*	-1.0*	-0.3	-2.0*	-2.0*	-2.1*
Myeloma	-0.1	-0.4	0.0	-0.8	-0.7*	-1.0
Leukemia:	-0.2	-0.5	0.0	-1.8*	-2.2*	-1.4*
Lymphocytic:	-1.7	-1.8	-1.5	-2.6*	-3.8*	-0.9
Acute lymphocytic	0.0	-0.8	1.0	1.0	-0.9	3.0
Chronic lymphocytic	-2.0	-1.6	-2.6	-3.8*	-4.6*	-2.6*
Other lymphocytic	-3.9*	-8.4*	3.1	0.7	-	2.7
Myeloid & Monocytic:	1.2	0.9	1.3	0.6	0.4	0.8
Acute myeloid	1.7*	1.2	2.0*	0.5	0.1	0.9
Chronic myeloid	0.8	1.0	0.5	-0.9	-1.5	-0.8
Acute monocytic	-2.6	-0.1	-5.0	-	-	-
Other myeloid & monocytic	-3.3	-5.1	-0.9	3.8*	6.2*	1.5
Other leukemia:	-1.3	-1.6	-0.9	-5.5*	-5.1*	-6.2*
Other acute leukemia	0.1	0.2	1.2	-7.3*	-8.0*	-6.7*
Aleukemic, subleukemic & NOS	-1.4	-2.1	-0.8	-4.7*	-4.0*	-5.9*
Kaposi Sarcoma ^e	-3.5*	-3.6*	-3.2	-	-	-
Mesothelioma ^e	-2.6	-3.1	-1.6	-	-	-
Ill-defined & unspecified	-2.2*	-2.4*	-2.1*	-2.1*	-2.6*	-1.6*

The APC is the Annual Percent Change over the time interval.

Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

- ^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
- ^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.
- ^c Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.
- ^d Due to coding changes, Brain & Nervous System mortality are no longer shown separately.
- ^e Trend not shown for mortality. Category did not exist in mortality coding until 1999.
- * The APC is significantly different from zero (p<.05).
- Statistic could not be calculated. Trend based on less than 10 cases for at least one year within the time interval.

Table 1.10

Age Distribution (%) of Incidence Cases by Site, 2014-2018

All Races, Both Sexes

Site	Age at Diagnosis								All Ages	Cases
	<20	20-34	35-44	45-54	55-64	65-74	75-84	85+		
All Sites	1.0	2.8	4.7	12.0	24.3	28.7	18.5	8.1	100.0%	3,038,750
Oral Cavity & Pharynx:	0.4	1.9	4.0	15.6	30.9	26.7	14.2	6.3	100.0%	79,238
Lip	0.1	1.3	2.9	11.9	22.6	25.9	21.7	13.6	100.0%	4,042
Tongue	0.1	1.7	3.7	15.1	32.8	28.6	13.5	4.6	100.0%	24,936
Salivary gland	1.6	6.2	6.6	12.5	19.1	23.9	18.5	11.6	100.0%	8,627
Floor of mouth	0.1	0.3	1.8	14.8	35.4	28.3	14.2	5.0	100.0%	3,143
Gum & other oral cavity	0.6	1.9	3.3	11.1	23.3	26.6	20.8	12.4	100.0%	10,500
Nasopharynx	2.2	5.9	11.5	21.7	28.5	19.2	8.2	2.8	100.0%	4,046
Tonsil	0.0	0.3	3.4	22.3	39.6	25.1	7.7	1.6	100.0%	14,703
Oropharynx	0.0	0.4	2.1	15.3	37.6	29.3	11.8	3.6	100.0%	3,734
Hypopharynx	0.0	0.3	1.5	11.6	33.0	31.5	16.9	5.3	100.0%	3,789
Other oral cavity & pharynx	0.2	0.3	2.4	12.6	31.7	30.4	14.3	8.1	100.0%	1,718
Digestive System:	0.3	1.4	3.5	12.1	24.1	27.5	20.4	10.6	100.0%	547,425
Esophagus	0.0	0.4	1.8	9.0	26.5	32.6	21.0	8.8	100.0%	29,446
Stomach	0.1	1.6	4.6	11.1	22.3	27.2	22.1	11.0	100.0%	48,492
Small intestine	0.1	1.7	5.1	13.8	24.5	29.0	18.9	6.8	100.0%	16,412
Colon & Rectum:	0.3	1.9	4.6	15.1	22.4	24.8	19.6	11.2	100.0%	253,218
Colon	0.4	1.9	4.1	12.7	20.4	25.5	21.9	13.2	100.0%	176,989
Rectum	0.0	1.9	5.9	20.7	27.2	23.3	14.3	6.7	100.0%	76,229
Colon & Rectum (Male)	0.3	1.7	4.6	15.8	24.8	26.2	18.3	8.3	100.0%	132,227
Colon & Rectum (Female)	0.4	2.0	4.6	14.4	19.9	23.3	21.0	14.4	100.0%	120,991
Anus, anal canal & anorectum	0.0	1.1	4.4	17.9	32.2	25.0	13.2	6.2	100.0%	13,481
Liver & intrahepatic bile duct	0.7	0.7	1.7	8.9	33.9	31.1	16.6	6.4	100.0%	64,281
Gallbladder	0.0	0.5	2.2	8.6	20.7	29.3	25.3	13.4	100.0%	8,153
Other biliary	0.0	0.6	2.0	7.8	20.6	29.3	26.2	13.4	100.0%	12,408
Pancreas	0.1	0.6	1.8	7.8	21.7	30.6	24.4	12.9	100.0%	90,391
Retroperitoneum	7.7	4.2	6.0	14.6	22.7	25.1	14.1	5.5	100.0%	2,568
Peritoneum, omentum & mesentery	0.3	0.9	2.4	8.9	23.0	35.2	21.4	7.9	100.0%	3,220
Other digestive system	0.1	0.8	2.2	8.0	20.6	27.3	25.4	15.5	100.0%	5,355
Respiratory System:	0.1	0.3	1.0	6.5	22.4	34.1	26.0	9.5	100.0%	387,972
Nose, nasal cavity & middle ear	1.4	3.8	6.4	13.1	24.5	25.1	16.7	9.1	100.0%	4,514
Larynx	0.0	0.4	1.8	12.0	31.7	31.2	17.1	5.8	100.0%	19,557
Lung & bronchus	0.0	0.2	0.9	6.1	21.9	34.4	26.6	9.7	100.0%	362,632
Lung & bronchus (Male)	0.0	0.2	0.8	5.8	22.6	35.1	26.5	8.9	100.0%	182,725
Lung & bronchus (Female)	0.0	0.2	1.0	6.5	21.2	33.6	26.8	10.6	100.0%	179,907
Pleura	5.2	1.3	1.9	7.1	14.8	23.9	29.0	16.8	100.0%	155
Trachea & other respiratory organs	14.4	20.8	8.3	9.2	15.1	16.1	11.7	4.5	100.0%	1,114
Bones & joints	25.1	15.0	9.1	11.2	13.8	13.2	8.1	4.5	100.0%	6,025
Soft tissue (including heart)	7.5	9.3	8.0	12.7	19.0	20.3	15.1	8.0	100.0%	22,423
Skin (excl. basal & squamous):	0.4	4.9	6.8	13.0	22.1	25.2	18.3	9.5	100.0%	164,223
Melanoma of the skin	0.4	4.9	6.9	13.4	22.7	25.3	17.7	8.8	100.0%	150,938
Other non-epithelial skin	1.2	4.5	5.2	7.9	15.0	23.5	24.9	17.8	100.0%	13,285
Breast (Female)	0.0	1.9	8.2	19.2	25.6	26.0	13.7	5.4	100.0%	454,865
Breast (Female -in situ)	0.0	0.8	9.2	25.7	27.8	25.1	9.7	1.7	100.0%	112,506

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
 Percents may not sum to 100 due to rounding.

Table 1.10 - continued

Age Distribution (%) of Incidence Cases by Site, 2014-2018

All Races, Both Sexes

Site	Age at Diagnosis								All Ages	Cases
	<20	20-34	35-44	45-54	55-64	65-74	75-84	85+		
Female Genital System:	0.3	3.7	7.4	16.0	28.8	25.8	12.7	5.3	100.0%	184,845
Cervix uteri	0.1	13.7	22.8	22.4	19.7	12.2	6.4	2.6	100.0%	23,195
Corpus uteri	0.0	1.5	4.9	14.9	33.9	29.6	11.7	3.5	100.0%	100,976
Uterus, NOS	0.2	1.7	5.2	14.9	22.4	25.1	17.0	13.4	100.0%	3,282
Ovary ^a	1.3	4.1	6.6	16.6	24.7	23.7	15.3	7.6	100.0%	38,769
Vagina	1.0	1.1	4.4	12.1	22.3	26.4	20.8	12.0	100.0%	2,431
Vulva	0.1	1.6	4.5	13.3	20.1	24.4	21.1	14.9	100.0%	9,383
Other female genital system	0.3	2.9	3.4	11.9	25.2	30.7	17.7	7.9	100.0%	6,809
Male Genital System:	0.2	2.3	1.4	7.9	30.8	38.6	14.9	3.9	100.0%	388,910
Prostate	0.0	0.0	0.3	7.7	32.0	40.5	15.5	4.0	100.0%	368,221
Testis	4.8	50.9	23.6	12.0	5.9	1.9	0.6	0.2	100.0%	17,240
Penis	0.0	1.3	4.7	12.2	20.1	26.3	22.5	12.9	100.0%	2,683
Other male genital system	2.0	2.9	3.5	12.5	22.3	28.9	21.0	6.9	100.0%	766
Urinary System:	0.5	1.1	3.2	9.6	21.9	29.9	23.0	10.9	100.0%	250,038
Urinary bladder	0.0	0.4	1.2	5.5	18.0	31.1	28.6	15.1	100.0%	132,816
Kidney & renal pelvis	1.0	1.8	5.7	14.8	26.9	28.4	15.9	5.5	100.0%	110,924
Ureter	0.1	0.1	0.5	3.2	14.0	30.3	34.5	17.3	100.0%	3,554
Other urinary system	0.0	0.4	1.2	5.2	17.0	29.0	30.0	17.1	100.0%	2,744
Eye & Orbit	10.1	3.9	5.5	12.6	23.2	24.0	14.7	6.0	100.0%	5,558
Brain & Nervous System:	11.9	8.6	7.5	12.4	20.6	20.8	13.1	5.1	100.0%	40,725
Brain	10.9	8.5	7.4	12.3	20.9	21.3	13.4	5.2	100.0%	38,253
Cranial nerves & other nervous system	26.3	10.9	9.8	13.2	16.0	12.9	7.4	3.4	100.0%	2,472
Endocrine System:	2.8	15.6	17.6	21.1	21.3	14.6	5.7	1.3	100.0%	101,081
Thyroid	1.9	16.1	18.1	21.6	21.3	14.4	5.4	1.2	100.0%	95,873
Other endocrine & thymus	18.5	7.0	7.5	12.8	21.0	19.6	10.5	3.2	100.0%	5,208
Lymphoma:	2.7	6.5	5.8	11.3	20.4	25.2	19.5	8.7	100.0%	145,717
Hodgkin lymphoma	12.2	30.7	13.4	12.2	12.3	10.8	6.4	2.0	100.0%	15,765
Non-Hodgkin lymphoma	1.6	3.6	4.9	11.1	21.3	26.9	21.0	9.5	100.0%	129,952
Myeloma	0.0	0.4	2.7	10.3	22.7	31.2	23.4	9.2	100.0%	47,966
Leukemia:	7.7	4.3	4.2	9.2	18.3	24.8	20.6	10.8	100.0%	93,243
Lymphocytic:	11.7	2.7	2.9	8.5	19.7	25.3	19.0	10.2	100.0%	46,345
Acute lymphocytic	53.5	11.0	5.9	7.0	8.9	7.7	4.3	1.7	100.0%	10,054
Chronic lymphocytic	0.0	0.3	1.5	8.3	22.6	30.8	23.7	12.7	100.0%	33,669
Other lymphocytic	0.9	1.8	8.7	17.1	23.3	23.3	15.4	9.5	100.0%	2,622
Myeloid & Monocytic:	3.7	6.1	5.7	9.9	17.3	24.6	22.1	10.6	100.0%	42,245
Acute myeloid	4.4	5.5	4.9	8.9	16.8	25.8	22.9	10.9	100.0%	27,720
Chronic myeloid	2.1	7.6	7.5	12.5	18.5	22.0	19.9	9.8	100.0%	12,450
Acute monocytic	5.5	5.1	5.5	9.4	17.1	23.6	23.4	10.3	100.0%	1,178
Other myeloid & monocytic	4.1	5.8	4.7	7.7	15.8	23.5	24.0	14.4	100.0%	897
Other leukemia:	3.9	4.3	4.5	8.7	14.9	21.4	22.4	19.8	100.0%	4,653
Other acute leukemia	9.1	6.5	3.6	6.4	10.4	18.4	22.8	22.7	100.0%	1,328
Aleukemic, subleukemic & NOS	1.9	3.5	4.8	9.6	16.8	22.6	22.2	18.7	100.0%	3,325
Kaposi Sarcoma	0.1	21.6	16.7	19.5	14.7	10.3	10.2	6.9	100.0%	2,832
Mesothelioma	0.0	1.0	2.1	5.1	13.4	29.6	32.3	16.5	100.0%	5,603
Ill-defined & unspecified	1.2	1.7	2.7	6.9	16.3	25.3	26.6	19.3	100.0%	106,210

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Percents may not sum to 100 due to rounding.

^a Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Table 1.11
Median Age of Cancer Patients at Diagnosis^a, 2014-2018
By Primary Cancer Site, Race and Sex

Site	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	66.0	67.0	65.0	67.0	68.0	66.0	64.0	64.0	63.0
Oral Cavity & Pharynx:	64.0	63.0	65.0	64.0	64.0	66.0	61.0	61.0	60.0
Lip	69.0	68.0	70.0	69.0	69.0	71.0	57.0	59.0	54.0
Tongue	64.0	63.0	64.0	64.0	63.0	65.0	61.0	62.0	61.0
Salivary gland	66.0	68.0	63.0	68.0	70.0	65.0	58.0	58.0	58.0
Floor of mouth	64.0	63.0	65.0	64.0	64.0	66.0	62.0	62.0	61.0
Gum & other oral cavity	68.0	66.0	71.0	69.0	67.0	72.0	62.0	62.0	64.0
Nasopharynx	58.0	58.0	58.0	61.0	60.0	61.0	56.0	56.0	56.0
Tonsil	60.0	60.0	62.0	61.0	60.0	62.0	60.0	60.0	60.0
Oropharynx	63.0	63.0	64.0	63.0	63.0	64.0	62.0	62.0	61.5
Hypopharynx	65.0	66.0	64.0	66.0	66.0	66.0	63.0	63.0	61.0
Other oral cavity & pharynx	65.0	65.0	67.0	66.0	65.0	69.0	63.0	64.0	60.0
Digestive System:	67.0	66.0	69.0	68.0	67.0	70.0	64.0	64.0	65.0
Esophagus	68.0	68.0	71.0	69.0	68.0	72.0	65.0	65.0	66.0
Stomach	68.0	68.0	69.0	69.0	69.0	69.0	67.0	66.0	67.0
Small intestine	66.0	66.0	66.0	67.0	66.0	67.0	64.0	64.0	64.0
Colon & Rectum:	67.0	65.0	68.0	68.0	66.0	69.0	63.0	63.0	64.0
Colon	69.0	67.0	70.0	70.0	68.0	71.0	65.0	64.0	66.0
Rectum	62.0	62.0	63.0	63.0	63.0	63.0	60.0	60.0	60.0
Anus, anal canal & anorectum	63.0	61.0	64.0	63.0	63.0	64.0	57.0	54.0	61.0
Liver & intrahepatic bile duct	65.0	65.0	68.0	66.0	65.0	69.0	64.0	63.0	65.0
Gallbladder	71.0	70.0	71.0	72.0	71.0	72.0	67.0	68.0	67.0
Other biliary	71.0	70.0	72.0	72.0	71.0	73.0	67.0	67.0	68.0
Pancreas	70.0	69.0	72.0	71.0	69.0	72.0	67.0	66.0	69.0
Retroperitoneum	62.0	62.0	62.0	64.0	63.0	64.0	59.0	59.5	59.0
Peritoneum, omentum & mesentery	68.0	67.0	69.0	69.0	69.0	69.0	66.0	62.0	67.0
Other digestive system	71.0	70.0	72.0	72.0	71.0	73.0	66.0	66.0	67.0
Respiratory System:	70.0	70.0	71.0	71.0	70.0	71.0	67.0	67.0	68.0
Nose, nasal cavity & middle ear	65.0	64.0	66.0	66.0	65.0	67.0	59.0	58.0	61.0
Larynx	66.0	66.0	64.0	66.0	66.0	65.0	64.0	64.0	63.0
Lung & bronchus	71.0	70.0	71.0	71.0	71.0	71.0	67.0	67.0	68.0
Pleura	73.0	74.0	72.0	74.0	76.0	73.0	-	-	-
Trachea & other respiratory organs	53.0	44.0	62.0	54.0	47.0	63.0	52.0	48.0	58.0
Bones & joints	46.0	44.0	47.0	48.0	47.0	49.0	35.0	34.5	36.0
Soft tissue (including heart)	61.0	62.0	60.0	63.0	64.0	62.0	55.0	54.0	56.0
Skin (excl. basal & squamous):	66.0	68.0	62.0	66.0	68.0	62.0	59.0	59.0	59.0
Melanoma of the skin	65.0	67.0	61.0	65.0	68.0	62.0	64.0	65.0	64.0
Other non-epithelial skin	72.0	73.0	69.0	73.0	74.0	72.0	54.0	53.0	54.0
Breast	63.0	68.0	63.0	64.0	69.0	64.0	60.0	64.0	60.0
Breast (<i>in situ</i>)	60.0	63.0	60.0	60.0	64.0	60.0	60.0	62.0	60.0

^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
- Statistic could not be calculated. Less than 16 cases were diagnosed during the time interval.

Table 1.11 - continued
Median Age of Cancer Patients at Diagnosis^a, 2014-2018
By Primary Cancer Site, Race and Sex

Site	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	62.0	-	62.0	63.0	-	63.0	62.0	-	62.0
Cervix uteri	50.0	-	50.0	50.0	-	50.0	53.0	-	53.0
Corpus uteri	63.0	-	63.0	63.0	-	63.0	64.0	-	64.0
Uterus, NOS	66.0	-	66.0	67.0	-	67.0	65.0	-	65.0
Ovary ^b	63.0	-	63.0	64.0	-	64.0	61.0	-	61.0
Vagina	68.0	-	68.0	69.0	-	69.0	65.0	-	65.0
Vulva	69.0	-	69.0	70.0	-	70.0	60.0	-	60.0
Other female genital system	66.0	-	66.0	67.0	-	67.0	63.0	-	63.0
Male Genital System:	66.0	66.0	-	67.0	67.0	-	64.0	64.0	-
Prostate	67.0	67.0	-	67.0	67.0	-	64.0	64.0	-
Testis	33.0	33.0	-	33.0	33.0	-	35.0	35.0	-
Penis	69.0	69.0	-	70.0	70.0	-	65.0	65.0	-
Other male genital system	67.0	67.0	-	68.0	68.0	-	57.0	57.0	-
Urinary System:	69.0	69.0	69.0	70.0	70.0	69.0	65.0	64.0	66.0
Urinary bladder	73.0	72.0	73.0	73.0	73.0	73.0	70.0	69.0	72.0
Kidney & renal pelvis	64.0	64.0	65.0	65.0	65.0	66.0	62.0	61.0	63.5
Ureter	75.0	75.0	76.0	75.0	75.0	76.0	71.5	68.0	72.0
Other urinary system	73.5	74.0	73.0	74.0	74.0	75.0	67.0	66.0	69.0
Eye & Orbit	62.0	62.0	62.0	63.0	63.0	63.0	46.0	49.0	41.0
Brain & Nervous System:	59.0	59.0	60.0	60.0	60.0	61.0	53.0	52.0	54.0
Brain	60.0	60.0	61.0	61.0	61.0	61.0	53.0	53.0	54.5
Cranial nerves & other nervous system	47.0	46.0	48.0	47.0	46.0	49.0	45.0	46.5	42.0
Endocrine System:	51.0	55.0	50.0	52.0	56.0	50.0	53.0	56.0	52.0
Thyroid	51.0	55.0	50.0	52.0	56.0	50.0	53.0	56.0	52.0
Other endocrine & thymus	57.0	55.0	59.0	58.0	56.0	59.0	56.0	52.0	59.0
Lymphoma:	66.0	65.0	67.0	67.0	66.0	68.0	58.0	57.0	60.0
Hodgkin lymphoma	39.0	42.0	37.0	40.0	43.0	38.0	39.0	40.0	38.0
Non-Hodgkin lymphoma	67.0	67.0	68.0	68.0	67.0	69.0	60.0	59.0	62.0
Myeloma	69.0	69.0	69.0	70.0	69.0	70.0	66.0	66.0	67.0
Leukemia:	67.0	67.0	67.0	68.0	68.0	68.0	62.0	62.0	63.0
Lymphocytic:	66.0	66.0	67.0	67.0	66.0	68.0	64.0	63.0	64.0
Acute lymphocytic	17.0	17.0	17.0	17.0	17.0	17.0	16.0	16.0	16.0
Chronic lymphocytic	70.0	69.0	71.0	70.0	70.0	72.0	67.0	66.0	68.0
Other lymphocytic	64.0	63.0	68.0	64.0	63.0	68.0	66.0	60.5	69.0
Myeloid & Monocytic:	68.0	68.0	67.0	69.0	69.0	68.0	61.0	61.0	62.0
Acute myeloid	68.0	69.0	68.0	69.0	70.0	69.0	62.0	62.0	62.0
Chronic myeloid	65.0	65.0	65.0	67.0	66.0	67.0	59.0	58.0	60.0
Acute monocytic	68.0	70.0	65.0	69.0	70.0	66.0	62.0	65.0	56.5
Other myeloid & monocytic	70.0	70.0	70.0	71.0	71.0	71.0	64.0	63.0	67.0
Other leukemia:	71.0	70.0	71.0	73.0	72.0	73.0	63.0	63.0	64.0
Other acute leukemia	72.0	70.0	75.0	74.0	72.0	76.0	64.0	64.0	64.0
Aleukemic, subleukemic & NOS	70.0	71.0	70.0	72.0	73.0	72.0	63.0	63.0	63.0
Kaposi Sarcoma	50.0	48.0	76.0	55.0	53.0	79.0	38.0	37.0	46.0
Mesothelioma	74.0	75.0	72.0	75.0	75.0	72.0	70.0	72.0	66.0
Ill-defined & unspecified	73.0	72.0	74.0	74.0	73.0	75.0	68.0	67.0	69.0

^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^b Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

- Statistic could not be calculated. Less than 16 cases were diagnosed during the time interval.

Table 1.12
Age Distribution (%) of Deaths by Site, 2014-2018
All Races, Both Sexes

Site	Age at Death								All Ages	Deaths
	<20	20-34	35-44	45-54	55-64	65-74	75-84	85+		
All Sites	0.3	0.8	1.8	6.9	19.3	27.7	26.0	17.2	100.0%	2,984,000
Oral Cavity & Pharynx:	0.1	0.7	1.8	10.1	26.8	28.1	19.6	12.9	100.0%	49,612
Lip	0.3	0.3	1.1	5.9	15.6	20.2	24.8	31.8	100.0%	371
Tongue	0.0	1.1	2.2	10.0	26.9	28.9	19.5	11.4	100.0%	12,921
Salivary gland	0.0	1.1	2.3	6.9	16.7	23.9	24.7	24.3	100.0%	4,955
Floor of mouth	0.0	0.0	1.1	13.0	29.1	28.0	18.0	10.9	100.0%	440
Gum & other oral cavity	0.1	0.5	1.3	7.3	20.7	25.6	22.4	22.2	100.0%	7,087
Nasopharynx	0.6	2.4	5.2	14.3	29.4	24.8	15.9	7.3	100.0%	3,528
Tonsil	0.0	0.1	1.5	14.6	34.4	30.5	13.7	5.2	100.0%	5,147
Oropharynx	0.0	0.3	1.2	11.0	31.1	29.4	17.8	9.1	100.0%	5,606
Hypopharynx	0.0	0.3	0.9	10.7	29.0	31.1	20.3	7.5	100.0%	1,921
Other oral cavity & pharynx	0.1	0.1	1.0	9.2	29.0	29.9	20.2	10.5	100.0%	7,636
Digestive System:	0.0	0.5	1.9	7.9	21.7	27.6	24.2	16.1	100.0%	785,689
Esophagus	0.0	0.3	1.4	7.8	24.9	31.7	22.7	11.2	100.0%	76,345
Stomach	0.0	1.3	3.7	9.6	19.4	24.5	24.4	16.9	100.0%	56,275
Small intestine	0.0	0.7	2.3	7.6	18.9	27.5	27.2	15.8	100.0%	7,754
Colon & Rectum:	0.0	0.7	2.7	9.3	19.1	23.9	23.7	20.6	100.0%	261,043
Colon & Rectum (Male)	0.0	0.8	2.8	10.1	21.6	26.1	23.3	15.4	100.0%	138,045
Colon & Rectum (Female)	0.0	0.7	2.5	8.3	16.4	21.4	24.3	26.4	100.0%	122,998
Anus, anal canal & anorectum	0.0	0.8	3.6	13.4	27.3	25.1	17.9	11.9	100.0%	5,438
Liver & intrahepatic bile duct	0.2	0.4	1.3	7.3	29.7	29.9	21.0	10.3	100.0%	131,816
Gallbladder	0.0	0.2	1.6	6.4	17.4	28.6	28.4	17.4	100.0%	10,945
Other biliary	0.0	0.3	1.5	5.1	17.3	27.3	28.2	20.3	100.0%	8,814
Pancreas	0.0	0.2	1.0	6.2	19.9	30.1	26.9	15.7	100.0%	213,715
Retroperitoneum	0.7	1.5	2.5	8.8	20.1	27.0	24.7	14.7	100.0%	1,376
Peritoneum, omentum & mesentery	0.1	0.4	1.9	6.1	17.7	29.3	28.6	15.9	100.0%	5,020
Other digestive system	0.0	0.6	1.7	6.8	18.3	26.4	26.3	19.8	100.0%	7,148
Respiratory System:	0.0	0.1	0.6	5.4	20.5	32.3	28.2	12.9	100.0%	770,417
Nose, nasal cavity & middle ear	0.5	2.1	4.5	10.7	21.2	24.3	20.3	16.5	100.0%	2,626
Larynx	0.0	0.1	0.7	8.1	28.1	31.7	21.1	10.2	100.0%	18,871
Lung & bronchus	0.0	0.1	0.6	5.3	20.3	32.4	28.3	12.9	100.0%	746,042
Lung & bronchus (Male)	0.0	0.1	0.6	5.2	21.3	33.6	27.8	11.4	100.0%	404,206
Lung & bronchus (Female)	0.0	0.1	0.6	5.5	19.2	30.9	29.0	14.7	100.0%	341,836
Pleura	0.1	0.1	0.6	2.5	10.1	27.8	38.0	20.8	100.0%	1,527
Trachea & other respiratory organs	1.1	3.4	3.1	7.9	21.1	27.2	22.1	14.1	100.0%	1,351
Bones & joints	11.4	12.0	5.1	7.9	13.9	18.2	16.9	14.6	100.0%	8,295
Soft tissue (including heart)	3.4	5.5	5.9	11.2	20.2	22.8	19.5	11.5	100.0%	24,377
Skin (excl. basal & squamous):	0.1	1.3	3.1	8.0	17.7	23.8	24.4	21.7	100.0%	62,610
Melanoma of the skin	0.1	1.7	4.0	9.3	18.9	24.6	23.9	17.5	100.0%	42,652
Other non-epithelial skin	0.0	0.5	1.0	5.2	15.1	22.0	25.3	30.8	100.0%	19,958
Breast (Female)	0.0	1.0	4.5	12.0	21.5	23.8	20.0	17.3	100.0%	208,686

Source: US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.
Percents may not sum to 100 due to rounding.

Table 1.12 - continued
Age Distribution (%) of Deaths by Site, 2014-2018
All Races, Both Sexes

Site	Age at Death								All Ages	Deaths
	<20	20-34	35-44	45-54	55-64	65-74	75-84	85+		
Female Genital System:	0.0	1.2	3.5	9.8	21.8	28.3	22.1	13.1	100.0%	155,955
Cervix uteri	0.0	5.4	13.2	21.5	23.9	18.6	11.2	6.3	100.0%	20,823
Corpus uteri	0.0	0.4	1.6	6.4	22.9	34.5	22.8	11.5	100.0%	26,298
Uterus, NOS	0.0	0.4	1.9	7.6	22.7	31.3	22.1	14.0	100.0%	26,490
Ovary	0.1	0.8	2.2	9.0	21.4	28.4	24.4	13.7	100.0%	70,279
Vagina	0.0	0.5	2.0	6.5	16.1	23.5	26.1	25.2	100.0%	2,057
Vulva	0.0	0.4	1.4	6.2	14.2	21.2	27.0	29.7	100.0%	6,011
Other female genital system	0.1	1.1	1.6	8.9	20.7	29.7	25.2	12.8	100.0%	3,997
Male Genital System:	0.0	0.5	0.4	1.6	9.4	22.9	32.8	32.4	100.0%	153,554
Prostate	0.0	0.0	0.1	1.4	9.3	23.0	33.3	33.0	100.0%	149,535
Testis	1.9	35.2	18.9	15.7	12.2	8.4	4.3	3.5	100.0%	2,042
Penis	0.0	1.2	3.6	9.6	17.2	24.4	25.0	19.1	100.0%	1,626
Other male genital system	0.0	0.6	1.7	7.4	13.1	31.3	26.5	19.4	100.0%	351
Urinary System:	0.1	0.3	1.0	4.8	15.2	25.0	28.7	24.8	100.0%	156,710
Urinary bladder	0.0	0.1	0.5	2.9	11.0	22.3	31.6	31.6	100.0%	81,973
Kidney & renal pelvis	0.3	0.6	1.6	7.2	20.3	28.3	25.1	16.6	100.0%	70,300
Ureter	0.0	0.0	0.3	1.6	8.9	22.9	36.1	30.2	100.0%	2,066
Other urinary system	0.0	0.3	1.2	3.5	12.3	24.0	32.5	26.2	100.0%	2,371
Eye & Orbit	2.3	1.5	2.7	8.2	21.2	27.6	21.2	15.2	100.0%	1,686
Brain & Nervous System:	3.2	3.2	5.0	11.5	23.7	27.0	18.5	7.8	100.0%	83,029
Endocrine System:	4.6	2.0	3.2	8.5	18.4	24.5	23.4	15.3	100.0%	14,823
Thyroid	0.1	0.7	1.9	7.0	17.5	26.4	27.5	19.0	100.0%	9,685
Other endocrine & thymus	13.1	4.6	5.7	11.3	20.2	21.0	15.6	8.4	100.0%	5,138
Lymphoma:	0.3	1.5	1.8	5.1	13.7	24.4	30.5	22.8	100.0%	106,799
Hodgkin lymphoma	0.9	8.1	5.3	10.0	15.4	22.7	23.5	14.2	100.0%	5,244
Non-Hodgkin lymphoma	0.3	1.1	1.7	4.8	13.6	24.5	30.8	23.2	100.0%	101,555
Myeloma	0.0	0.1	0.7	4.6	14.9	28.2	32.2	19.3	100.0%	61,257
Leukemia:	2.0	2.5	2.3	5.0	12.3	23.7	29.8	22.4	100.0%	116,728
Lymphocytic:	3.3	3.4	2.2	3.9	9.6	18.5	28.1	30.9	100.0%	31,274
Acute lymphocytic	13.2	13.7	8.1	10.4	15.0	16.6	14.3	8.7	100.0%	7,652
Chronic lymphocytic	0.0	0.1	0.3	1.6	7.6	19.0	32.7	38.7	100.0%	21,478
Other lymphocytic	0.6	0.9	1.4	3.7	10.0	20.7	30.7	32.0	100.0%	2,144
Myeloid & Monocytic:	1.5	2.2	2.5	5.8	14.3	27.2	30.1	16.3	100.0%	62,582
Acute myeloid	1.7	2.3	2.5	5.9	14.9	28.3	29.7	14.5	100.0%	51,689
Chronic myeloid	0.3	2.5	3.6	6.4	11.8	18.4	30.4	26.7	100.0%	5,653
Acute monocytic	1.4	1.6	1.4	4.8	13.5	22.8	31.7	22.6	100.0%	495
Other myeloid & monocytic	0.5	0.9	1.5	3.5	10.1	26.3	34.3	22.9	100.0%	4,745
Other leukemia:	1.9	2.0	1.8	4.4	10.3	21.2	31.3	27.1	100.0%	22,872
Other acute leukemia	1.3	2.3	2.0	4.5	9.6	21.7	32.0	26.6	100.0%	7,363
Aleukemic, subleukemic & NOS	2.1	1.9	1.7	4.3	10.7	21.0	30.9	27.3	100.0%	15,509
Ill-defined & unspecified	0.2	0.7	1.5	6.0	17.8	26.1	26.7	21.0	100.0%	221,387

Source: US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.
Percents may not sum to 100 due to rounding.

Table 1.13
Median Age of Cancer Patients at Death^a, 2014-2018
By Primary Cancer Site, Race and Sex

Site	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	72.0	72.0	73.0	73.0	72.0	73.0	68.0	68.0	68.0
Oral Cavity & Pharynx:	68.0	67.0	72.0	69.0	67.0	73.0	64.0	63.0	65.0
Lip	77.0	74.0	85.0	78.0	75.0	85.0	-	-	-
Tongue	68.0	66.0	71.0	68.0	67.0	71.0	63.0	63.0	64.0
Salivary gland	74.0	74.0	74.0	75.0	75.0	75.0	65.0	65.0	67.0
Floor of mouth	66.5	65.0	72.0	67.0	65.0	72.5	65.0	65.0	-
Gum & other oral cavity	72.0	68.0	79.0	73.0	69.0	80.0	66.0	64.5	70.0
Nasopharynx	64.0	63.0	66.0	66.0	65.0	69.0	61.0	61.0	64.0
Tonsil	64.0	64.0	67.0	65.0	64.0	68.0	62.0	62.0	61.0
Oropharynx	67.0	66.0	71.0	67.0	66.0	72.0	63.0	63.0	64.0
Hypopharynx	67.0	67.0	67.5	68.0	68.0	69.0	64.0	65.0	60.0
Other oral cavity & pharynx	68.0	67.0	70.0	68.0	68.0	71.0	65.0	64.0	65.0
Digestive System:	71.0	69.0	74.0	72.0	70.0	75.0	67.0	65.0	69.0
Esophagus	69.0	69.0	73.0	70.0	69.0	74.0	66.0	65.0	66.0
Stomach	71.0	70.0	73.0	72.0	70.0	74.0	69.0	68.0	72.0
Small intestine	72.0	71.0	73.0	73.0	72.0	74.0	67.0	67.0	67.0
Colon & Rectum	72.0	70.0	75.0	73.0	71.0	76.0	67.0	66.0	69.0
Anus, anal canal & anorectum	66.0	65.0	67.0	67.0	66.0	68.0	61.0	58.0	64.0
Liver & intrahepatic bile duct	68.0	66.0	72.0	69.0	67.0	73.0	64.0	64.0	67.0
Gallbladder	73.0	72.0	73.0	74.0	73.0	74.0	69.0	70.0	69.0
Other biliary	74.0	73.0	75.0	75.0	73.0	76.0	69.0	68.0	71.0
Pancreas	72.0	70.0	74.0	73.0	71.0	75.0	68.0	67.0	70.0
Retroperitoneum	70.0	70.0	71.0	71.0	70.0	72.0	69.0	68.0	70.0
Peritoneum, omentum & mesentery	73.0	69.0	74.0	73.0	70.0	74.0	69.0	65.0	70.0
Other digestive system	73.0	71.0	76.0	74.0	71.0	77.0	69.0	68.0	71.0
Respiratory System:	72.0	71.0	73.0	72.0	72.0	73.0	68.0	68.0	69.0
Nose, nasal cavity & middle ear	69.0	67.0	73.0	70.0	68.0	74.0	64.0	62.0	66.0
Larynx	68.0	68.0	69.0	69.0	69.0	69.0	66.0	66.0	67.0
Lung & bronchus	72.0	71.0	73.0	72.0	72.0	73.0	69.0	68.0	70.0
Pleura	77.0	77.0	78.0	77.0	77.0	78.0	70.0	72.0	69.0
Trachea & other respiratory organs	70.0	67.0	73.0	70.0	67.0	74.0	65.0	65.0	69.5
Bones & joints	64.0	62.0	67.0	65.0	63.0	68.0	58.0	57.0	58.0
Soft tissue (including heart)	66.0	67.0	66.0	68.0	68.0	67.0	59.0	58.0	60.0
Skin (excl. basal & squamous):	73.0	72.0	74.0	73.0	73.0	74.0	65.0	64.0	68.0
Melanoma of the skin	71.0	71.0	71.0	71.0	71.0	71.0	69.0	67.0	72.0
Other non-epithelial skin	77.0	76.0	82.0	78.0	76.0	82.0	63.0	62.0	66.0
Breast	69.0	70.0	69.0	70.0	71.0	70.0	64.0	67.0	63.0

^a US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.
- Statistic could not be calculated. Less than 16 deaths occurred during the time interval.

Table 1.13 - continued
Median Age of Cancer Patients at Death^a, 2014-2018
By Primary Cancer Site, Race and Sex

Site	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	69.0	-	69.0	70.0	-	70.0	66.0	-	66.0
Cervix uteri	58.0	-	58.0	58.0	-	58.0	59.0	-	59.0
Corpus uteri	70.0	-	70.0	70.0	-	70.0	68.0	-	68.0
Uterus, NOS	70.0	-	70.0	71.0	-	71.0	67.0	-	67.0
Ovary	70.0	-	70.0	71.0	-	71.0	67.0	-	67.0
Vagina	75.0	-	75.0	76.0	-	76.0	71.0	-	71.0
Vulva	77.0	-	77.0	78.0	-	78.0	69.0	-	69.0
Other female genital system	70.0	-	70.0	71.0	-	71.0	67.0	-	67.0
Male Genital System:	79.0	79.0	-	80.0	80.0	-	75.0	75.0	-
Prostate	80.0	80.0	-	81.0	81.0	-	76.0	76.0	-
Testis	41.0	41.0	-	41.0	41.0	-	44.0	44.0	-
Penis	72.0	72.0	-	73.0	73.0	-	68.0	68.0	-
Other male genital system	73.0	73.0	-	74.5	74.5	-	68.0	68.0	-
Urinary System:	76.0	75.0	78.0	76.0	75.0	78.0	71.0	69.0	73.0
Urinary bladder	79.0	79.0	80.0	79.0	79.0	81.0	74.0	73.0	76.0
Kidney & renal pelvis	72.0	70.0	74.0	72.0	71.0	75.0	67.0	66.0	71.0
Ureter	79.0	78.0	80.0	80.0	79.0	81.0	73.0	73.0	74.0
Other urinary system	77.0	77.0	79.0	78.0	77.0	80.0	71.0	72.0	70.0
Eye & Orbit	70.0	68.0	71.0	70.0	69.0	71.0	63.0	59.5	71.0
Brain & Nervous System	66.0	65.0	67.0	66.0	65.0	67.0	61.0	60.0	63.0
Endocrine System:	70.0	68.0	72.0	71.0	69.0	72.0	65.5	63.0	67.0
Thyroid	73.0	71.0	75.0	74.0	72.0	75.0	69.0	66.0	72.0
Other endocrine & thymus	62.0	62.0	63.0	63.0	62.0	64.0	59.0	58.0	59.0
Lymphoma:	76.0	74.0	78.0	76.0	75.0	78.0	66.0	64.0	69.0
Hodgkin lymphoma	69.0	68.0	72.0	70.0	69.0	73.0	56.0	55.0	58.0
Non-Hodgkin lymphoma	76.0	74.0	78.0	77.0	75.0	79.0	67.0	65.0	70.0
Myeloma	75.0	74.0	76.0	76.0	75.0	77.0	72.0	70.0	73.0
Leukemia:	75.0	74.0	76.0	76.0	75.0	77.0	69.0	68.0	70.0
Lymphocytic:	78.0	76.0	81.0	79.0	77.0	82.0	71.0	69.0	74.0
Acute lymphocytic	58.0	55.0	61.0	59.0	56.0	62.0	52.0	47.0	56.0
Chronic lymphocytic	81.0	79.0	84.0	82.0	80.0	85.0	75.0	73.0	79.0
Other lymphocytic	79.0	78.0	80.0	79.0	78.0	81.0	72.0	69.0	76.5
Myeloid & Monocytic:	73.0	73.0	74.0	74.0	74.0	74.0	67.0	67.0	68.0
Acute myeloid	73.0	73.0	73.0	73.0	73.0	74.0	67.0	67.0	67.0
Chronic myeloid	77.0	76.0	79.0	78.0	77.0	80.0	66.0	63.0	71.0
Acute monocytic	76.0	77.0	76.0	77.0	77.0	77.0	74.0	76.0	-
Other myeloid & monocytic	77.0	76.0	78.0	77.0	76.0	78.0	70.0	70.0	71.0
Other leukemia:	77.0	76.0	79.0	78.0	77.0	80.0	70.0	69.0	73.0
Other acute leukemia	78.0	76.0	79.0	78.0	77.0	80.0	71.0	70.0	74.0
Aleukemic, subleukemic & NOS	77.0	76.0	79.0	78.0	77.0	80.0	70.0	69.0	73.0
Ill-defined & unspecified	74.0	73.0	75.0	74.0	73.0	76.0	68.0	67.0	70.0

^a US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.
- Statistic could not be calculated. Less than 16 deaths occurred during the time interval.

Table 1.14

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Both Sexes, 21 SEER Areas, 2016-2018

Site	All Races	Whites	Blacks
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	39.24 (39.17, 39.31)	39.40 (39.33, 39.48)	35.89 (35.69, 36.08)
Invasive and In Situ	42.51 (42.44, 42.58)	42.69 (42.61, 42.77)	37.88 (37.68, 38.08)
Oral Cavity and Pharynx	1.18 (1.17, 1.19)	1.24 (1.23, 1.26)	0.77 (0.75, 0.80)
Esophagus	0.50 (0.50, 0.51)	0.54 (0.53, 0.55)	0.37 (0.35, 0.39)
Stomach	0.83 (0.82, 0.84)	0.73 (0.72, 0.74)	1.04 (1.00, 1.08)
Colon and Rectum	4.09 (4.07, 4.11)	4.03 (4.01, 4.06)	4.06 (3.99, 4.13)
Invasive and In Situ	4.22 (4.20, 4.25)	4.16 (4.13, 4.18)	4.21 (4.14, 4.28)
Liver and Intrahepatic Bile Duct	1.04 (1.03, 1.05)	0.95 (0.94, 0.96)	1.07 (1.04, 1.10)
Pancreas	1.67 (1.66, 1.69)	1.67 (1.65, 1.68)	1.69 (1.65, 1.74)
Larynx	0.30 (0.30, 0.31)	0.31 (0.30, 0.32)	0.35 (0.33, 0.37)
Invasive and In Situ	0.33 (0.32, 0.33)	0.34 (0.33, 0.34)	0.37 (0.35, 0.39)
Lung and Bronchus	6.14 (6.11, 6.17)	6.31 (6.27, 6.34)	5.43 (5.35, 5.51)
Melanoma of the Skin	2.25 (2.24, 2.27)	2.66 (2.64, 2.68)	0.09 (0.08, 0.10)
Invasive and In Situ	3.96 (3.94, 3.98)	4.57 (4.55, 4.60)	0.13 (0.11, 0.14)
Breast	6.64 (6.61, 6.67)	6.68 (6.65, 6.71)	6.22 (6.14, 6.30)
Invasive and In Situ	7.82 (7.79, 7.85)	7.80 (7.77, 7.84)	7.46 (7.38, 7.55)
Urinary Bladder (Invasive and In Situ)	2.41 (2.39, 2.43)	2.62 (2.60, 2.64)	1.27 (1.23, 1.31)
Kidney and Renal Pelvis	1.71 (1.70, 1.73)	1.78 (1.76, 1.79)	1.56 (1.52, 1.60)
Brain and Other Nervous System	0.62 (0.61, 0.63)	0.68 (0.67, 0.69)	0.35 (0.33, 0.36)
Thyroid	1.25 (1.24, 1.26)	1.29 (1.28, 1.31)	0.72 (0.70, 0.75)
Hodgkin Lymphoma	0.21 (0.21, 0.22)	0.23 (0.22, 0.23)	0.19 (0.18, 0.20)
Non-Hodgkin Lymphoma	2.14 (2.13, 2.16)	2.25 (2.23, 2.27)	1.37 (1.34, 1.41)
Myeloma	0.83 (0.82, 0.84)	0.76 (0.75, 0.77)	1.46 (1.42, 1.50)
Leukemia	1.57 (1.55, 1.58)	1.65 (1.64, 1.67)	1.08 (1.04, 1.11)
Acute Lymphocytic Leukemia	0.14 (0.13, 0.14)	0.15 (0.14, 0.15)	0.08 (0.07, 0.09)
Chronic Lymphocytic Leukemia	0.59 (0.58, 0.60)	0.65 (0.64, 0.66)	0.33 (0.31, 0.35)
Acute Myeloid Leukemia	0.49 (0.48, 0.49)	0.50 (0.49, 0.51)	0.38 (0.36, 0.40)
Chronic Myeloid Leukemia	0.21 (0.20, 0.21)	0.21 (0.21, 0.22)	0.17 (0.16, 0.18)
Kaposi Sarcoma	0.11 (0.10, 0.11)	0.12 (0.11, 0.12)	0.05 (0.04, 0.06)
Mesothelioma	0.04 (0.04, 0.04)	0.03 (0.03, 0.03)	0.07 (0.07, 0.08)

Devcan Version 6.7.9, April 2021s, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Note: Invasive cancer only unless specified otherwise.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.14 - continued

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Both Sexes, 21 SEER Areas, 2016-2018

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives ^a	Hispanics ^b
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	34.14 (33.88, 34.40)	27.22 (26.31, 28.21)	36.23 (36.00, 36.46)
Invasive and In Situ	36.34 (36.07, 36.61)	28.52 (27.58, 29.53)	38.35 (38.11, 38.59)
Oral Cavity and Pharynx	0.97 (0.93, 1.02)	0.78 (0.66, 1.01)	0.84 (0.80, 0.87)
Esophagus	0.33 (0.31, 0.36)	0.47 (0.34, 0.72)	0.38 (0.35, 0.40)
Stomach	1.48 (1.43, 1.55)	0.79 (0.63, 1.06)	1.32 (1.28, 1.37)
Colon and Rectum	4.15 (4.06, 4.25)	3.87 (3.52, 4.30)	4.09 (4.02, 4.18)
Invasive and In Situ	4.29 (4.19, 4.39)	3.94 (3.59, 4.38)	4.25 (4.17, 4.33)
Liver and Intrahepatic Bile Duct	1.74 (1.68, 1.80)	1.52 (1.34, 1.78)	1.77 (1.72, 1.82)
Pancreas	1.65 (1.59, 1.72)	1.38 (1.16, 1.69)	1.72 (1.67, 1.78)
Larynx	0.16 (0.14, 0.18)	0.25 (0.17, 0.45)	0.26 (0.24, 0.28)
Invasive and In Situ	0.16 (0.14, 0.19)	0.25 (0.18, 0.45)	0.28 (0.26, 0.30)
Lung and Bronchus	5.48 (5.37, 5.60)	4.25 (3.87, 4.70)	3.97 (3.89, 4.05)
Melanoma of the Skin	0.16 (0.14, 0.18)	0.56 (0.42, 0.81)	0.55 (0.52, 0.58)
Invasive and In Situ	0.22 (0.20, 0.25)	0.88 (0.71, 1.15)	0.87 (0.84, 0.91)
Breast	6.04 (5.95, 6.14)	3.85 (3.57, 4.22)	5.61 (5.53, 5.69)
Invasive and In Situ	7.46 (7.36, 7.56)	4.35 (4.06, 4.73)	6.64 (6.56, 6.73)
Urinary Bladder (Invasive and In Situ)	1.46 (1.40, 1.52)	1.18 (1.00, 1.46)	1.61 (1.55, 1.67)
Kidney and Renal Pelvis	1.09 (1.05, 1.14)	1.91 (1.71, 2.20)	1.87 (1.82, 1.92)
Brain and Other Nervous System	0.42 (0.39, 0.45)	0.32 (0.21, 0.55)	0.54 (0.52, 0.57)
Thyroid	1.38 (1.34, 1.42)	0.86 (0.71, 1.11)	1.25 (1.22, 1.29)
Hodgkin Lymphoma	0.11 (0.10, 0.13)	0.10 (0.06, 0.28)	0.20 (0.19, 0.22)
Non-Hodgkin Lymphoma	1.80 (1.74, 1.86)	1.20 (1.01, 1.49)	2.22 (2.17, 2.28)
Myeloma	0.54 (0.51, 0.58)	0.71 (0.55, 0.97)	0.88 (0.84, 0.91)
Leukemia	1.05 (1.00, 1.10)	0.89 (0.75, 1.13)	1.25 (1.21, 1.30)
Acute Lymphocytic Leukemia	0.13 (0.12, 0.15)	0.13 (0.10, 0.31)	0.20 (0.19, 0.22)
Chronic Lymphocytic Leukemia	0.18 (0.15, 0.20)	0.22 (0.15, 0.42)	0.28 (0.26, 0.31)
Acute Myeloid Leukemia	0.47 (0.44, 0.51)	0.29 (0.22, 0.49)	0.45 (0.43, 0.48)
Chronic Myeloid Leukemia	0.17 (0.15, 0.19)	0.11 (0.06, 0.30)	0.18 (0.17, 0.20)
Kaposi Sarcoma	0.05 (0.04, 0.07)	0.08 (0.03, 0.27)	0.09 (0.08, 0.10)
Mesothelioma	0.02 (0.01, 0.03)	0.05 (0.02, 0.24)	0.07 (0.06, 0.08)

Devcan Version 6.7.9, April 2021s, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Note: Invasive cancer only unless specified otherwise.

^a Underlying incidence data for American Indian/Alaska Native are based on the PRCDA (Purchased/Referred Care Delivery Areas) counties.^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.15

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Males, 21 SEER Areas, 2016-2018

Site	All Races	Whites	Blacks
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	40.18 (40.08, 40.28)	39.90 (39.78, 40.01)	37.78 (37.48, 38.09)
Invasive and In Situ	42.67 (42.56, 42.78)	42.44 (42.32, 42.56)	38.76 (38.45, 39.06)
Oral Cavity and Pharynx	1.66 (1.64, 1.68)	1.75 (1.73, 1.77)	1.11 (1.06, 1.16)
Esophagus	0.79 (0.78, 0.81)	0.85 (0.83, 0.87)	0.53 (0.50, 0.57)
Stomach	1.02 (1.00, 1.03)	0.91 (0.89, 0.93)	1.23 (1.17, 1.30)
Colon and Rectum	4.23 (4.20, 4.26)	4.14 (4.11, 4.18)	4.19 (4.09, 4.29)
Invasive and In Situ	4.37 (4.34, 4.41)	4.28 (4.24, 4.32)	4.35 (4.24, 4.45)
Liver and Intrahepatic Bile Duct	1.45 (1.43, 1.47)	1.32 (1.30, 1.34)	1.58 (1.53, 1.64)
Pancreas	1.70 (1.68, 1.73)	1.72 (1.69, 1.74)	1.61 (1.55, 1.68)
Larynx	0.50 (0.49, 0.51)	0.50 (0.49, 0.52)	0.58 (0.55, 0.62)
Invasive and In Situ	0.54 (0.53, 0.55)	0.54 (0.53, 0.56)	0.61 (0.58, 0.65)
Lung and Bronchus	6.37 (6.32, 6.41)	6.38 (6.33, 6.43)	6.14 (6.02, 6.27)
Melanoma of the Skin	2.76 (2.73, 2.79)	3.22 (3.19, 3.26)	0.08 (0.07, 0.10)
Invasive and In Situ	4.77 (4.73, 4.80)	5.44 (5.40, 5.49)	0.12 (0.10, 0.14)
Breast	0.14 (0.13, 0.14)	0.14 (0.13, 0.14)	0.17 (0.15, 0.20)
Invasive and In Situ	0.15 (0.14, 0.16)	0.15 (0.14, 0.15)	0.19 (0.17, 0.21)
Prostate	12.52 (12.46, 12.57)	11.70 (11.65, 11.76)	16.71 (16.52, 16.90)
Testis	0.41 (0.40, 0.42)	0.49 (0.48, 0.50)	0.11 (0.10, 0.13)
Urinary Bladder (Invasive and In Situ)	3.78 (3.74, 3.81)	4.09 (4.05, 4.13)	1.81 (1.73, 1.88)
Kidney and Renal Pelvis	2.19 (2.16, 2.21)	2.27 (2.24, 2.29)	1.92 (1.86, 1.99)
Brain and Other Nervous System	0.70 (0.69, 0.71)	0.77 (0.75, 0.78)	0.39 (0.36, 0.42)
Thyroid	0.67 (0.66, 0.68)	0.71 (0.70, 0.73)	0.30 (0.28, 0.32)
Hodgkin Lymphoma	0.23 (0.22, 0.24)	0.24 (0.24, 0.25)	0.20 (0.18, 0.22)
Non-Hodgkin Lymphoma	2.38 (2.35, 2.40)	2.49 (2.46, 2.52)	1.48 (1.42, 1.54)
Myeloma	0.95 (0.93, 0.97)	0.89 (0.87, 0.91)	1.51 (1.45, 1.58)
Leukemia	1.86 (1.84, 1.88)	1.96 (1.93, 1.98)	1.22 (1.17, 1.28)
Acute Lymphocytic Leukemia	0.15 (0.15, 0.16)	0.16 (0.16, 0.17)	0.08 (0.07, 0.10)
Chronic Lymphocytic Leukemia	0.73 (0.71, 0.74)	0.78 (0.77, 0.80)	0.43 (0.39, 0.46)
Acute Myeloid Leukemia	0.56 (0.54, 0.57)	0.57 (0.56, 0.59)	0.40 (0.37, 0.44)
Chronic Myeloid Leukemia	0.25 (0.24, 0.26)	0.26 (0.25, 0.27)	0.19 (0.17, 0.22)
Kaposi Sarcoma	0.16 (0.16, 0.17)	0.18 (0.17, 0.19)	0.09 (0.07, 0.12)
Mesothelioma	0.07 (0.06, 0.07)	0.05 (0.05, 0.06)	0.13 (0.12, 0.15)

Devcan Version 6.7.9, April 2021s, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Note: Invasive cancer only unless specified otherwise.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.15 - continued

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Males, 21 SEER Areas, 2016-2018

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives ^a	Hispanics ^b
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	34.55 (34.14, 34.96)	26.08 (24.85, 27.49)	36.87 (36.52, 37.24)
Invasive and In Situ	35.71 (35.30, 36.13)	26.96 (25.69, 28.42)	38.11 (37.74, 38.48)
Oral Cavity and Pharynx	1.31 (1.25, 1.39)	1.22 (0.99, 1.72)	1.15 (1.10, 1.22)
Esophagus	0.52 (0.47, 0.57)	0.65 (0.49, 1.11)	0.62 (0.57, 0.68)
Stomach	1.82 (1.73, 1.92)	0.86 (0.65, 1.35)	1.56 (1.48, 1.64)
Colon and Rectum	4.53 (4.39, 4.68)	3.35 (2.96, 3.98)	4.45 (4.33, 4.58)
Invasive and In Situ	4.70 (4.55, 4.85)	3.48 (3.07, 4.12)	4.62 (4.50, 4.75)
Liver and Intrahepatic Bile Duct	2.43 (2.33, 2.54)	2.14 (1.85, 2.69)	2.35 (2.27, 2.44)
Pancreas	1.65 (1.55, 1.75)	1.58 (1.21, 2.21)	1.66 (1.58, 1.74)
Larynx	0.29 (0.25, 0.33)	0.39 (0.26, 0.85)	0.45 (0.41, 0.49)
Invasive and In Situ	0.30 (0.26, 0.35)	0.39 (0.27, 0.85)	0.48 (0.45, 0.53)
Lung and Bronchus	6.50 (6.31, 6.69)	3.91 (3.44, 4.59)	4.42 (4.29, 4.56)
Melanoma of the Skin	0.18 (0.15, 0.22)	0.64 (0.45, 1.12)	0.54 (0.50, 0.59)
Invasive and In Situ	0.26 (0.22, 0.30)	0.91 (0.69, 1.41)	0.84 (0.78, 0.90)
Breast	0.09 (0.07, 0.12)	0.02 (0.00, 0.49)	0.08 (0.07, 0.11)
Invasive and In Situ	0.10 (0.08, 0.12)	0.03 (0.00, 0.50)	0.09 (0.07, 0.11)
Prostate	8.22 (8.04, 8.41)	5.49 (4.92, 6.27)	11.09 (10.91, 11.28)
Testis	0.16 (0.15, 0.19)	0.28 (0.21, 0.71)	0.39 (0.38, 0.42)
Urinary Bladder (Invasive and In Situ)	2.40 (2.28, 2.52)	1.86 (1.52, 2.44)	2.58 (2.47, 2.70)
Kidney and Renal Pelvis	1.44 (1.37, 1.52)	2.41 (2.08, 2.98)	2.33 (2.25, 2.42)
Brain and Other Nervous System	0.48 (0.44, 0.54)	0.33 (0.23, 0.78)	0.60 (0.56, 0.64)
Thyroid	0.72 (0.68, 0.77)	0.35 (0.25, 0.79)	0.57 (0.54, 0.62)
Hodgkin Lymphoma	0.13 (0.11, 0.16)	0.07 (0.03, 0.52)	0.22 (0.21, 0.25)
Non-Hodgkin Lymphoma	2.10 (2.00, 2.20)	1.25 (0.99, 1.77)	2.40 (2.32, 2.50)
Myeloma	0.64 (0.58, 0.70)	0.74 (0.56, 1.22)	0.97 (0.92, 1.03)
Leukemia	1.29 (1.21, 1.38)	1.11 (0.87, 1.62)	1.43 (1.37, 1.51)
Acute Lymphocytic Leukemia	0.14 (0.12, 0.17)	0.14 (0.09, 0.58)	0.22 (0.21, 0.24)
Chronic Lymphocytic Leukemia	0.23 (0.19, 0.27)	0.34 (0.22, 0.80)	0.33 (0.30, 0.38)
Acute Myeloid Leukemia	0.57 (0.52, 0.64)	0.33 (0.22, 0.77)	0.49 (0.46, 0.54)
Chronic Myeloid Leukemia	0.21 (0.18, 0.25)	0.12 (0.04, 0.58)	0.20 (0.18, 0.24)
Kaposi Sarcoma	0.09 (0.07, 0.12)	0.09 (0.02, 0.56)	0.13 (0.11, 0.16)
Mesothelioma	0.03 (0.02, 0.05)	0.07 (0.02, 0.54)	0.12 (0.10, 0.15)

Devcan Version 6.7.9, April 2021s, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Note: Invasive cancer only unless specified otherwise.

^a Underlying incidence data for American Indian/Alaska Native are based on the PRCDA (Purchased/Referred Care Delivery Areas) counties.^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.16

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Females, 21 SEER Areas, 2016-2018

Site	All Races			Whites			Blacks		
	Percent	(95% C.I.)		Percent	(95% C.I.)		Percent	(95% C.I.)	
All Sites	38.53	(38.43, 38.62)		39.14	(39.03, 39.24)		34.33	(34.07, 34.60)	
Invasive and In Situ	42.59	(42.49, 42.69)		43.21	(43.09, 43.32)		37.25	(36.97, 37.53)	
Oral Cavity and Pharynx	0.72	(0.70, 0.73)		0.74	(0.73, 0.76)		0.48	(0.45, 0.51)	
Esophagus	0.23	(0.22, 0.24)		0.23	(0.23, 0.24)		0.23	(0.21, 0.26)	
Stomach	0.66	(0.64, 0.67)		0.57	(0.55, 0.58)		0.89	(0.84, 0.93)	
Colon and Rectum	3.96	(3.93, 3.99)		3.92	(3.89, 3.96)		3.96	(3.87, 4.05)	
Invasive and In Situ	4.08	(4.05, 4.11)		4.04	(4.00, 4.07)		4.10	(4.00, 4.19)	
Liver and Intrahepatic Bile Duct	0.64	(0.62, 0.65)		0.58	(0.57, 0.60)		0.61	(0.58, 0.65)	
Pancreas	1.64	(1.62, 1.66)		1.62	(1.60, 1.64)		1.76	(1.70, 1.83)	
Larynx	0.12	(0.11, 0.13)		0.12	(0.12, 0.13)		0.15	(0.13, 0.17)	
Invasive and In Situ	0.13	(0.12, 0.14)		0.13	(0.13, 0.14)		0.16	(0.14, 0.18)	
Lung and Bronchus	5.97	(5.93, 6.01)		6.27	(6.23, 6.32)		4.85	(4.75, 4.96)	
Melanoma of the Skin	1.80	(1.78, 1.82)		2.15	(2.13, 2.18)		0.09	(0.08, 0.11)	
Invasive and In Situ	3.23	(3.21, 3.26)		3.78	(3.75, 3.81)		0.13	(0.12, 0.15)	
Breast	12.92	(12.87, 12.97)		13.18	(13.12, 13.24)		11.55	(11.41, 11.70)	
Invasive and In Situ	15.25	(15.20, 15.31)		15.42	(15.36, 15.48)		13.89	(13.74, 14.05)	
Cervix Uteri	0.63	(0.62, 0.64)		0.61	(0.59, 0.62)		0.76	(0.73, 0.80)	
Corpus and Uterus, NOS	3.15	(3.12, 3.17)		3.17	(3.14, 3.20)		3.14	(3.07, 3.22)	
Invasive and In Situ	3.16	(3.13, 3.19)		3.19	(3.16, 3.22)		3.17	(3.09, 3.24)	
Ovary ^a	1.17	(1.15, 1.19)		1.21	(1.19, 1.23)		0.92	(0.88, 0.97)	
Urinary Bladder (Invasive and In Situ)	1.16	(1.15, 1.18)		1.25	(1.23, 1.27)		0.83	(0.78, 0.88)	
Kidney and Renal Pelvis	1.26	(1.24, 1.28)		1.30	(1.28, 1.32)		1.25	(1.20, 1.30)	
Brain and Other Nervous System	0.54	(0.53, 0.55)		0.60	(0.58, 0.61)		0.31	(0.28, 0.33)	
Thyroid	1.82	(1.81, 1.84)		1.90	(1.87, 1.92)		1.11	(1.07, 1.15)	
Hodgkin Lymphoma	0.19	(0.19, 0.20)		0.21	(0.20, 0.21)		0.18	(0.16, 0.20)	
Non-Hodgkin Lymphoma	1.92	(1.90, 1.95)		2.02	(1.99, 2.04)		1.29	(1.24, 1.34)	
Myeloma	0.73	(0.71, 0.74)		0.64	(0.62, 0.65)		1.42	(1.37, 1.48)	
Leukemia	1.30	(1.28, 1.31)		1.37	(1.35, 1.39)		0.96	(0.92, 1.01)	
Acute Lymphocytic Leukemia	0.12	(0.12, 0.13)		0.13	(0.12, 0.13)		0.07	(0.06, 0.09)	
Chronic Lymphocytic Leukemia	0.47	(0.46, 0.48)		0.51	(0.50, 0.53)		0.26	(0.23, 0.28)	
Acute Myeloid Leukemia	0.42	(0.41, 0.43)		0.43	(0.42, 0.45)		0.36	(0.33, 0.39)	
Chronic Myeloid Leukemia	0.17	(0.16, 0.18)		0.17	(0.17, 0.18)		0.16	(0.14, 0.18)	
Kaposi Sarcoma	0.05	(0.05, 0.06)		0.06	(0.06, 0.07)		0.02	(0.02, 0.03)	
Mesothelioma	0.01	(0.01, 0.01)		0.01	(0.01, 0.01)		0.01	(0.01, 0.02)	

Devcan Version 6.7.9, April 2021s, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Note: Invasive cancer only unless specified otherwise.

^a Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.16 - continued

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Females, 21 SEER Areas, 2016-2018

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives ^a	Hispanics ^b
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	33.96 (33.62, 34.31)	28.48 (27.15, 29.96)	36.19 (35.88, 36.50)
Invasive and In Situ	37.09 (36.73, 37.45)	30.21 (28.86, 31.71)	39.18 (38.87, 39.50)
Oral Cavity and Pharynx	0.68 (0.63, 0.73)	0.37 (0.25, 0.72)	0.56 (0.52, 0.60)
Esophagus	0.18 (0.15, 0.21)	0.30 (0.13, 0.73)	0.16 (0.14, 0.19)
Stomach	1.20 (1.12, 1.28)	0.72 (0.48, 1.17)	1.13 (1.07, 1.19)
Colon and Rectum	3.83 (3.71, 3.96)	4.33 (3.79, 5.04)	3.81 (3.71, 3.92)
Invasive and In Situ	3.93 (3.81, 4.07)	4.36 (3.81, 5.07)	3.95 (3.85, 4.06)
Liver and Intrahepatic Bile Duct	1.14 (1.07, 1.22)	0.92 (0.73, 1.31)	1.23 (1.17, 1.30)
Pancreas	1.66 (1.57, 1.75)	1.20 (0.94, 1.66)	1.79 (1.71, 1.87)
Larynx	0.04 (0.03, 0.07)	0.12 (0.05, 0.46)	0.09 (0.07, 0.11)
Invasive and In Situ	0.05 (0.03, 0.07)	0.12 (0.05, 0.46)	0.09 (0.08, 0.11)
Lung and Bronchus	4.65 (4.50, 4.79)	4.58 (4.02, 5.30)	3.63 (3.53, 3.74)
Melanoma of the Skin	0.13 (0.11, 0.16)	0.49 (0.29, 0.91)	0.57 (0.53, 0.61)
Invasive and In Situ	0.19 (0.17, 0.22)	0.85 (0.61, 1.30)	0.93 (0.88, 0.98)
Breast	11.23 (11.06, 11.41)	7.59 (7.04, 8.30)	10.75 (10.60, 10.90)
Invasive and In Situ	13.89 (13.70, 14.08)	8.58 (8.00, 9.31)	12.77 (12.61, 12.93)
Cervix Uteri	0.63 (0.59, 0.67)	0.55 (0.43, 0.90)	0.87 (0.83, 0.92)
Corpus and Uterus, NOS	2.56 (2.48, 2.64)	2.06 (1.80, 2.50)	2.91 (2.83, 2.99)
Invasive and In Situ	2.56 (2.49, 2.65)	2.06 (1.80, 2.50)	2.92 (2.85, 3.00)
Ovary ^c	1.05 (1.00, 1.11)	0.92 (0.73, 1.31)	1.21 (1.15, 1.26)
Urinary Bladder (Invasive and In Situ)	0.68 (0.62, 0.74)	0.55 (0.39, 0.93)	0.82 (0.76, 0.88)
Kidney and Renal Pelvis	0.79 (0.74, 0.85)	1.44 (1.21, 1.86)	1.47 (1.41, 1.53)
Brain and Other Nervous System	0.36 (0.33, 0.40)	0.29 (0.13, 0.71)	0.50 (0.47, 0.54)
Thyroid	1.98 (1.91, 2.04)	1.35 (1.09, 1.81)	1.94 (1.89, 2.00)
Hodgkin Lymphoma	0.10 (0.09, 0.12)	0.13 (0.07, 0.47)	0.18 (0.16, 0.20)
Non-Hodgkin Lymphoma	1.55 (1.48, 1.63)	1.16 (0.88, 1.63)	2.08 (2.01, 2.16)
Myeloma	0.47 (0.43, 0.51)	0.66 (0.43, 1.11)	0.80 (0.76, 0.85)
Leukemia	0.85 (0.79, 0.91)	0.69 (0.53, 1.06)	1.10 (1.05, 1.16)
Acute Lymphocytic Leukemia	0.12 (0.11, 0.15)	0.12 (0.07, 0.45)	0.19 (0.17, 0.21)
Chronic Lymphocytic Leukemia	0.13 (0.11, 0.16)	0.10 (0.04, 0.45)	0.24 (0.21, 0.27)
Acute Myeloid Leukemia	0.39 (0.35, 0.43)	0.26 (0.16, 0.60)	0.42 (0.39, 0.46)
Chronic Myeloid Leukemia	0.13 (0.10, 0.16)	0.11 (0.05, 0.44)	0.16 (0.14, 0.18)
Kaposi Sarcoma	0.03 (0.02, 0.05)	0.07 (0.01, 0.42)	0.06 (0.04, 0.07)
Mesothelioma	0.01 (0.00, 0.02)	0.02 (0.00, 0.37)	0.02 (0.01, 0.04)

Devcan Version 6.7.9, April 2021s, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Note: Invasive cancer only unless specified otherwise.

^a Underlying incidence data for American Indian/Alaska Native are based on the PRCDA(Purchased/Referred Care Delivery Areas) counties.^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.^c Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.17

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity

Both Sexes, Total U.S., 2016-2018

Site	All Races	Whites	Blacks
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	19.08 (19.05, 19.10)	19.24 (19.22, 19.27)	18.86 (18.78, 18.94)
Oral Cavity and Pharynx	0.30 (0.30, 0.30)	0.31 (0.30, 0.31)	0.26 (0.25, 0.27)
Esophagus	0.46 (0.45, 0.46)	0.49 (0.48, 0.49)	0.31 (0.29, 0.32)
Stomach	0.35 (0.35, 0.35)	0.30 (0.30, 0.31)	0.55 (0.53, 0.57)
Colon and Rectum	1.68 (1.68, 1.69)	1.66 (1.65, 1.67)	1.91 (1.88, 1.94)
Liver and Intrahepatic Bile Duct	0.79 (0.78, 0.79)	0.75 (0.74, 0.76)	0.87 (0.85, 0.89)
Pancreas	1.39 (1.38, 1.39)	1.39 (1.38, 1.39)	1.45 (1.42, 1.47)
Larynx	0.11 (0.11, 0.11)	0.11 (0.10, 0.11)	0.16 (0.15, 0.16)
Lung and Bronchus	4.54 (4.53, 4.56)	4.66 (4.65, 4.68)	4.10 (4.06, 4.14)
Melanoma of the Skin	0.26 (0.25, 0.26)	0.30 (0.29, 0.30)	0.03 (0.03, 0.04)
Breast	1.32 (1.31, 1.32)	1.29 (1.28, 1.29)	1.64 (1.61, 1.67)
Urinary Bladder	0.61 (0.61, 0.62)	0.64 (0.64, 0.65)	0.42 (0.41, 0.44)
Kidney and Renal Pelvis	0.44 (0.44, 0.45)	0.46 (0.45, 0.46)	0.36 (0.35, 0.37)
Brain and Other Nervous System	0.47 (0.47, 0.48)	0.52 (0.51, 0.52)	0.25 (0.24, 0.26)
Thyroid	0.06 (0.06, 0.07)	0.07 (0.06, 0.07)	0.05 (0.05, 0.06)
Hodgkin Lymphoma	0.03 (0.03, 0.03)	0.03 (0.03, 0.03)	0.02 (0.02, 0.02)
Non-Hodgkin Lymphoma	0.70 (0.69, 0.70)	0.73 (0.73, 0.74)	0.41 (0.39, 0.42)
Myeloma	0.41 (0.41, 0.42)	0.39 (0.38, 0.39)	0.66 (0.64, 0.67)
Leukemia	0.80 (0.79, 0.80)	0.83 (0.82, 0.84)	0.57 (0.56, 0.59)
Acute Lymphocytic Leukemia	0.04 (0.04, 0.04)	0.05 (0.04, 0.05)	0.03 (0.03, 0.03)
Chronic Lymphocytic Leukemia	0.17 (0.17, 0.17)	0.18 (0.17, 0.18)	0.12 (0.11, 0.13)
Acute Myeloid Leukemia	0.34 (0.33, 0.34)	0.35 (0.35, 0.36)	0.23 (0.22, 0.24)
Chronic Myeloid Leukemia	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	0.03 (0.03, 0.04)

Devcan Version 6.7.9, April 2021s, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).
Source: NCHS public use data file for the total US.
A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.17 - continued

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity

Both Sexes, Total U.S., 2016-2018

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives ^a	Hispanics ^b
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	17.33 (17.15, 17.52)	15.46 (15.05, 15.90)	16.85 (16.73, 16.96)
Oral Cavity and Pharynx	0.31 (0.29, 0.34)	0.22 (0.17, 0.30)	0.22 (0.21, 0.23)
Esophagus	0.26 (0.24, 0.29)	0.33 (0.28, 0.41)	0.29 (0.27, 0.30)
Stomach	0.90 (0.86, 0.95)	0.49 (0.42, 0.60)	0.70 (0.68, 0.73)
Colon and Rectum	1.70 (1.64, 1.77)	1.65 (1.51, 1.82)	1.71 (1.67, 1.75)
Liver and Intrahepatic Bile Duct	1.40 (1.35, 1.45)	1.12 (1.02, 1.25)	1.33 (1.30, 1.37)
Pancreas	1.37 (1.31, 1.42)	0.98 (0.88, 1.11)	1.34 (1.31, 1.38)
Larynx	0.05 (0.04, 0.06)	0.08 (0.06, 0.14)	0.09 (0.08, 0.10)
Lung and Bronchus	3.78 (3.69, 3.87)	3.41 (3.21, 3.63)	2.51 (2.46, 2.56)
Melanoma of the Skin	0.06 (0.05, 0.08)	0.07 (0.04, 0.13)	0.10 (0.09, 0.11)
Breast	1.01 (0.97, 1.06)	0.94 (0.84, 1.08)	1.08 (1.05, 1.11)
Urinary Bladder	0.43 (0.40, 0.48)	0.37 (0.29, 0.48)	0.46 (0.43, 0.48)
Kidney and Renal Pelvis	0.30 (0.28, 0.33)	0.61 (0.53, 0.73)	0.50 (0.48, 0.53)
Brain and Other Nervous System	0.32 (0.30, 0.35)	0.24 (0.19, 0.32)	0.39 (0.37, 0.41)
Thyroid	0.12 (0.10, 0.14)	0.06 (0.03, 0.13)	0.11 (0.10, 0.12)
Hodgkin Lymphoma	0.02 (0.01, 0.03)	0.03 (0.01, 0.08)	0.05 (0.04, 0.06)
Non-Hodgkin Lymphoma	0.69 (0.65, 0.73)	0.49 (0.41, 0.60)	0.73 (0.70, 0.76)
Myeloma	0.30 (0.28, 0.33)	0.42 (0.35, 0.53)	0.41 (0.39, 0.43)
Leukemia	0.61 (0.57, 0.65)	0.42 (0.35, 0.52)	0.66 (0.63, 0.69)
Acute Lymphocytic Leukemia	0.04 (0.03, 0.05)	0.04 (0.03, 0.10)	0.07 (0.06, 0.07)
Chronic Lymphocytic Leukemia	0.06 (0.04, 0.07)	0.04 (0.02, 0.10)	0.09 (0.08, 0.10)
Acute Myeloid Leukemia	0.33 (0.30, 0.36)	0.17 (0.13, 0.24)	0.27 (0.26, 0.29)
Chronic Myeloid Leukemia	0.03 (0.02, 0.04)	0.03 (0.01, 0.08)	0.03 (0.03, 0.04)

Devcan Version 6.7.9, April 2021s, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

^a Underlying mortality data for American Indian/Alaska Native are based on the PRCDA (Purchased/Referred Care Delivery Areas) counties.^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.
A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.18

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity

Males, Total U.S., 2016-2018

Site	All Races	Whites	Blacks
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	20.51 (20.47, 20.55)	20.67 (20.62, 20.71)	20.23 (20.11, 20.36)
Oral Cavity and Pharynx	0.42 (0.41, 0.42)	0.42 (0.41, 0.43)	0.39 (0.37, 0.41)
Esophagus	0.73 (0.72, 0.74)	0.78 (0.78, 0.79)	0.44 (0.42, 0.46)
Stomach	0.42 (0.41, 0.42)	0.37 (0.36, 0.37)	0.67 (0.65, 0.70)
Colon and Rectum	1.76 (1.75, 1.78)	1.73 (1.72, 1.75)	2.03 (1.99, 2.07)
Liver and Intrahepatic Bile Duct	1.03 (1.02, 1.04)	0.98 (0.97, 0.99)	1.18 (1.15, 1.21)
Pancreas	1.41 (1.40, 1.42)	1.42 (1.41, 1.43)	1.37 (1.34, 1.41)
Larynx	0.18 (0.17, 0.18)	0.17 (0.17, 0.18)	0.26 (0.25, 0.28)
Lung and Bronchus	4.95 (4.93, 4.97)	5.01 (4.98, 5.03)	4.81 (4.74, 4.87)
Melanoma of the Skin	0.35 (0.34, 0.35)	0.40 (0.39, 0.41)	0.03 (0.03, 0.04)
Breast	0.03 (0.03, 0.03)	0.03 (0.03, 0.03)	0.04 (0.04, 0.05)
Prostate	2.44 (2.42, 2.45)	2.30 (2.28, 2.31)	3.82 (3.76, 3.89)
Testis	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.01 (0.01, 0.01)
Urinary Bladder	0.92 (0.91, 0.93)	0.97 (0.96, 0.98)	0.53 (0.51, 0.56)
Kidney and Renal Pelvis	0.57 (0.56, 0.58)	0.59 (0.58, 0.60)	0.47 (0.45, 0.49)
Brain and Other Nervous System	0.53 (0.53, 0.54)	0.58 (0.57, 0.59)	0.27 (0.25, 0.28)
Thyroid	0.06 (0.06, 0.06)	0.06 (0.06, 0.06)	0.04 (0.03, 0.04)
Hodgkin Lymphoma	0.04 (0.03, 0.04)	0.04 (0.04, 0.04)	0.03 (0.02, 0.03)
Non-Hodgkin Lymphoma	0.79 (0.78, 0.80)	0.83 (0.82, 0.84)	0.46 (0.44, 0.48)
Myeloma	0.46 (0.45, 0.47)	0.44 (0.43, 0.44)	0.68 (0.65, 0.71)
Leukemia	0.93 (0.93, 0.94)	0.98 (0.97, 0.99)	0.62 (0.60, 0.65)
Acute Lymphocytic Leukemia	0.05 (0.05, 0.05)	0.05 (0.05, 0.05)	0.03 (0.02, 0.03)
Chronic Lymphocytic Leukemia	0.20 (0.20, 0.21)	0.21 (0.21, 0.22)	0.14 (0.12, 0.15)
Acute Myeloid Leukemia	0.39 (0.39, 0.40)	0.41 (0.41, 0.42)	0.25 (0.23, 0.26)
Chronic Myeloid Leukemia	0.04 (0.04, 0.05)	0.05 (0.04, 0.05)	0.04 (0.03, 0.04)

Devcan Version 6.7.9, April 2021s, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).
Source: NCHS public use data file for the total US.
A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.18 - continued

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity

Males, Total U.S., 2016-2018

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives ^a	Hispanics ^b
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	19.49 (19.20, 19.79)	16.02 (15.42, 16.68)	18.84 (18.65, 19.03)
Oral Cavity and Pharynx	0.45 (0.40, 0.49)	0.29 (0.23, 0.45)	0.31 (0.29, 0.34)
Esophagus	0.40 (0.36, 0.45)	0.49 (0.40, 0.66)	0.49 (0.46, 0.52)
Stomach	1.06 (0.99, 1.14)	0.56 (0.44, 0.76)	0.81 (0.77, 0.85)
Colon and Rectum	1.79 (1.69, 1.89)	1.59 (1.42, 1.84)	1.94 (1.88, 2.01)
Liver and Intrahepatic Bile Duct	1.87 (1.79, 1.96)	1.39 (1.24, 1.61)	1.69 (1.64, 1.74)
Pancreas	1.36 (1.28, 1.44)	0.98 (0.85, 1.19)	1.28 (1.23, 1.33)
Larynx	0.09 (0.07, 0.12)	0.14 (0.10, 0.29)	0.17 (0.16, 0.19)
Lung and Bronchus	4.62 (4.47, 4.78)	3.46 (3.19, 3.80)	3.08 (3.00, 3.16)
Melanoma of the Skin	0.06 (0.05, 0.09)	0.08 (0.04, 0.23)	0.12 (0.11, 0.14)
Breast	0.02 (0.01, 0.04)	0.02 (0.00, 0.17)	0.02 (0.01, 0.03)
Prostate	2.25 (2.12, 2.39)	1.98 (1.70, 2.34)	2.79 (2.70, 2.89)
Testis	0.01 (0.01, 0.02)	0.02 (0.01, 0.17)	0.02 (0.02, 0.03)
Urinary Bladder	0.67 (0.60, 0.75)	0.48 (0.35, 0.69)	0.70 (0.65, 0.75)
Kidney and Renal Pelvis	0.43 (0.38, 0.49)	0.77 (0.65, 0.97)	0.65 (0.62, 0.69)
Brain and Other Nervous System	0.37 (0.34, 0.42)	0.23 (0.17, 0.39)	0.41 (0.38, 0.44)
Thyroid	0.09 (0.07, 0.12)	0.04 (0.02, 0.18)	0.09 (0.08, 0.11)
Hodgkin Lymphoma	0.02 (0.01, 0.04)	0.02 (0.00, 0.17)	0.05 (0.04, 0.06)
Non-Hodgkin Lymphoma	0.80 (0.74, 0.87)	0.59 (0.46, 0.81)	0.81 (0.77, 0.86)
Myeloma	0.35 (0.31, 0.40)	0.40 (0.31, 0.58)	0.46 (0.43, 0.49)
Leukemia	0.76 (0.70, 0.82)	0.54 (0.42, 0.74)	0.76 (0.72, 0.81)
Acute Lymphocytic Leukemia	0.04 (0.03, 0.06)	0.05 (0.03, 0.19)	0.07 (0.06, 0.08)
Chronic Lymphocytic Leukemia	0.08 (0.06, 0.11)	0.08 (0.04, 0.23)	0.11 (0.10, 0.14)
Acute Myeloid Leukemia	0.41 (0.36, 0.46)	0.19 (0.13, 0.34)	0.30 (0.28, 0.33)
Chronic Myeloid Leukemia	0.04 (0.03, 0.06)	0.03 (0.01, 0.18)	0.05 (0.04, 0.06)

Devcan Version 6.7.9, April 2021s, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

^a Underlying mortality data for American Indian/Alaska Native are based on the PRCDA (Purchased/Referred Care Delivery Areas) counties.^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.19

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity
Females, Total U.S., 2016-2018

Site	All Races	Whites	Blacks
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	17.88 (17.84, 17.91)	18.04 (18.00, 18.08)	17.90 (17.79, 18.01)
Oral Cavity and Pharynx	0.19 (0.18, 0.19)	0.19 (0.19, 0.20)	0.14 (0.13, 0.15)
Esophagus	0.19 (0.19, 0.20)	0.20 (0.19, 0.20)	0.19 (0.17, 0.20)
Stomach	0.28 (0.28, 0.29)	0.25 (0.24, 0.25)	0.45 (0.43, 0.47)
Colon and Rectum	1.61 (1.60, 1.62)	1.59 (1.57, 1.60)	1.82 (1.78, 1.86)
Liver and Intrahepatic Bile Duct	0.55 (0.54, 0.56)	0.52 (0.52, 0.53)	0.59 (0.56, 0.61)
Pancreas	1.37 (1.35, 1.38)	1.35 (1.34, 1.36)	1.51 (1.48, 1.55)
Larynx	0.04 (0.04, 0.05)	0.04 (0.04, 0.05)	0.07 (0.06, 0.07)
Lung and Bronchus	4.18 (4.16, 4.20)	4.35 (4.33, 4.37)	3.49 (3.44, 3.54)
Melanoma of the Skin	0.18 (0.17, 0.18)	0.20 (0.20, 0.21)	0.04 (0.03, 0.04)
Breast	2.54 (2.53, 2.56)	2.50 (2.49, 2.52)	3.04 (3.00, 3.09)
Cervix Uteri	0.22 (0.21, 0.22)	0.21 (0.20, 0.21)	0.32 (0.30, 0.33)
Corpus and Uterus, NOS	0.65 (0.64, 0.66)	0.61 (0.60, 0.61)	1.03 (1.00, 1.06)
Ovary	0.84 (0.83, 0.85)	0.88 (0.87, 0.89)	0.66 (0.64, 0.69)
Urinary Bladder	0.34 (0.34, 0.35)	0.35 (0.34, 0.35)	0.34 (0.32, 0.36)
Kidney and Renal Pelvis	0.32 (0.32, 0.33)	0.33 (0.33, 0.34)	0.27 (0.26, 0.29)
Brain and Other Nervous System	0.42 (0.41, 0.42)	0.46 (0.45, 0.46)	0.24 (0.23, 0.25)
Thyroid	0.07 (0.07, 0.07)	0.07 (0.07, 0.07)	0.06 (0.06, 0.07)
Hodgkin Lymphoma	0.03 (0.03, 0.03)	0.03 (0.03, 0.03)	0.02 (0.01, 0.02)
Non-Hodgkin Lymphoma	0.61 (0.60, 0.62)	0.64 (0.63, 0.65)	0.36 (0.35, 0.38)
Myeloma	0.37 (0.36, 0.37)	0.34 (0.33, 0.34)	0.64 (0.62, 0.67)
Leukemia	0.67 (0.66, 0.68)	0.69 (0.68, 0.70)	0.54 (0.52, 0.56)
Acute Lymphocytic Leukemia	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	0.03 (0.03, 0.04)
Chronic Lymphocytic Leukemia	0.14 (0.13, 0.14)	0.14 (0.14, 0.15)	0.11 (0.10, 0.12)
Acute Myeloid Leukemia	0.29 (0.28, 0.29)	0.30 (0.29, 0.30)	0.22 (0.21, 0.24)
Chronic Myeloid Leukemia	0.04 (0.03, 0.04)	0.04 (0.03, 0.04)	0.03 (0.03, 0.04)

Devcan Version 6.7.9, April 2021s, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).
Source: NCHS public use data file for the total US.
A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.19 - continued

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity

Females, Total U.S., 2016-2018

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives ^a	Hispanics ^b
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	15.69 (15.46, 15.94)	15.02 (14.44, 15.64)	15.38 (15.23, 15.53)
Oral Cavity and Pharynx	0.21 (0.18, 0.24)	0.15 (0.08, 0.28)	0.14 (0.12, 0.16)
Esophagus	0.15 (0.12, 0.18)	0.18 (0.12, 0.30)	0.12 (0.10, 0.13)
Stomach	0.78 (0.72, 0.84)	0.44 (0.35, 0.58)	0.61 (0.58, 0.65)
Colon and Rectum	1.63 (1.55, 1.72)	1.70 (1.48, 1.96)	1.52 (1.47, 1.58)
Liver and Intrahepatic Bile Duct	1.00 (0.94, 1.07)	0.86 (0.73, 1.03)	1.01 (0.97, 1.05)
Pancreas	1.38 (1.31, 1.46)	0.98 (0.83, 1.18)	1.39 (1.34, 1.44)
Larynx	0.02 (0.01, 0.04)	0.03 (0.01, 0.12)	0.02 (0.02, 0.03)
Lung and Bronchus	3.11 (3.00, 3.22)	3.36 (3.08, 3.68)	2.04 (1.98, 2.10)
Melanoma of the Skin	0.06 (0.04, 0.09)	0.06 (0.03, 0.16)	0.08 (0.07, 0.09)
Breast	1.83 (1.75, 1.92)	1.85 (1.64, 2.10)	2.02 (1.97, 2.08)
Cervix Uteri	0.22 (0.20, 0.25)	0.21 (0.16, 0.32)	0.29 (0.27, 0.30)
Corpus and Uterus, NOS	0.52 (0.48, 0.56)	0.40 (0.32, 0.53)	0.61 (0.58, 0.64)
Ovary	0.66 (0.62, 0.71)	0.67 (0.56, 0.83)	0.72 (0.69, 0.75)
Urinary Bladder	0.25 (0.21, 0.30)	0.27 (0.17, 0.43)	0.27 (0.25, 0.30)
Kidney and Renal Pelvis	0.20 (0.17, 0.24)	0.45 (0.34, 0.62)	0.37 (0.35, 0.40)
Brain and Other Nervous System	0.28 (0.25, 0.31)	0.25 (0.18, 0.37)	0.37 (0.35, 0.40)
Thyroid	0.14 (0.11, 0.17)	0.07 (0.02, 0.20)	0.13 (0.11, 0.14)
Hodgkin Lymphoma	0.02 (0.01, 0.03)	0.03 (0.01, 0.13)	0.05 (0.04, 0.06)
Non-Hodgkin Lymphoma	0.60 (0.55, 0.66)	0.41 (0.31, 0.56)	0.66 (0.63, 0.70)
Myeloma	0.26 (0.23, 0.30)	0.43 (0.32, 0.60)	0.37 (0.35, 0.40)
Leukemia	0.49 (0.44, 0.54)	0.32 (0.24, 0.46)	0.58 (0.55, 0.61)
Acute Lymphocytic Leukemia	0.04 (0.03, 0.06)	0.04 (0.02, 0.13)	0.06 (0.06, 0.07)
Chronic Lymphocytic Leukemia	0.04 (0.03, 0.06)	0.01 (0.00, 0.11)	0.07 (0.06, 0.09)
Acute Myeloid Leukemia	0.26 (0.24, 0.30)	0.16 (0.11, 0.28)	0.24 (0.23, 0.26)
Chronic Myeloid Leukemia	0.02 (0.01, 0.04)	0.02 (0.01, 0.12)	0.02 (0.02, 0.03)

Devcan Version 6.7.9, April 2021s, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

^a Underlying mortality data for American Indian/Alaska Native are based on the PRCDA (Purchased/Referred Care Delivery Areas) counties.^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.20
U.S. and SEER Death Rates by Primary Cancer Site and Race/Ethnicity, 2014-2018

		Total United States ^a							SEER 21 Areas ^{ab}						
Site		Total	White	Black	AI/AN ^c	API ^d	Hisp ^e	W-NHisp ^e	Total	White	Black	AI/AN ^c	API ^d	Hisp ^e	W-NHisp ^e
All Sites	Both Sexes	155.5	156.3	177.5	141.1	97.2	110.8	160.2	149.0	152.6	166.4	119.8	100.7	110.9	156.6
	Male	185.5	185.9	221.1	169.3	114.6	134.0	190.2	176.6	180.0	205.3	144.7	120.0	132.8	184.4
	Female	133.5	134.3	150.5	120.1	84.6	94.6	137.8	129.4	132.8	142.8	101.2	86.8	96.0	136.5
Oral Cavity & Pharynx	Both Sexes	2.5	2.5	2.6	2.2	2.0	1.5	2.7	2.4	2.4	2.3	1.9	2.1	1.6	2.6
	Male	3.9	3.9	4.4	3.5	3.2	2.4	4.1	3.8	3.8	3.9	3.1	3.3	2.5	3.9
	Female	1.3	1.4	1.2	1.1	1.1	0.8	1.4	1.3	1.3	1.2	0.8	1.1	0.8	1.4
Esophagus	Both Sexes	3.9	4.1	3.0	3.3	1.6	2.0	4.4	3.6	4.0	2.8	3.0	1.6	2.1	4.2
	Male	6.9	7.4	5.0	5.9	2.7	3.7	7.7	6.4	7.0	4.7	4.7	2.8	3.8	7.4
	Female	1.4	1.4	1.6	1.3	0.7	0.7	1.5	1.4	1.4	1.4	1.5	0.7	0.8	1.5
Stomach	Both Sexes	3.0	2.6	5.2	4.7	5.0	4.9	2.2	3.4	3.0	5.1	4.9	5.2	5.3	2.4
	Male	4.0	3.5	7.6	6.3	6.3	6.3	3.1	4.5	4.0	7.4	7.0	6.7	6.7	3.4
	Female	2.2	1.9	3.5	3.5	4.0	3.9	1.6	2.5	2.2	3.5	3.2	4.1	4.3	1.7
Colon & Rectum	Both Sexes	13.7	13.4	18.0	15.1	9.4	10.9	13.6	13.1	13.0	16.7	14.2	9.8	10.6	13.2
	Male	16.3	15.9	22.5	18.5	11.2	14.0	16.1	15.5	15.3	20.6	16.0	11.9	13.2	15.5
	Female	11.5	11.3	14.8	12.4	7.9	8.6	11.5	11.1	11.1	14.0	12.6	8.1	8.5	11.3
Liver & Intrahepatic Bile Duct	Both Sexes	6.6	6.2	8.4	10.6	8.8	9.3	5.8	6.8	6.4	8.0	9.1	8.9	9.5	5.7
	Male	9.7	9.0	13.1	14.8	13.1	13.3	8.4	9.9	9.2	12.5	12.6	13.3	13.6	8.3
	Female	4.0	3.8	4.8	7.0	5.4	6.0	3.6	4.2	3.9	4.5	6.3	5.4	6.2	3.5
Pancreas	Both Sexes	11.0	11.0	13.3	8.7	7.5	8.6	11.2	10.9	11.1	12.4	7.1	8.0	8.7	11.3
	Male	12.7	12.8	15.0	10.1	8.1	9.5	13.0	12.4	12.7	13.8	9.4	8.7	9.5	13.0
	Female	9.6	9.5	12.0	7.5	7.1	7.8	9.6	9.6	9.7	11.3	5.4	7.4	7.9	9.8
Larynx	Both Sexes	0.9	0.9	1.5	0.8	0.3	0.7	0.9	0.8	0.8	1.3	0.6	0.3	0.6	0.9
	Male	1.7	1.6	2.9	1.6	0.6	1.3	1.6	1.5	1.5	2.6	1.4	0.5	1.2	1.5
	Female	0.4	0.4	0.5	-	0.1	0.1	0.4	0.3	0.3	0.5	-	0.1	0.1	0.4
Lung & Bronchus	Both Sexes	38.5	39.3	40.1	32.1	21.2	16.8	41.7	34.4	35.7	35.8	22.6	22.1	16.0	38.4
	Male	46.9	47.1	55.4	38.4	28.0	23.0	49.4	41.4	41.9	49.0	27.7	29.8	21.2	44.5
	Female	32.0	33.3	29.7	27.4	16.3	12.3	35.6	29.1	31.0	26.9	18.6	16.3	12.2	33.7
Melanoma of the Skin	Both Sexes	2.3	2.6	0.3	0.6	0.3	0.7	2.9	2.1	2.6	0.3	0.5	0.3	0.7	2.9
	Male	3.4	3.9	0.4	0.9	0.4	0.9	4.2	3.1	3.8	0.3	-	0.4	0.9	4.3
	Female	1.4	1.7	0.3	0.5	0.3	0.5	1.8	1.3	1.6	0.2	-	0.3	0.5	1.8
Breast	Female	20.1	19.6	27.3	14.8	11.7	13.8	20.1	19.7	19.6	26.4	13.1	12.2	13.7	20.2

^a US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b The SEER 21 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts.

^c Rates for American Indian/Alaska Native (AI/AN) are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^d Asian/Pacific Islander.

^e Hispanic (Hisp) and White Non-Hispanic (W-NHisp) are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table 1.20 - continued
U.S. and SEER Death Rates by Primary Cancer Site and Race/Ethnicity, 2014-2018

		Total United States ^a							SEER 21 Areas ^{ab}						
Site		Total	White	Black	AI/AN ^c	API ^d	Hisp ^e	W-NHisp ^e	Total	White	Black	AI/AN ^c	API ^d	Hisp ^e	W-NHisp ^e
Cervix	Female	2.2	2.1	3.3	2.4	1.7	2.6	2.0	2.1	2.0	3.1	1.9	1.8	2.5	1.8
Corpus & Uterus, NOS	Female	4.9	4.5	8.7	3.5	3.2	4.1	4.5	5.1	4.8	9.0	2.9	3.4	4.2	4.8
Ovary	Female	6.7	6.9	5.9	6.0	4.4	5.1	7.1	6.8	7.2	5.9	5.2	4.5	5.3	7.4
Prostate	Male	19.0	17.9	37.4	18.5	8.8	15.6	17.9	19.2	18.6	36.4	16.5	9.2	16.4	18.7
Testis	Male	0.3	0.3	0.1	0.4	0.1	0.3	0.3	0.3	0.3	0.1	-	0.1	0.3	0.3
Urinary Bladder	Both Sexes	4.3	4.5	3.5	2.7	1.7	2.3	4.7	4.2	4.6	3.3	2.7	1.8	2.3	4.8
	Male	7.4	7.8	5.3	4.0	2.8	3.8	8.2	7.2	7.9	5.0	4.1	3.0	3.7	8.4
	Female	2.1	2.2	2.3	1.7	0.9	1.3	2.2	2.1	2.2	2.2	1.6	0.9	1.4	2.3
Kidney & Renal Pelvis	Both Sexes	3.6	3.8	3.5	5.5	1.7	3.4	3.8	3.4	3.6	3.1	4.7	1.8	3.2	3.6
	Male	5.3	5.5	5.3	8.3	2.5	4.9	5.5	5.0	5.3	5.0	7.0	2.7	4.7	5.2
	Female	2.3	2.3	2.2	3.2	1.1	2.2	2.3	2.1	2.2	1.9	2.9	1.1	2.1	2.2
Brain & Nervous System	Both Sexes	4.4	4.8	2.7	2.5	2.3	3.0	5.1	4.3	4.9	2.6	2.3	2.3	3.1	5.2
	Male	5.4	5.9	3.2	2.7	2.7	3.5	6.2	5.3	5.9	3.1	2.9	2.8	3.6	6.3
	Female	3.6	3.9	2.3	2.3	1.9	2.6	4.1	3.5	4.0	2.1	1.8	2.0	2.6	4.2
Thyroid	Both Sexes	0.5	0.5	0.5	0.4	0.6	0.7	0.5	0.5	0.6	0.5	-	0.6	0.7	0.5
	Male	0.5	0.5	0.4	0.4	0.5	0.6	0.5	0.6	0.6	0.4	-	0.5	0.7	0.5
	Female	0.5	0.5	0.5	0.4	0.7	0.7	0.5	0.5	0.5	0.5	-	0.7	0.8	0.5
Hodgkin Lymphoma	Both Sexes	0.3	0.3	0.3	0.2	0.1	0.4	0.3	0.3	0.3	0.3	-	0.1	0.4	0.3
	Male	0.4	0.4	0.3	-	0.2	0.4	0.4	0.4	0.4	0.3	-	0.2	0.4	0.4
	Female	0.2	0.2	0.2	-	0.1	0.3	0.2	0.2	0.2	0.2	-	0.1	0.3	0.2
Non-Hodgkin Lymphoma	Both Sexes	5.4	5.6	4.0	4.2	3.7	4.6	5.7	5.3	5.6	3.9	3.7	3.8	4.7	5.7
	Male	7.0	7.3	5.1	5.5	4.8	5.8	7.4	6.9	7.3	5.0	4.5	5.0	5.8	7.4
	Female	4.1	4.3	3.1	3.3	2.9	3.7	4.3	4.1	4.3	3.1	3.1	3.0	3.8	4.3
Myeloma	Both Sexes	3.2	3.0	6.0	3.4	1.6	2.7	3.0	3.1	3.0	5.5	3.1	1.6	2.7	3.0
	Male	4.1	3.8	7.3	3.9	2.0	3.3	3.9	3.9	3.9	6.8	3.0	2.0	3.3	3.9
	Female	2.6	2.3	5.1	3.1	1.3	2.2	2.3	2.5	2.3	4.7	3.1	1.3	2.3	2.3
Leukemia	Both Sexes	6.3	6.5	5.3	4.0	3.5	4.5	6.6	6.0	6.4	5.0	3.2	3.7	4.5	6.5
	Male	8.4	8.7	6.8	5.5	4.7	5.6	8.9	8.0	8.5	6.4	4.8	4.9	5.6	8.7
	Female	4.7	4.9	4.3	2.8	2.6	3.6	4.9	4.6	4.9	4.2	1.9	2.8	3.7	4.9

^a US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b The SEER 21 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts.

^c Rates for American Indian/Alaska Native (AI/AN) are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^d Asian/Pacific Islander.

^e Hispanic (Hisp) and White Non-Hispanic (W-NHisp) are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table 1.21
U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2018^a
Using Different Tumor Inclusion Criteria^b

Site	Sex	5-Year Limited Duration			26-year Limited Duration	
		1st Invasive Tumor Ever ^c	1st Per Site in Previous 26 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 26 Years ^d
All Sites	Both Sexes	4,880,121	5,050,887	5,593,196	14,419,319	14,915,902
	Male	2,378,282	2,435,676	2,705,061	6,982,721	7,134,746
	Female	2,501,839	2,615,211	2,888,135	7,436,598	7,781,156
Oral Cavity & Pharynx	Both Sexes	123,575	147,227	152,996	312,390	354,830
	Male	89,094	104,227	107,930	216,952	243,022
	Female	34,481	43,000	45,066	95,438	111,808
Esophagus	Both Sexes	22,707	28,561	28,734	39,975	48,079
	Male	18,122	22,446	22,560	31,401	37,428
	Female	4,585	6,115	6,174	8,574	10,651
Stomach	Both Sexes	45,793	54,879	55,846	96,886	112,569
	Male	26,723	32,118	32,507	55,172	63,993
	Female	19,070	22,761	23,339	41,714	48,576
Colon & Rectum	Both Sexes	399,424	461,307	469,550	1,134,250	1,272,980
	Male	207,974	238,379	242,731	580,992	645,984
	Female	191,450	222,928	226,819	553,258	626,996
Liver & Intrahepatic Bile Duct	Both Sexes	53,795	62,920	63,305	81,772	93,247
	Male	38,455	44,554	44,839	58,224	65,633
	Female	15,340	18,366	18,466	23,548	27,614
Pancreas	Both Sexes	47,649	59,939	60,010	65,973	81,172
	Male	24,303	30,509	30,544	33,041	40,627
	Female	23,346	29,430	29,466	32,932	40,545
Larynx	Both Sexes	28,391	34,454	34,947	76,081	87,212
	Male	23,247	28,028	28,445	62,231	70,977
	Female	5,144	6,426	6,502	13,850	16,235
Lung & Bronchus	Both Sexes	248,933	328,150	340,962	423,209	543,260
	Male	112,552	149,779	154,619	184,864	237,505
	Female	136,381	178,371	186,343	238,345	305,755
Melanoma of the Skin	Both Sexes	316,066	371,450	394,522	995,989	1,115,391
	Male	174,737	209,450	225,195	519,840	589,435
	Female	141,329	162,000	169,327	476,149	525,956
Breast	Female	955,157	1,053,306	1,118,496	3,096,156	3,361,799
Cervix	Female	41,149	43,646	43,844	182,868	192,459
Corpus & Uterus, NOS	Female	213,645	240,805	241,088	632,326	699,551
Ovary ^f	Female	61,640	70,244	70,335	167,758	190,297

^a U.S. 2018 cancer prevalence counts are based on 2018 cancer prevalence proportions from the SEER 13 registries (not including the Alaska Natives Registry) and 1/1/2018 U.S. population estimates based on the average of 2017 and 2018 population estimates from the U.S. Bureau of the Census.

^b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

^c (c) First invasive tumor ever
^d (d) First invasive tumor for each cancer site diagnosed during the previous 26 years (1992-2017)
^e (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2013-2017)
For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2011; Melanoma in 2012.
In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 26-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2018.
In method (d) the 1981 melanoma is counted for the melanoma and all sites 26-year limited duration prevalence. The 2011 breast cancer is counted for the breast 5-year and 26-year limited duration prevalence.
In method (e) the 2011 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2012 melanoma is counted for 5-year limited duration prevalence for melanoma.

^f Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Table 1.21 - continued
U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2018^a
Using Different Tumor Inclusion Criteria^b

Site	Sex	5-Year Limited Duration			26-year Limited Duration	
		1st Invasive Tumor Ever ^c	1st Per Site in Previous 26 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 26 Years ^d
Prostate	Male	848,271	925,831	925,944	3,017,103	3,216,087
Testis	Male	45,457	46,348	46,918	197,380	201,333
Urinary Bladder	Both Sexes	206,551	262,551	269,110	555,999	666,514
	Male	159,177	202,966	208,207	421,030	504,748
	Female	47,374	59,585	60,903	134,969	161,766
Kidney & Renal Pelvis	Both Sexes	179,670	219,423	223,467	451,550	532,888
	Male	113,525	139,334	142,065	276,850	327,963
	Female	66,145	80,089	81,402	174,700	204,925
Brain & Nervous System	Both Sexes	45,116	48,855	49,316	129,633	135,594
	Male	24,479	26,587	26,865	68,587	71,585
	Female	20,637	22,268	22,451	61,046	64,009
Thyroid	Both Sexes	203,921	230,954	231,660	660,323	724,365
	Male	47,921	56,780	56,975	143,367	162,275
	Female	156,000	174,174	174,685	516,956	562,090
Hodgkin Lymphoma	Both Sexes	34,619	37,258	37,283	151,373	157,887
	Male	19,074	20,680	20,688	79,452	82,850
	Female	15,545	16,578	16,595	71,921	75,037
Non-Hodgkin Lymphoma	Both Sexes	218,558	260,111	265,977	615,513	699,378
	Male	118,252	141,099	144,166	327,916	372,109
	Female	100,306	119,012	121,811	287,597	327,269
Myeloma	Both Sexes	72,752	86,937	87,460	126,684	147,663
	Male	40,442	48,917	49,291	69,683	82,159
	Female	32,310	38,020	38,169	57,001	65,504
Leukemia	Both Sexes	137,850	164,784	165,287	373,716	422,183
	Male	80,968	97,034	97,350	215,372	243,137
	Female	56,882	67,750	67,937	158,344	179,046
Acute Lymphocytic Leukemia	Both Sexes	20,174	21,068	21,084	76,226	77,711
	Male	11,454	11,904	11,912	42,622	43,296
	Female	8,720	9,164	9,172	33,604	34,415
Childhood (Ages 0-19)	Both Sexes	70,886	71,020	71,510	293,997	294,727
	Male	37,593	37,665	37,938	154,711	155,080
	Female	33,293	33,355	33,572	139,286	139,647
Kaposi Sarcoma	Both Sexes	7,006	7,607	7,607	33,086	34,867
	Male	6,406	6,885	6,885	31,467	33,007
	Female	600	722	722	1,619	1,860
Mesothelioma	Both Sexes	3,263	4,303	4,303	4,768	6,044
	Male	2,274	3,004	3,004	2,991	3,853
	Female	989	1,299	1,299	1,777	2,191

^a U.S. 2018 cancer prevalence counts are based on 2018 cancer prevalence proportions from the SEER 9 registries and 1/1/2018 U.S. population estimates based on the average of 2017 and 2018 population estimates from the U.S. Bureau of the Census.

^b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

^c (c) First invasive tumor ever
^d (d) First invasive tumor for each cancer site diagnosed during the previous 26 years (1992-2017)
^e (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2013-2017)
For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2011; Melanoma in 2012.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 26-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2018. In method (d) the 1981 melanoma is counted for the melanoma and all sites 26-year limited duration prevalence. The 2011 breast cancer is counted for the breast 5-year and 26-year limited duration prevalence. In method (e) the 2011 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2012 melanoma is counted for 5-year limited duration prevalence for melanoma.

Table 1.22
U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2018^a
By Age at Prevalence

Site/Sex	Age at Prevalence								
	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
All Sites									
Males	7,505,669	19,862	49,240	96,083	180,670	335,822	909,233	1,971,545	3,943,213
Females	8,847,752	17,753	41,566	96,287	268,119	650,428	1,475,237	2,302,303	3,996,060
Oral Cavity & Pharynx									
Males	269,596	73	484	1,500	3,868	13,005	48,826	90,629	111,211
Females	127,341	38	526	1,677	3,761	8,853	20,939	33,857	57,690
Esophagus									
Males	38,335	0	0	27	161	969	4,638	12,150	20,390
Females	11,115	0	0	16	65	201	1,051	3,171	6,610
Stomach									
Males	68,418	0	33	160	931	2,864	8,900	18,019	37,512
Females	51,883	0	31	239	1,059	2,809	7,732	12,431	27,582
Colon & Rectum									
Males	684,455	8	658	1,921	8,059	27,902	98,969	176,027	370,911
Females	680,680	38	828	2,515	8,193	27,136	88,095	151,975	401,899
Liver & Intrahep									
Males	66,438	670	806	590	659	1,663	9,884	30,858	21,308
Females	29,740	575	733	421	682	1,150	4,070	10,305	11,805
Pancreas									
Males	41,865	14	73	122	606	1,893	6,875	13,689	18,592
Females	41,912	0	104	373	1,005	2,551	5,920	12,411	19,547
Larynx									
Males	78,352	0	5	79	333	1,448	8,233	22,428	45,826
Females	17,670	0	0	53	163	528	2,868	5,296	8,763
Lung & Bronchus									
Males	258,486	73	114	428	1,308	4,405	22,920	70,123	159,114
Females	324,145	74	80	490	1,576	5,917	31,857	82,223	201,928
Melanoma of the Skin									
Males	663,784	46	500	4,021	16,372	39,705	98,334	173,862	330,944
Females	631,102	126	746	7,416	33,393	66,792	126,331	160,996	235,302

^a U.S. 2018 cancer prevalence counts are based on 2018 cancer prevalence proportions from the SEER 13 areas not including the Alaska Natives Registry (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, Rural Georgia, San Jose-Monterey, and Los Angeles) and 1/1/2018 U.S. population estimates based on the average of 2017 and 2018 population estimates from the U.S. Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 26 years. Cases diagnosed more than 26 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^c Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

Table 1.22 - continued
U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2018^a
By Age at Prevalence

Site/Sex	Age at Prevalence								
	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
Breast									
Males	20,786	0	0	4	153	573	2,317	4,929	12,810
Females	3,676,262	8	82	3,180	42,927	211,749	605,824	1,005,322	1,807,170
Cervix									
Females	293,394	0	33	1,511	14,936	39,664	64,977	74,049	98,224
Corpus & Uterus, NOS									
Females	813,861	0	44	894	7,867	30,259	101,835	238,387	434,574
Ovary ^d									
Females	235,081	48	1,186	4,398	9,165	18,677	44,682	65,833	91,091
Prostate									
Males	3,245,430	32	61	81	142	11,967	207,046	855,584	2,170,516
Urinary Bladder									
Males	544,935	81	69	621	2,135	8,355	38,095	118,443	377,136
Females	178,810	33	82	274	1,004	2,909	12,556	35,885	126,067
Kidney & Renal Pelvis									
Males	356,913	1,494	2,197	2,587	9,229	23,570	58,084	100,411	159,341
Females	225,814	1,675	2,628	3,291	7,228	16,209	34,668	57,445	102,668
Hodgkin Lymphoma									
Males	112,578	169	2,333	10,026	15,925	20,933	27,090	21,569	14,532
Females	106,550	29	1,774	9,047	16,474	21,063	25,044	18,966	14,154
Non-Hodgkin Lymphoma									
Males	394,545	946	4,144	8,455	14,859	28,296	61,683	100,701	175,460
Females	348,631	524	1,900	4,969	10,369	21,583	49,290	86,675	173,321
Myeloma									
Males	83,038	0	8	72	702	3,692	11,948	24,947	41,669
Females	66,918	3	9	78	504	2,844	9,857	20,284	33,339
Leukemia									
Males	260,650	6,976	16,133	17,880	14,147	17,808	33,353	55,685	98,669
Females	198,408	6,391	12,430	14,279	12,520	14,524	23,954	38,278	76,033
Acute Lymphocytic Leuk									
Males	56,452	5,705	13,467	13,809	9,153	7,129	4,281	1,912	994
Females	47,084	5,197	10,623	10,597	8,134	6,150	3,628	1,657	1,098

^a U.S. 2018 cancer prevalence counts are based on 2018 cancer prevalence proportions from the SEER 13 areas not including the Alaska Natives Registry (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, Rural Georgia, San Jose-Monterey, and Los Angeles) and 1/1/2018 U.S. population estimates based on the average of 2017 and 2018 population estimates from the U.S. Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 26 years. Cases diagnosed more than 26 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^c Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

Table 1.23
Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites^a by Race/Ethnicity
Both Sexes

All Races			White			Black		
	Rate ^b 2014-2018	APC ^c 2009-2018		Rate ^b 2014-2018	APC ^c 2009-2018		Rate ^b 2014-2018	APC ^c 2009-2018
All Sites	450.5	-0.9*	All Sites	460.9	-1.0*	All Sites	445.2	-1.5*
Breast	69.1	0.1	Breast	69.7	-0.1	Prostate ^f	74.8	-3.5*
Lung and Bronchus	53.1	-2.2*	Lung and Bronchus	54.9	-2.2*	Breast	71.1	0.0
Prostate ^f	50.9	-3.2*	Prostate ^f	48.2	-3.6*	Lung and Bronchus	53.7	-2.8*
Colon and Rectum	37.8	-1.9*	Colon and Rectum	37.4	-1.8*	Colon and Rectum	42.6	-2.9*
Melanoma of the Skin	22.8	1.0*	Melanoma of the Skin	27.4	1.1*	Kidney and Renal Pelvis	17.4	-0.2
Urinary Bladder	19.7	-1.5*	Urinary Bladder	21.7	-1.5*	Corpus and Uterus, NOS ^f	16.3	1.5*
Non-Hodgkin Lymphoma	19.6	-0.7*	Non-Hodgkin Lymphoma	20.6	-0.8*	Pancreas	15.5	0.2
Kidney and Renal Pelvis	16.4	0.6*	Kidney and Renal Pelvis	17.0	0.6*	Non-Hodgkin Lymphoma	14.7	-0.7*
Thyroid	15.5	0.1	Thyroid	16.2	-0.1	Myeloma	13.8	-0.1
Corpus and Uterus, NOS ^f	14.9	0.8*	Leukemia	15.2	-0.7	Urinary Bladder	11.5	-1.2*
Leukemia	14.3	-0.6	Corpus and Uterus, NOS ^f	15.0	0.5*	Leukemia	11.0	-0.2
Pancreas	13.2	0.6*	Pancreas	13.3	0.7*	Liver & IBD ^g	10.6	0.0
Oral Cavity and Pharynx	11.5	0.5*	Oral Cavity and Pharynx	12.1	0.6*	Stomach	10.0	-2.3*
Liver & IBD ^g	9.0	1.0*	Liver & IBD ^g	8.2	1.6*	Thyroid	9.4	0.0
Stomach	7.2	-1.0*	Brain and ONS ^g	7.1	-0.5*	Oral Cavity and Pharynx	8.5	-1.3*
Asian/Pacific Islander			American Indian/Alaska Native ^d			Hispanic ^e		
	Rate ^b 2014-2018	APC ^c 2009-2018		Rate ^b 2014-2018	APC ^c 2009-2018		Rate ^b 2014-2018	APC ^c 2009-2018
All Sites	307.9	-0.7*	All Sites	315.1	-1.0*	All Sites	355.3	-1.0*
Breast	57.5	1.5*	Breast	43.8	-0.7	Breast	53.7	0.5
Lung and Bronchus	35.7	-1.1*	Colon and Rectum	38.5	-1.7*	Prostate ^f	40.4	-4.7*
Colon and Rectum	31.3	-2.4*	Lung and Bronchus	37.7	-1.5*	Colon and Rectum	33.7	-1.5*
Prostate ^f	25.5	-3.7*	Prostate ^f	23.6	-5.4*	Lung and Bronchus	28.6	-2.2*
Thyroid	15.8	0.7	Kidney and Renal Pelvis	18.5	0.7	Non-Hodgkin Lymphoma	18.1	-0.6*
Non-Hodgkin Lymphoma	13.6	-0.3	Liver & IBD ^g	14.6	0.9	Kidney and Renal Pelvis	16.4	1.3*
Liver & IBD ^g	12.7	-2.6*	Non-Hodgkin Lymphoma	10.8	-3.5*	Thyroid	14.3	1.6*
Corpus and Uterus, NOS ^f	12.1	2.0*	Corpus and Uterus, NOS ^f	10.6	-0.1	Liver & IBD ^g	13.8	0.1
Stomach	10.1	-3.1*	Pancreas	10.4	1.4	Corpus and Uterus, NOS ^f	13.4	1.9*
Pancreas	10.0	0.3	Urinary Bladder	9.8	2.2	Pancreas	11.8	0.5
Urinary Bladder	8.9	-0.9*	Thyroid	9.6	2.2*	Leukemia	11.0	-0.7
Kidney and Renal Pelvis	8.8	0.9	Leukemia	8.9	0.9	Urinary Bladder	11.0	-1.6*
Oral Cavity and Pharynx	8.5	0.7	Oral Cavity and Pharynx	7.9	-1.7	Stomach	10.4	-1.4*
Leukemia	8.2	-0.3	Stomach	7.8	-3.3	Oral Cavity and Pharynx	7.1	-0.6
Ovary ^{fh}	5.1	-0.8	Myeloma	5.8	3.2	Myeloma	6.9	-0.1

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^a Top 15 cancer sites selected based on 2014-2018 age-adjusted rates for the race/ethnic group.

^b Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^c The APC is the Annual Percent Change over the time interval.

Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^d Rates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^e Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^f The rates for sex-specific cancer sites are calculated using the population for both sexes combined.

^g IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

^h Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

* The APC is significantly different from zero ($p < .05$).

- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

Table 1.24
Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites^a by Race/Ethnicity

All Races			White			Black		
	Rate ^b	APC ^c		Rate ^b	APC ^c		Rate ^b	APC ^c
	2014-2018	2009-2018		2014-2018	2009-2018		2014-2018	2009-2018
All Sites	489.2	-1.6*	All Sites	495.8	-1.6*	All Sites	518.9	-2.5*
Prostate	111.3	-3.4*	Prostate	104.1	-3.8*	Prostate	175.8	-3.7*
Lung and Bronchus	60.1	-3.0*	Lung and Bronchus	60.5	-3.0*	Lung and Bronchus	69.3	-3.6*
Colon and Rectum	43.2	-2.0*	Colon and Rectum	42.5	-2.0*	Colon and Rectum	49.9	-3.0*
Urinary Bladder	34.2	-1.7*	Urinary Bladder	37.5	-1.7*	Kidney and Renal Pelvis	24.4	-0.3
Melanoma of the Skin	29.3	0.9*	Melanoma of the Skin	34.7	1.0*	Urinary Bladder	19.2	-1.6*
Non-Hodgkin Lymphoma	23.7	-0.8*	Non-Hodgkin Lymphoma	24.9	-0.8*	Non-Hodgkin Lymphoma	17.7	-1.0*
Kidney and Renal Pelvis	22.6	0.5*	Kidney and Renal Pelvis	23.2	0.5*	Liver & IBD ^f	17.6	0.0
Leukemia	18.3	-0.7	Leukemia	19.4	-0.8	Pancreas	17.0	0.0
Oral Cavity and Pharynx	17.3	0.5*	Oral Cavity and Pharynx	18.2	0.7*	Myeloma	16.3	-0.4
Pancreas	15.0	0.6*	Pancreas	15.2	0.7*	Leukemia	13.9	-0.5
Liver & IBD ^f	13.8	0.7	Liver & IBD ^f	12.5	1.1*	Stomach	13.5	-2.2*
Stomach	9.7	-1.6*	Stomach	8.7	-1.6*	Oral Cavity and Pharynx	13.2	-1.3*
Myeloma	8.8	0.0	Thyroid	8.5	0.6	Larynx	7.0	-3.8*
Thyroid	8.0	0.8	Brain and ONS ^f	8.3	-0.5*	Esophagus	5.8	-4.1*
Brain and ONS ^f	7.6	-0.5*	Myeloma	8.2	0.0	Brain and ONS ^f	4.6	-0.5

Asian/Pacific Islander			American Indian/Alaska Native ^d			Hispanic ^e		
	Rate ^b	APC ^c		Rate ^b	APC ^c		Rate ^b	APC ^c
	2014-2018	2009-2018		2014-2018	2009-2018		2014-2018	2009-2018
All Sites	309.1	-1.8*	All Sites	326.7	-1.6*	All Sites	375.3	-2.2*
Prostate	57.7	-3.8*	Prostate	53.1	-5.4*	Prostate	90.9	-5.0*
Lung and Bronchus	45.0	-1.9*	Lung and Bronchus	40.9	-3.4*	Colon and Rectum	39.5	-2.0*
Colon and Rectum	37.1	-2.3*	Colon and Rectum	39.6	-3.5*	Lung and Bronchus	34.4	-2.9*
Liver & IBD ^f	19.4	-2.6*	Kidney and Renal Pelvis	24.2	0.9	Kidney and Renal Pelvis	21.6	1.2*
Non-Hodgkin Lymphoma	16.5	-0.4	Liver & IBD ^f	21.7	1.5	Non-Hodgkin Lymphoma	20.7	-0.8
Urinary Bladder	15.6	-0.8	Urinary Bladder	17.0	1.5	Liver & IBD ^f	20.4	-0.6
Stomach	13.4	-3.1*	Pancreas	13.4	2.5	Urinary Bladder	19.1	-1.8*
Kidney and Renal Pelvis	12.3	0.4	Oral Cavity and Pharynx	12.2	-0.5	Leukemia	13.2	-0.9
Oral Cavity and Pharynx	12.1	0.5	Non-Hodgkin Lymphoma	11.8	-2.7	Stomach	13.1	-2.0*
Pancreas	10.9	0.4	Leukemia	11.7	2.9	Pancreas	12.8	0.1
Leukemia	10.3	-0.4	Stomach	10.1	-4.0	Oral Cavity and Pharynx	10.3	-1.2
Thyroid	7.9	1.6*	Myeloma	6.8	-	Myeloma	8.2	-0.7
Myeloma	4.8	-1.2	Melanoma of the Skin	6.4	1.6	Thyroid	6.0	2.2*
Brain and ONS ^f	4.5	-0.1	Esophagus	6.4	-	Brain and ONS ^f	5.8	-0.3
Esophagus	3.8	0.0	Testis	5.3	-1.0	Testis	5.5	1.9*

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^a Top 15 cancer sites selected based on 2014-2018 age-adjusted rates for the race/ethnic group.

^b Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^c The APC is the Annual Percent Change over the time interval.

Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^d Rates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^e Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^f IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

* The APC is significantly different from zero ($p < .05$).

- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

Table 1.25
Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites^a by Race/Ethnicity

Females

All Races			White			Black		
	Rate ^b	APC ^c		Rate ^b	APC ^c		Rate ^b	APC ^c
	2014-2018	2009-2018		2014-2018	2009-2018		2014-2018	2009-2018
All Sites	425.6	-0.3*	All Sites	439.5	-0.3*	All Sites	396.4	-0.6*
Breast	129.1	0.3	Breast	131.8	0.1	Breast	124.7	0.2
Lung and Bronchus	47.9	-1.5*	Lung and Bronchus	50.8	-1.4*	Lung and Bronchus	43.3	-2.1*
Colon and Rectum	33.3	-1.9*	Colon and Rectum	33.0	-1.7*	Colon and Rectum	37.5	-2.9*
Corpus and Uterus, NOS	28.1	1.0*	Corpus and Uterus, NOS	28.6	0.7*	Corpus and Uterus, NOS	28.5	1.7*
Thyroid	22.8	0.0	Thyroid	23.9	-0.3	Pancreas	14.3	0.4
Melanoma of the Skin	18.0	1.1*	Melanoma of the Skin	22.1	1.2*	Thyroid	14.0	0.1
Non-Hodgkin Lymphoma	16.2	-0.7*	Non-Hodgkin Lymphoma	17.0	-0.8*	Non-Hodgkin Lymphoma	12.4	-0.3
Pancreas	11.8	0.6*	Leukemia	11.8	-0.7	Kidney and Renal Pelvis	12.1	-0.1
Kidney and Renal Pelvis	11.2	0.6*	Pancreas	11.7	0.6*	Myeloma	12.1	0.0
Leukemia	11.1	-0.6	Kidney and Renal Pelvis	11.6	0.6*	Leukemia	9.1	0.0
Ovary ^g	10.9	-2.3*	Ovary ^g	11.3	-2.6*	Ovary ^g	9.0	-1.7*
Urinary Bladder	8.5	-1.5*	Urinary Bladder	9.3	-1.5*	Cervix Uteri	8.6	-1.5*
Cervix Uteri	7.5	-0.3	Cervix Uteri	7.3	-0.3	Stomach	7.7	-2.3*
Oral Cavity and Pharynx	6.5	0.2	Oral Cavity and Pharynx	6.7	0.3*	Urinary Bladder	6.4	-1.1*
Myeloma	5.7	0.3	Brain and ONS ^f	6.0	-0.6	Liver & IBD ^f	5.3	0.1
Asian/Pacific Islander			American Indian/Alaska Native ^d			Hispanic ^e		
	Rate ^b	APC ^c		Rate ^b	APC ^c		Rate ^b	APC ^c
	2014-2018	2009-2018		2014-2018	2009-2018		2014-2018	2009-2018
All Sites	311.5	0.1	All Sites	311.1	-0.5	All Sites	348.4	0.2
Breast	105.1	1.5*	Breast	81.7	-0.7	Breast	100.3	0.8*
Lung and Bronchus	28.7	-0.3	Colon and Rectum	37.5	-0.1	Colon and Rectum	29.3	-1.0*
Colon and Rectum	26.5	-2.7*	Lung and Bronchus	35.5	0.5	Corpus and Uterus, NOS	25.3	2.2*
Thyroid	22.8	0.4	Corpus and Uterus, NOS	20.0	0.0	Lung and Bronchus	24.6	-1.4*
Corpus and Uterus, NOS	22.3	2.0*	Thyroid	14.7	2.6*	Thyroid	22.5	1.6*
Non-Hodgkin Lymphoma	11.3	-0.2	Kidney and Renal Pelvis	14.0	0.3	Non-Hodgkin Lymphoma	16.0	-0.4
Ovary ^g	9.4	-0.7	Non-Hodgkin Lymphoma	10.1	-3.6	Kidney and Renal Pelvis	12.1	1.3*
Pancreas	9.3	0.2	Liver & IBD ^f	8.6	0.3	Pancreas	11.1	0.9*
Stomach	7.6	-3.3*	Ovary ^g	8.5	-1.8	Ovary ^g	10.3	-0.8
Liver & IBD ^f	7.1	-2.5*	Pancreas	8.2	-0.2	Cervix Uteri	9.3	-0.9
Leukemia	6.6	-0.3	Cervix Uteri	7.6	-0.6	Leukemia	9.3	-0.6
Cervix Uteri	6.4	-0.6	Leukemia	6.6	-1.4	Stomach	8.4	-0.6
Kidney and Renal Pelvis	5.9	1.5*	Stomach	5.8	-2.8	Liver & IBD ^f	8.2	1.3
Oral Cavity and Pharynx	5.6	0.9	Melanoma of the Skin	5.0	-0.6	Myeloma	6.0	0.5
Urinary Bladder	3.7	-1.6*	Myeloma	4.9	0.2	Urinary Bladder	5.0	-1.4*

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^a Top 15 cancer sites selected based on 2014-2018 age-adjusted rates for the race/ethnic group.

^b Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^c The APC is the Annual Percent Change over the time interval.

Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^d Rates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^e Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^f IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

^g Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

Table 1.26
Age-Adjusted U.S. Death Rates and Trends for the Top 15 Cancer Sites^a by Race/Ethnicity
Both Sexes

All Races			White			Black		
	Rate ^b 2014-2018	APC ^c 2009-2018		Rate ^b 2014-2018	APC ^c 2009-2018		Rate ^b 2014-2018	APC ^c 2009-2018
All Sites	155.5	-1.6*	All Sites	156.3	-1.5*	All Sites	177.5	-2.2*
Lung and Bronchus	38.5	-3.6*	Lung and Bronchus	39.3	-3.4*	Lung and Bronchus	40.1	-4.0*
Colon and Rectum	13.7	-2.0*	Colon and Rectum	13.4	-1.8*	Colon and Rectum	18.0	-2.8*
Breast	11.1	-1.5*	Pancreas	11.0	0.3*	Breast	16.0	-1.6*
Pancreas	11.0	0.2*	Breast	10.8	-1.5*	Prostate ^f	13.9	-2.7*
Prostate ^f	7.8	-1.1*	Prostate ^f	7.4	-0.8*	Pancreas	13.3	-0.3*
Liver & IBD ^g	6.6	1.5*	Leukemia	6.5	-1.7*	Liver & IBD ^g	8.4	0.8*
Leukemia	6.3	-1.8*	Liver & IBD ^g	6.2	1.9*	Myeloma	6.0	-0.8
Non-Hodgkin Lymphoma	5.4	-2.2*	Non-Hodgkin Lymphoma	5.6	-2.2*	Leukemia	5.3	-1.8*
Brain and ONS ^g	4.4	0.4*	Brain and ONS ^g	4.8	0.5*	Stomach	5.2	-3.2*
Urinary Bladder	4.3	-0.5*	Urinary Bladder	4.5	-0.4	Corpus and Uterus, NOS ^f	5.1	1.7*
Esophagus	3.9	-1.3*	Esophagus	4.1	-0.8*	Non-Hodgkin Lymphoma	4.0	-2.0*
Ovary ^f	3.7	-2.6*	Kidney and Renal Pelvis	3.8	-1.2*	Kidney and Renal Pelvis	3.5	-1.6*
Kidney and Renal Pelvis	3.6	-1.3*	Ovary ^f	3.8	-2.6*	Urinary Bladder	3.5	-0.8*
Myeloma	3.2	-0.8*	Myeloma	3.0	-0.8*	Ovary ^f	3.4	-2.4*
Stomach	3.0	-2.1*	Melanoma of the Skin	2.6	-3.3*	Esophagus	3.0	-4.5*
Asian/Pacific Islander			American Indian/Alaska Native ^d			Hispanic ^e		
	Rate ^b 2014-2018	APC ^c 2009-2018		Rate ^b 2014-2018	APC ^c 2009-2018		Rate ^b 2014-2018	APC ^c 2009-2018
All Sites	97.2	-1.6*	All Sites	141.1	-1.4*	All Sites	110.8	-1.2*
Lung and Bronchus	21.2	-2.8*	Lung and Bronchus	32.1	-2.9*	Lung and Bronchus	16.8	-3.3*
Colon and Rectum	9.4	-2.3*	Colon and Rectum	15.1	-1.4	Colon and Rectum	10.9	-1.7*
Liver & IBD ^g	8.8	-2.1*	Liver & IBD ^g	10.6	1.5	Liver & IBD ^g	9.3	0.7*
Pancreas	7.5	-0.6	Pancreas	8.7	0.7	Pancreas	8.6	0.0
Breast	6.5	0.5	Breast	8.3	0.4	Breast	7.6	-1.1*
Stomach	5.0	-3.2*	Prostate ^f	7.6	-1.2	Prostate ^f	6.4	-1.5*
Non-Hodgkin Lymphoma	3.7	-1.8*	Kidney and Renal Pelvis	5.5	-2.0	Stomach	4.9	-1.8*
Prostate ^f	3.6	-0.5	Stomach	4.7	-2.3	Non-Hodgkin Lymphoma	4.6	-2.1*
Leukemia	3.5	-2.2*	Non-Hodgkin Lymphoma	4.2	-1.4	Leukemia	4.5	-1.5*
Ovary ^f	2.4	-0.7	Leukemia	4.0	-1.7	Kidney and Renal Pelvis	3.4	-0.5
Brain and ONS ^g	2.3	2.2*	Myeloma	3.4	3.4	Brain and ONS ^g	3.0	1.0*
Oral Cavity and Pharynx	2.0	0.4	Esophagus	3.3	-0.8	Ovary ^f	2.8	-2.0*
Corpus and Uterus, NOS ^f	1.8	2.1*	Ovary ^f	3.3	-2.2	Myeloma	2.7	-1.0*
Kidney and Renal Pelvis	1.7	-2.8*	Urinary Bladder	2.7	2.3	Urinary Bladder	2.3	0.0
Urinary Bladder	1.7	-0.7	Brain and ONS ^g	2.5	1.1	Corpus and Uterus, NOS ^f	2.2	2.2*

Source: US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^a Top 15 cancer sites selected based on 2014-2018 age-adjusted rates for the race/ethnic group.

^b Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^c The APC is the Annual Percent Change over the time interval.

Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^d Rates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^e Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^f The rates for sex-specific cancer sites are calculated using the population for both sexes combined.

^g IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

* The APC is significantly different from zero ($p < .05$).

- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

Table 1.27
Age-Adjusted U.S. Death Rates and Trends for the Top 15 Cancer Sites^a by Race/Ethnicity

Males								
All Races			White			Black		
	Rate ^b 2014-2018	APC ^c 2009-2018		Rate ^b 2014-2018	APC ^c 2009-2018		Rate ^b 2014-2018	APC ^c 2009-2018
All Sites	185.5	-1.9*	All Sites	185.9	-1.8*	All Sites	221.1	-2.8*
Lung and Bronchus	46.9	-4.1*	Lung and Bronchus	47.1	-4.1*	Lung and Bronchus	55.4	-4.7*
Prostate	19.0	-1.7*	Prostate	17.9	-1.5*	Prostate	37.4	-3.3*
Colon and Rectum	16.3	-2.1*	Colon and Rectum	15.9	-2.0*	Colon and Rectum	22.5	-2.7*
Pancreas	12.7	0.2*	Pancreas	12.8	0.3*	Pancreas	15.0	-0.1
Liver & IBD ^f	9.7	1.3*	Liver & IBD ^f	9.0	1.6*	Liver & IBD ^f	13.1	0.5
Leukemia	8.4	-1.9*	Leukemia	8.7	-1.8*	Stomach	7.6	-3.2*
Urinary Bladder	7.4	-0.7*	Urinary Bladder	7.8	-0.6*	Myeloma	7.3	-0.7*
Non-Hodgkin Lymphoma	7.0	-2.0*	Esophagus	7.4	-0.9*	Leukemia	6.8	-2.2*
Esophagus	6.9	-1.4*	Non-Hodgkin Lymphoma	7.3	-1.9*	Kidney and Renal Pelvis	5.3	-1.1
Brain and ONS ^f	5.4	0.4	Brain and ONS ^f	5.9	0.4*	Urinary Bladder	5.3	-0.6
Kidney and Renal Pelvis	5.3	-1.3*	Kidney and Renal Pelvis	5.5	-1.2*	Non-Hodgkin Lymphoma	5.1	-2.0*
Myeloma	4.1	-0.8*	Oral Cavity and Pharynx	3.9	1.0*	Esophagus	5.0	-5.2*
Stomach	4.0	-2.4*	Melanoma of the Skin	3.9	-3.5*	Oral Cavity and Pharynx	4.4	-2.2*
Oral Cavity and Pharynx	3.9	0.7*	Myeloma	3.8	-0.8*	Brain and ONS ^f	3.2	0.4
Melanoma of the Skin	3.4	-3.7*	Stomach	3.5	-2.3*	Larynx	2.9	-3.5*
Asian/Pacific Islander			American Indian/Alaska Native ^d			Hispanic ^e		
	Rate ^b 2014-2018	APC ^c 2009-2018		Rate ^b 2014-2018	APC ^c 2009-2018		Rate ^b 2014-2018	APC ^c 2009-2018
All Sites	114.6	-2.0*	All Sites	169.3	-1.4*	All Sites	134.0	-1.7*
Lung and Bronchus	28.0	-3.4*	Lung and Bronchus	38.4	-3.5*	Lung and Bronchus	23.0	-4.2*
Liver & IBD ^f	13.1	-2.0*	Colon and Rectum	18.5	-0.3	Prostate	15.6	-1.9*
Colon and Rectum	11.2	-2.2*	Prostate	18.5	-1.6	Colon and Rectum	14.0	-1.7*
Prostate	8.8	-0.8	Liver & IBD ^f	14.8	1.5	Liver & IBD ^f	13.3	0.5
Pancreas	8.1	-0.5	Pancreas	10.1	1.8	Pancreas	9.5	-0.3
Stomach	6.3	-3.7*	Kidney and Renal Pelvis	8.3	-0.9	Stomach	6.3	-2.5*
Non-Hodgkin Lymphoma	4.8	-1.0*	Stomach	6.3	-3.7	Non-Hodgkin Lymphoma	5.8	-1.7*
Leukemia	4.7	-1.5*	Esophagus	5.9	0.3	Leukemia	5.6	-1.5*
Oral Cavity and Pharynx	3.2	1.0	Non-Hodgkin Lymphoma	5.5	0.2	Kidney and Renal Pelvis	4.9	-0.3
Urinary Bladder	2.8	-0.5	Leukemia	5.5	-2.1	Urinary Bladder	3.8	-0.3
Brain and ONS ^f	2.7	2.7*	Urinary Bladder	4.0	0.6	Esophagus	3.7	-2.1*
Esophagus	2.7	-1.4*	Myeloma	3.9	5.2*	Brain and ONS ^f	3.5	0.3
Kidney and Renal Pelvis	2.5	-3.2*	Oral Cavity and Pharynx	3.5	-0.5	Myeloma	3.3	-1.2
Myeloma	2.0	-2.0*	Brain and ONS ^f	2.7	-1.1	Oral Cavity and Pharynx	2.4	-0.2
Soft Tissue including Heart	1.0	-0.4	Larynx	1.6	-	Larynx	1.3	-3.8*

Source: US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^a Top 15 cancer sites selected based on 2014-2018 age-adjusted rates for the race/ethnic group.

^b Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^c The APC is the Annual Percent Change over the time interval.

Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^d Rates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^e Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^f IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

* The APC is significantly different from zero ($p < .05$).

- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

Table 1.28
Age-Adjusted U.S. Death Rates and Trends for the Top 15 Cancer Sites^a by Race/Ethnicity

Females

All Races			White			Black		
	Rate ^b	APC ^c		Rate ^b	APC ^c		Rate ^b	APC ^c
	2014-2018	2009-2018		2014-2018	2009-2018		2014-2018	2009-2018
All Sites	133.5	-1.5*	All Sites	134.3	-1.4*	All Sites	150.5	-1.7*
Lung and Bronchus	32.0	-3.0*	Lung and Bronchus	33.3	-2.8*	Lung and Bronchus	29.7	-3.3*
Breast	20.1	-1.4*	Breast	19.6	-1.4*	Breast	27.3	-1.5*
Colon and Rectum	11.5	-2.0*	Colon and Rectum	11.3	-1.8*	Colon and Rectum	14.8	-3.0*
Pancreas	9.6	0.1	Pancreas	9.5	0.2*	Pancreas	12.0	-0.3
Ovary	6.7	-2.4*	Ovary	6.9	-2.4*	Corpus and Uterus, NOS	8.7	1.9*
Corpus and Uterus, NOS	4.9	2.0*	Leukemia	4.9	-1.7*	Ovary	5.9	-2.2*
Leukemia	4.7	-1.8*	Corpus and Uterus, NOS	4.5	1.9*	Myeloma	5.1	-1.0
Non-Hodgkin Lymphoma	4.1	-2.6*	Non-Hodgkin Lymphoma	4.3	-2.6*	Liver & IBD ^f	4.8	1.5*
Liver & IBD ^f	4.0	1.9*	Brain and ONS ^f	3.9	0.5	Leukemia	4.3	-1.4*
Brain and ONS ^f	3.6	0.4	Liver & IBD ^f	3.8	2.2*	Stomach	3.5	-3.5*
Myeloma	2.6	-0.9*	Kidney and Renal Pelvis	2.3	-1.4*	Cervix Uteri	3.3	-3.0*
Kidney and Renal Pelvis	2.3	-1.6*	Myeloma	2.3	-1.0*	Non-Hodgkin Lymphoma	3.1	-2.1*
Cervix Uteri	2.2	-0.5*	Urinary Bladder	2.2	-0.4	Urinary Bladder	2.3	-1.3*
Stomach	2.2	-1.9*	Cervix Uteri	2.1	0.2	Brain and ONS ^f	2.3	1.0
Urinary Bladder	2.1	-0.6*	Stomach	1.9	-1.8*	Kidney and Renal Pelvis	2.2	-2.6*

Asian/Pacific Islander			American Indian/Alaska Native ^d			Hispanic ^e		
	Rate ^b	APC ^c		Rate ^b	APC ^c		Rate ^b	APC ^c
	2014-2018	2009-2018		2014-2018	2009-2018		2014-2018	2009-2018
All Sites	84.6	-1.3*	All Sites	120.1	-1.5*	All Sites	94.6	-0.8*
Lung and Bronchus	16.3	-2.3*	Lung and Bronchus	27.4	-2.3*	Breast	13.8	-1.0*
Breast	11.7	0.6	Breast	14.8	0.3	Lung and Bronchus	12.3	-2.1*
Colon and Rectum	7.9	-2.6*	Colon and Rectum	12.4	-2.7*	Colon and Rectum	8.6	-1.8*
Pancreas	7.1	-0.7	Pancreas	7.5	-0.3	Pancreas	7.8	0.3
Liver & IBD ^f	5.4	-2.3*	Liver & IBD ^f	7.0	1.7	Liver & IBD ^f	6.0	1.1*
Ovary	4.4	-0.6	Ovary	6.0	-2.0	Ovary	5.1	-1.7*
Stomach	4.0	-2.7*	Corpus and Uterus, NOS	3.5	0.4	Corpus and Uterus, NOS	4.1	2.4*
Corpus and Uterus, NOS	3.2	2.3*	Stomach	3.5	-0.4	Stomach	3.9	-1.1*
Non-Hodgkin Lymphoma	2.9	-2.8*	Non-Hodgkin Lymphoma	3.3	-2.4	Non-Hodgkin Lymphoma	3.7	-2.5*
Leukemia	2.6	-3.2*	Kidney and Renal Pelvis	3.2	-4.0*	Leukemia	3.6	-1.6*
Brain and ONS ^f	1.9	1.6	Myeloma	3.1	1.4	Brain and ONS ^f	2.6	1.8*
Cervix Uteri	1.7	-0.7	Leukemia	2.8	-2.2	Cervix Uteri	2.6	-0.9
Myeloma	1.3	0.0	Cervix Uteri	2.4	-4.7*	Myeloma	2.2	-0.9
Oral Cavity and Pharynx	1.1	-1.2	Brain and ONS ^f	2.3	3.9	Kidney and Renal Pelvis	2.2	-1.0
Kidney and Renal Pelvis	1.1	-2.1*	Urinary Bladder	1.7	-	Urinary Bladder	1.3	0.2

Source: US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^a Top 15 cancer sites selected based on 2014-2018 age-adjusted rates for the race/ethnic group.

^b Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^c The APC is the Annual Percent Change over the time interval.

Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^d Rates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^e Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^f IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

* The APC is significantly different from zero ($p < .05$).

- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

Surveillance, Epidemiology, and End Results (SEER) Program: SEER 9, 13, 18, & 21 Geographic Areas National Cancer Institute, USA





Figure 1.1

Figure 1.2

Leading Causes of Death in US, 1975 vs 2018

Percent of All Causes of Death




Source: US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

Figure 1.3

Us Death Rates, 1975-2018


Heart Disease compared to Neoplasms, by age at death



Source: US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Figure 1.4

Trends in SEER Incidence and US Death Rates by Primary Cancer Site 2009-2018




Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts) and US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Underlying rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

For sex-specific cancer sites, the population was limited to the population of the appropriate sex.

* The APC is significantly different from zero ($p < .05$).

Figure 1.5

Trends in SEER Incidence Rates by Age Group and Primary Cancer Site 2009-2018



Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).


Underlying rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

For sex-specific cancer sites, the population was limited to the population of the appropriate sex.

* The APC is significantly different from zero ($p < .05$).

Figure 1.6

Trends in US Death Rates by Age Group and Primary Cancer Site 2009-2018




Source: US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.
Underlying rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
For sex-specific cancer sites, the population was limited to the population of the appropriate sex.

* The APC is significantly different from zero ($p < .05$).

Figure 1.7

Trends in SEER Incidence Rates by Sex and Primary Cancer Site 2009-2018



Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).


Underlying rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

For sex-specific cancer sites, the population was limited to the population of the appropriate sex.

* The APC is significantly different from zero ($p < .05$).

Figure 1.8


Trends in US Death Rates by Sex and Primary Cancer Site 2009-2018



Source: US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.
 Underlying rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
 For sex-specific cancer sites, the population was limited to the population of the appropriate sex.
 * The APC is significantly different from zero ($p < .05$).

Figure 1.9

SEER Incidence^a and US Death Rates,^b 2014-2018 5-Year Relative Survival,^c 2011-2017 All Cancer Combined, by Race and Sex




^a Incidence rates are from the SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts) and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

^b Death rates are from the US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

^c Survival rates are from the SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Figure 1.10


Trends in US Death Rates, 2009-2018 All Ages, by Race and Primary Cancer Site



Source: US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. The APC is the Annual Percent Change over the time interval. Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

Figure 1.11


5-Year Relative Survival (%) SEER Program, 2011-2017 Both Sexes, by Race and Cancer Site



Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Figure 1.12

SEER Cancer Incidence and US Death Rates, 2014-2018 By Cancer Site and Race/Ethnicity



Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts) and US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^a Rates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.


^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

Figure 1.13

SEER Incidence 2009-2018

Males by Race/Ethnicity



Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG), Idaho, New York and Massachusetts.

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 4.9, March 2021, National Cancer Institute.


^a Incidence rates for American Indian/Alaska Native (AI/AN) are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

Figure 1.14

SEER Incidence 2009-2018 Females by Race/Ethnicity



Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG), Idaho, New York and Massachusetts.

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).


Regression lines are calculated using the Joinpoint Regression Program Version 4.9, March 2021, National Cancer Institute.

^a Incidence rates for American Indian/Alaska Native (AI/AN) are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

Figure 1.15

US Mortality 2009-2018 Males by Race/Ethnicity



Source: US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).


Regression lines are calculated using the Joinpoint Regression Program Version 4.9, March 2021, National Cancer Institute.

^a Mortality rates for American Indian/Alaska Native (AI/AN) are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Figure 1.16

US Mortality 2009-2018 Females by Race/Ethnicity



Source: US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 4.9, March 2021, National Cancer Institute.

^a Mortality rates for American Indian/Alaska Native (AI/AN) are based on the CHSDA (Contract Health Service Delivery Area) counties.


^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Figure 1.17

Incidence Percent Change between 2009 and 2018

Numbers (burden) vs Rates (risk)

All Races, All Ages, Both Sexes



Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).


Risk is the change in the cancer incidence rates between 2009 and 2018.

Figure 1.18

Mortality Percent Change between 2009 and 2018

Numbers (burden) vs Rates (risk)

All Races, All Ages, Both Sexes




US Mortality estimates based on US age-specific rates applied to US population.

Burden is the change in the number of deaths between 2009 and 2018.


Risk is the change in the cancer death rates between 2009 and 2018.

Figure 1.19

Person-Years of Life Lost Due to Cancer All Races, Both Sexes, 2018




Average Years of Life Lost Per Person Dying of Cancer All Races, Both Sexes, 2018




Source: US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention and 2018 Life Tables.

Figure 1.20

Person-Years of Life Lost Due to Major Causes of Death in US All Races, Both Sexes, 2018



Average Years of Life Lost Per Person Due to Major Causes of Death in US All Races, Both Sexes, 2018



Source: US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention and 2018 Life Tables.